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ABSTRACT 
In recent years, Micro-Electrical Mechanical Systems (MEMS) have opened new areas of the human 
body to non-pharmacological treatment. Miniaturized implants have started to appear in volume or 
power constrained areas, such as the eye and the heart. In particular, the eye benefits from 
miniaturization, as it is very sensitive to pressure and volumetric changes, which can affect eyesight 
and blood flow.  
Diabetic retinopathy is the worldwide leading cause of blindness among working age adults. As the 
numbers of diabetics increases, so does the number of retinopathies. By 2030, 191 million people 
are expected to be affected by the disease. As a patient’s retinopathy progresses, the chronic 
hyperglycemia from diabetes causes permanent changes to the vasculature; vessels become leaky 
and occluded, tissue becomes hypoxic due to this ischemia and begins to release vascular endothelial 
growth factor (VEGF) to promote angiogenesis. 
Currently, treatments exist only for severe non-proliferative or proliferative DR, and rely on blocking 
VEGF (vascular endothelial growth factor) or panretinal laser photocoagulation to reduce retinal 
metabolic demand. VEGF antagonists are expensive; costing up to $164k per quality life adjusted 
year and must be administered by intravitreal injections monthly. Laser photocoagulation also 
requires retreatment and is known to reduce peripheral vision—up to 20% of the peripheral retina is 
ablated. Another treatment approach may be to supply oxygen. Oxygen is a strong vasoconstrictor 
and suppresses the hypoxic signaling that leads to release of VEGF. These two effects reduce the 
plasma volume leaked into tissue, which in turn reduces edema, and may help prevent ischemic 
related cell death. Literature supports this assertion. A study of nasally inspired oxygen in patients 
with macular edema showed a reduction of edema and improvement of visual acuity following 3 
months of treatment. Another study on rabbits with an induced ischemia demonstrated that 
intravitreal oxygenation maintained the retina to a near healthy condition.  
In this thesis, two devices, the oxytransporter and oxygenerator, that treat diabetic retinopathy are 
designed and tested. The former shuttles oxygen from areas of high concentration to the ischemic 
retina. The latter generates oxygen by electrolysis. 
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This thesis is grounded on a computational model of oxygen consumption in the retina. To estimate 
the oxygen consumption, the model accounts for the anatomical distribution of tissue and vasculature 
in the retina. Previous models in literature averaged over the effects in the inner retina. The model 
estimates that the devices must supply 0.25nmol/s of oxygen to the human macula with an oxygen 
tension dependent on the degree of ischemia. 
A nanoporous filler material was developed and integrated into the oxytransporter to allow this 
device to operate in the high humidity environment of the eye. The material is capable of 
withstanding an environment with water vapor 1.4 times the bulk saturation pressure. Theory behind 
the material was tested and compared to simulation. Benchtop testing over a month demonstrated 
the stability of the device in conditions similar to the eye. This oxytransporter was implanted in 
rabbits and the diffusor, or output membrane, reached the favorable mark of 100mmHg in the 
vitreous humor from atmospheric oxygen alone. This is estimated to be sufficient to treat a mild to 
moderate ischemia in humans.  
The oxygenerator is powered from a coil up to 3cm away, and can provide 0.25nmol/s continuously 
with an oxygen tension of up to 300mmHg for a human sized diffusor. A steady state test 
demonstrated the capability of maintaining the oxygen tension in the device by modulating the input 
power. The device is replenished through osmosis from the vitreous humor, and can absorb moisture 
at a rate comparable to the required oxygen consumption. One week implantation in vivo in rabbits 
demonstrated that the oxygen tension exceeded 200mmHg at the diffusor, which is estimated to be 
sufficient to treat severe ischemia. 
Future work should involve a study of the long term effects of oxygen in an ischemic animal model. 
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CHAPTER 1 – INTRODUCTION 
The technology and techniques of Micro-Electrical Mechanical Systems (MEMS) allow implants to 
be miniaturized, so that some diseases can be treated non-pharmacologically. Recently, miniaturized 
implants are targeting the eye (SecondSight’s Argus II retinal implant, Sensimed Triggerfish IOP 
sensor, Ahmed Glauocoma Drainage Valve [1.1]). The eye, being severely constrained, is an organ 
suitable for the application of MEMS technology. 
The World Health Organization (WHO) identifies as the leading causes for blindness: cataracts, 
glaucoma, age-related macular degeneration, corneal opacities, diabetic retinopathy (DR), trachoma, 
and eye conditions such as vitamin deficiencies in children [1.2]. WHO’s Global Data on Visual 
Impairments informs that 285 million have visual impairment, of which 39 million are blind [1.3]. 
Diabetic retinopathy (DR) lead the causes of blindness among working age adults [1.4], [1.5]. Even 
more troubling, all forms of diabetes related blindness are on the rise [1.2]. As of 2010, 95 million 
people have been diagnosed with some form of DR, of which 32 million suffer a form that may 
threaten vision. The number affected with DR is expected to increase to 191 million by 2030, of 
which the threatened with blindness is expected to increase to 56.3 million [1.6]. The Wisconsin 
Epidemiologic Study of Diabetic Retinopathy (WESDR) found that the 25-year cumulative rate of 
progression of DR was 83% for type 1 diabetes [1.7]. For patients diagnosed with diabetes before 
the age of 30, the WESDR found that 59% would develop retinopathy within 4 years of the study’s 
start, of which 17% would develop proliferative DR (PDR) within 14 years [1.7]. The number of 
early detections is expected to increase even further with the new machine learning algorithms [1.8]. 
 Notwithstanding these overwhelming statistics, current early treatments of DR are limited to 
managing glucose levels, lipids, and blood pressure. Pharmacological or laser interventions, costly 
and with side-effects, are only applied for the vision threatening stages of the DR.   
MEMS technology has an important role to play in helping to treat DR. 
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1.1 ANATOMY OF THE HUMAN EYE, PATHOLOGY OF DIABETIC 
RETINOPATHY AND THE EFFECT OF OXYGEN 
1.1.1 THE STRUCTURE OF THE EYE 
As can be seen in Figure 1.1, the eye is comprised of two sections: the anterior chamber, where light 
enters the cornea and travels through the aqueous humor and the lens, focusing the light onto the 
retina, and the posterior chamber which contains the retina and a transparent gel, the vitreous humor.  
 
Figure 1.1: Cross section of the eye. Reprinted from [1.9] 
 
Upon reaching the photoreceptor cells in the outer retina, the light is converted into an 
electrochemical signal, which signals the nerve and ganglion layers in the inner retina. This signal 
travels down the optic nerve to the brain. To maintain optical clarity few vessels lie within the optical 
path from the cornea until the surface of the retina. However, a sparse layer of blood vessels supply 
nutrients and oxygen the nerve cells of the inner retina, through the central retinal artery and returning 
through the central retinal vein. The outer retina, containing the photoreceptors, is primarily supplied 
by a dense network of vessels directly behind it, named the capillary lamina of choroid. 
The exterior of the eye is covered by the (bulbar) conjunctiva, a thin membrane of epithelium, which 
surrounds the sclera, the white of the eye, and lines the inside of the eyelid (palpebral conjunctiva). 
The conjunctiva connects to the cornea in the anterior of the eye.  
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The sclera surrounds the cornea and extends to the optic nerve in the back of the eye. The sclera 
protects and maintains the shape of the eye. The choroid is a vascularized layer of tissue sandwiched 
between the retina and the sclera. 
The central retinal artery connects to the capillaries of the choroid and to the inner retinal capillary 
beds. The circulation system connects between the central retinal capillary and the central retinal 
vein through arterioles. The artery branches out into capillaries that are diffused through the tissue 
before connecting to a venule. The choroid’s dense blood vessel network feeds the rods and cones. 
The inner is supplied by its capillaries. 
 
Figure 1.2: Vascular network in the inner retina. Reprinted from [1.10] 
 
The human retina can be divided into the macula lutea and the peripheral retina. The center of the 
macula lutea contains the fovea centralis, a small pit with a high density of cone cells [1.11]. This 
fovea centralis allows for sharp vision. It is surrounded by the parafovea containing ganglion cells 
that receive signals from the cones of the fovea centralis as well as the densely packed cone cells in 
the parafovea. The parafovea has the thickest ganglion cell layer. Visual acuity falls off at the 
perifovea, the outermost ring of the macula [1.11]. The peripheral retina surrounds the macula and 
is comprised mostly of rod cells. Cone cells allow for color vision. There are three types of cone 
cells corresponding to different absorption spectrums. Rod cells respond solely to light intensity and 
are responsible for low light vision. The peripheral retina is therefore responsible for night vision. In 
a lighted environment, these cells are photo-bleached and desensitized (turned off). 
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Figure 1.3: Overlay and cross section of the macula. Reprinted from [1.12] 
 
Most large inner retinal capillaries (retinal branch arteries and veins) extend into the perifovea. Few 
other vessels extend into the parafovea or farther in. The vessels in the inner retina extend only up 
to the foveal avascular zone (1mm diameter). The foveal avascular zone thins out; consequently 
blood supply is exclusively from the choroid.  
1.1.2 THE STRUCTURE OF THE RETINA 
The retina may be broadly divided into the inner and outer retinas. The outer retina contains the 
photoreceptor cells (rods and cones) and the retinal pigment epithelium (RPE), which is in contact 
with the choroid. The photoreceptors are stacked vertically. The photoreceptor is divided into the 
outer segment of the photoreceptors (OSP), the inner segment of the photoreceptors (ISP) and the 
outer nuclear layer (ONL). The outer segment contains the photosensitive portions with photopsin’s 
(cones) or rhodopsin (rods). The inner segment contains the photoreceptor cell’s mitochondria and 
is responsible for the cell’s oxygen consumption. The nucleus of the cell lies in the outer nuclear 
layer with its synaptic terminal extending into the outer plexiform layer that connects with bipolar 
and horizontal cells. 
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Figure 1.4: Diagram of the retina divided into its constituent layers. Reprinted from [1.13] 
 
The inner retina contains the nerve cells and is responsible for transmitting the signal through the 
optic nerve to the brain. Bipolar cells act as intermediaries between ganglion cells and 
photoreceptors. Photoreceptors trigger ON bipolar cells to depolarize when light stimulates a 
photoreceptor, and cause OFF bipolar cells to hyperpolarize [1.14]. In the absence of light, 
photoreceptors will instead hyperpolarize ON bipolar cells, and depolarize OFF bipolar cells. This 
signal is transmitted to the ganglion cells either directly or indirectly. Horizontal cells form a negative 
feedback loop with neighboring photoreceptors; a photoreceptor will hyperpolarize a horizontal cell 
causing it to depolarize neighboring photoreceptor cells. Conversely, when no light is applied, a 
photoreceptor will depolarize horizontal cells, and hyperpolarize neighboring photoreceptor cells. 
This inhibition process results in increased contrast of images.  
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These bipolar and horizontal cells synapse with photoreceptors at the outer plexiform layer (OPL). 
The nuclei of these cells and cell bodies are located in the inner nuclear layer (INL). The INL is 
responsible for part of the inner retina’s oxygen and nutrient consumption. The axons of bipolar cells 
interact with the dendrites of ganglion cells in the inner plexiform layer (IPL). Ganglion cells receive 
information from many rod and cone cells and transmit the signal through the optic nerve. The 
number of photoreceptors with which a given ganglion cell interacts vary along the eye. The density 
of ganglion cells is highest in the fovea centralis [1.15]. This higher density results in a thicker GCL 
in the macula [1.16]. The nuclei of ganglion cells lie in the ganglion cell layer (GCL) with their 
axons residing in the nerve fiber layer (NFL). Finally, the inner limiting membrane (ILM) acts as a 
boundary between the inner retina and the vitreous humor, and contains an extracellular matrix 
which acts as a substrate for retinal tissue. 
The inner retina is served by a capillary network in the GCL, the superficial vascular plexus (SVP), 
and by a network in the INL, the deep capillary plexus (DCP) [1.16]. The highest density of these 
capillary networks corresponds to the layers containing inner retinal the nuclei and cell. Within the 
macula, the deep nuclear plexus divides into the intermediate capillary plexus (ICP) and the DCP 
[1.16]. The presence of these capillary networks and cells can be observed through the oxygen 
profiles of the mammalian retina. In a rat, the choroid, SVP, and DCP exhibited intraretinal oxygen 
peaks when Yu and Cringle [1.17] inserted an oxygen microprobe into the retina (Figure 1.5). The 
IPS consumption is reflected in the dip 250µm to 300µm. 
7 
 
 
Figure 1.5: Oxygen profile of in a rat retina. Two sequential measurements by Yu et al. 
Reprinted from [1.17] 
 
1.2 PATHOLOGY OF DIABETIC RETINOPATHY 
Diabetic retinopathy is a microangiopathy resultant from chronic hyperglycemia, an excess glucose 
in blood plasma. This chronic hyperglycemia results in an increase of inflammatory cytokines, 
leukocyte activation [1.18], [1.19], and loss of capillary pericytes—multi-functional cells that wrap 
around capillaries and venules [1.18]. Pericyte cells are important for microvascular autoregulation. 
Their loss impairs the blood-retina barrier [1.18]. Pericytes are responsible for exerting pressure on 
the capillary walls to counteract blood pressure. Their loss results in venous dilation and vascular 
endothelial proliferation that eventually cause microaneurysms [1.18]. Hypertension is an additional 
risk factor for microaneurysms as the weakened vessel wall is exposed to increased pressure. 
Retinopathy is also known to thicken the capillary basement membrane through the vacuolization of 
the membrane’s collagen [1.18]. This results in increased blood leakage from blood vessels. In 
addition, the tight junctions of the capillary are prone to failure (Figure 1.6) [1.19]. The weakened, 
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and now permeable, capillaries walls result in microaneurysms, which are the first clinically visible 
sign of DR [1.18]. These microaneurysms can be observed by either light microscopy or fluorescein 
angiography. Macular edema may result from the subfoveal fluid buildup from this breakdown of 
the blood-retina barrier. The edema may result in vision loss. This edema is usually treated with 
intravitreal corticosteroids (100mg doxycycline daily) to improve visual acuity and decrease foveal 
thickness [1.18] 
The permeability of the vasculature is increased in the presence of vascular endothelial growth factor 
A (VEGF-A) [1.18].  The factor is known to promote neovascularization in the diabetic retina/ BEGF 
increases vascular permeability and risk of aneurysms. Cells downstream from an aneurysm become 
ischemic. The photoreceptor metabolism theory states this hypoxia coupled with the increased 
consumption of the dark adapted retina increases VEGF production [1.18]. This is because rods 
increase their ATP consumption by a factor of four when dark adapted versus light adapted. This is 
supported by the success of panretinal photocoagulation in treating diabetic retinopathy [1.18]. 
VEGF-A was found to be upregulated in the early stages of DR, with the loss of pigmented 
epithelium-derived factor (PEDF), an anti-angiogenic protein, and the accumulation of glutamate 
being driving factors [1.20], [1.21]. High VEGF-A levels can result in neurodegeneration of the 
retina [1.19]. As VEGF-A overexpression continues and PEDF is suppressed, the neovascularization 
that defines PDR occurs.  
The early vascular changes of basement membrane thickening, tight junction failure and 
microaneurysms characterize mild and moderate non-proliferative DR (NPDR). DR is graded as 
severe NPDR when many intraretinal hemorrhages as well as microvascular abnormalities are 
observed in all 4 quadrants Signs of neovascularization mean the disease has advanced to the 
proliferative stage.  
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Figure 1.6: Pathology of diabetic retinopathy. Reprinted from [1.19]. 
 
The degeneration of retinal vasculature, which in turn leads to upregulation of VEGF-A, suggests an 
ischemic pathway for DR progression. Severe NPDR exhibits “cotton wool” spots which are lesions 
indicating retinal ischemia. Intraretinal veins exhibit abnormalities and aneurysms depriving 
downstream tissue from oxygen. Indeed, as NPDR progresses arterioles connected to now acellular 
capillaries can become occluded [1.18]. Tissue once supplied by these vessels can become hypoxic. 
Under hypoxia, hypoxia-inducible factors (HIF)-mediated signaling increases, which drives pro-
angiogenic gene expression, and the production VEGF. VEGF binds to VEGF receptors (VEGFR) 
in the endothelial cells of blood vessels, which triggers angiogenesis [1.22]. The process is generally 
beneficial, but in DR, the new vessels are tortuous and irregular and prone to aneurysm. These 
vessels obstruct sight and lead to further bleeds which increases the quantity of floaters. 
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Table 1.1: Ischemia for different severities of DR. Measurements of retinal blood flow and 
oxygen saturation from Tayyari et al. [1.23] and Hammer et al. [1.24] are used to estimate retinal 
oxygen consumption with respect to DR severity. Note that Tayyari et al. presents a single value 
for mild to moderate NPDR. This value was used as an estimate for more severe retinopathy. 
Information on oxygen solubility in blood and plasma from other sources was applied to convert 
saturation in a molar flow [1.25], [1.26], [1.27]. 
Severity 
Retinal Blood 
Flow Rate 
[1.23] 
(µL/min) 
Venous 
Saturation 
[1.24] (%) 
Arterial 
Saturation 
[1.23] (%) 
Net O2 
Consumption 
(nmol/s) 
O2 Deficit 
in DR 
(mol/s) 
Oxygen 
Deficit in 
DR (%) 
Healthy 42.7 63 92.9 1.90   
Mild NPDR 33 69 94.7 1.26 0.62 33 
Moderate NPDR 33 70 94.7 1.21 0.67 35 
Severe NPDR 33 75 94.7 0.97 0.91 48.5 
PDR 33 75 94.7 0.97 0.91 48.5 
 
Observations of retinal blood flow and blood oxygen saturation in DR further suggest that there is 
an ischemic component to the disease. Recent studies of retinal blood flow and oxygen saturation 
(SO2) allow the oxygen deficit from diabetic retinopathy to be estimated (Table 1.1) [1.23], [1.24]. 
Retinal blood flow is seen to be higher, 42.7µL/min, in non-proliferative diabetic retinopathy (DR) 
compared to healthy retina, 33.0µL/min [1.23]. While arterial SO2, remained close to identical for 
healthy and non-proliferative DR individuals, a larger change was observed for venous SO2; control 
being 63%, non-proliferative DR being 70%, and proliferative DR being 75%. Assuming a constant 
CO2 and pH, the oxygen-hemoglobin dissociation, results in an estimated oxygen deficit of 8.2% 
(5.8nmol/s) and 17.9% (12.7nmol/s) compared to a control patient for non-proliferative and 
proliferative DR, respectively. The trend shows a decrease in arterial oxygen supply, and a decrease 
in oxygen consumed in the retina. The elevated venous oxygen saturation suggests that oxygen in 
the retinal circulatory system is not consumed by the retina [1.23]. This is consistent with occlusions 
of the vasculature. Such occlusions would prevent tissue from receiving oxygen from capillaries. 
Since the oxygen is not consumed, venous saturation is not expected to drop. Tissue in ischemic 
areas will likely experience hypoxia, triggering HIF-mediated signaling. The estimate performed 
here assumes that nearly all oxygen consuming tissue is still alive albeit hypoxic. 
Laser photocoagulation ablates photoreceptors to reduce the oxygen consumption of the retina to the 
level of reduced oxygen supply of the retinopathic eye. 
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When 20% of the photoreceptors have been ablated [1.28], the severe NPDR and PDR symptoms 
stop, suggesting that the upper bound for dead tissue is likely around 35% (using deficits from Table 
1.1). The deficit in Table 1.1 shows the maximum oxygen that must be provided for all severities of 
the disease. At this point, VEGF-A production has been reduced, which in turn reduced the 
permeability of vessels [1.18], [1.28].  Macular edema is also reduced because of the reduced water 
content entering the retinal tissue. This water content is reduced by the lower vessel permeability 
and the vasoconstriction from increased oxygen tension [1.28]. Reducing VEGF production has the 
added benefit of decreasing neovascularization, which helps reduce the impact of proliferative DR. 
Current treatment to manage severe NPDR to PDR involves monthly or bimonthly intravitreal 
injections of VEGF antagonists, such as Bevacizumab and Ranibizumab [1.29], [1.30]. VEGF-A 
blocks the growth of abnormal blood vessels and reduces vessel permeability. A study of 854 eyes 
from 691 patients treated with Ranibizumab for 1 year, at intervals of 4 weeks, found that it 
performed as well as laser photocoagulation every 13 weeks, and that both resulted in significant 
improvement over the sham groups [1.18]. However, VEGF antagonist therapy is costly: lifetime 
intravitreal anti-VEGF therapy ranges from $138k to $164k per quality life adjusted year [1.31]. 
None of these approaches treat the underlying ischemia.  
1.3 TREATING WITH OXYGEN 
Using oxygen to treat DR allows earlier intervention in the ischemic pathway. Oxygen is a used in 
many therapies [1.32]: hyperbaric chambers and normobaric hyperoxia have been well studied as a 
treatments for tissue hypoxia and for improvement of immune response [1.32]. In a study of macular 
edema, 43.5% patients treated with 3 months of 4L/min nasally inspired oxygen from oxygen 
canisters showed an improvement in visual acuity and a reduction in the thickness of the macula 
[1.33]. In addition, a study of vitreal oxygenation on 20 rabbits showed mitigation of the effects of 
retinal ischemia (Figure 1.7) [1.34]. 
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Figure 1.7: Oxygenating an ischemic rabbit retina. Reprinted from W. Abdallah et al. [1.34]. 
Ischemia was produced in 20 rabbits, with 10 being oxygenated by electrodes in the vitreous, 5 
being treated with a sham device and 5 left untreated. Oxygenation preserved the rabbit retina. 
 
There are two ways of balancing the supply and demand of oxygen in the eye: to reduce oxygen 
demand destroying retinal cells or to increase oxygen supply. Laser photocoagulation destroys 
photoreceptor cells. Oxygen canisters increase oxygen supply but are impractical and impoverish 
the patient's quality of life.  
This thesis aims to the design of microelectromechanical devices to increase oxygen supply to the 
eye without the deleterious effects of laser photocoagulation or the burdensome oxygen canisters  
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CHAPTER 2 – MODELING OXYGEN TRANSPORT IN 
THE RETINA 
As explained in CHAPTER 1, oxygen is the key element in the treatment of DR of any degree of 
severity. 
Current therapies of laser photocoagulation, or VEGF antagonists are, respectively, deleterious, or 
very expensive.  
Alternatively, MEMS technology can design efficient devices to implant on the eye to provide the 
oxygen needed. To that end, it is necessary to thoroughly understand how oxygen is transported in 
the eye.. 
2.1 SIMPLE, 4-LAYER, 1-DIMENSIONAL MODEL OF THE RETINA 
Magnus W. Roos's (2004) model is a starting point to estimate retinal oxygenation. It divides the 
retina into 4 layers: the inner retina, and 3 layers of the outer retina comprised of the outer segment 
of the photoreceptors (OPS), inner segment of the photoreceptors (IPS), and the outer nuclear layer 
(ONL) (Figure 2.1) [2.1]. Oxygen consumption occurs in the inner retina, which is highly 
vascularized, and in the inner segment of the photoreceptors, where the mitochondria (the 
powerhouses of the photoreceptors) lie. The outer retina is avascular, with most of the blood supply 
arriving from the choroid through the outer segments of the retina. 
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Figure 2.1: Layers of the retina for computational models. Grey shaded layers are oxygen 
consuming. Capillaries are shaded red. 4 Layer model contains blood vessels evenly distributed 
throughout the inner retina with consumption evenly distributed. The thicknesses used match those 
of Roos’s paper (2004), [2.1]. The 9 layer model has 3 capillary networks: superficial vascular 
plexus which is evenly distributed over the nerve fiber layer (NFL), intermediate capillary plexus 
between the inner plexiform and inner nuclear layers, and the deep capillary plexus between the 
inner nuclear and outer plexiform layers (OPL). 
 
Fick’s diffusion equation with source, 𝑆, and reaction (consumption), 𝑅, terms describes a general 
model of oxygen transport: 
 𝑑𝑐
𝑑𝑡⏟
0 for stationary solutions
= 𝐷∇2𝑐⏟  
diffusive transport
− 𝑅⏟
reaction (consumption) term
+ 𝑆⏟
source term
 (2.1) 
The constant of diffusion, 𝐷, is taken to be 1.97×10-5 cm2/s as per Braun et al’s paper [2.2]. Cellular 
oxygen consumption is described as a Michaelis-Menten reaction: 
 𝐸 + 𝑂𝑥 ↔ 𝐸𝑂𝑥 → 𝐸 + 𝑃 (2.2) 
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where oxygen is consumed, but the cell, 𝐸, is not. Of note, such kinetics assume the reaction is not 
ATP limited and is driven entirely by the availability of oxygen. Oxygen profiles of the cat retina by 
Braun et al., and upregulation of VEGF in diabetic retinopathy support this assumption [2.2], [2.3].  
Michaelis-Menten reactions have the relationship:  
 
𝑅 = 𝑞𝑚𝑎𝑥 (
𝑝𝑂2
𝑝𝑂2 + 𝐾𝑚
) (2.3) 
where 𝑞𝑚𝑎𝑥 describes the maximum consumption rate achievable, 𝑝𝑂2 describes the oxygen tension 
and 𝐾𝑚 describes the partial pressure or concentration at which the rate equals half the maximum 
rate.  
The source term in equation (2.1) includes the difference between venous and arterial oxygen 
tensions in the capillaries of the inner retina. The source term accounts for oxygen dissolved in blood, 
and oxygen bound to hemoglobin. Oxygen bound to hemoglobin is described by the Hill equation, 
which estimates the amount of bound ligand, 𝜃, (in this case oxygen) using the amount of unbound 
ligand, [𝑂2], and the concentration, 𝐾, when half the ligand is bound. The equation is a sigmoid 
function: 
 
𝜃 =
[𝑂2]
𝑛
[𝑂2]𝑛 + 𝐾𝑛
 (2.4) 
where 𝑛 describes the number of binding sites on hemoglobin. The oxygen tension, 𝑝𝑂2, tracks the 
oxygen concentration (𝑝𝑂2 = 𝐻𝑠𝑜𝑙[𝑂2]). Therefore, the source term as per Roos’s model averages 
over all capillaries: 
 𝑆 = 𝐵𝐹[(𝑝𝑂2,𝑎𝑟𝑡 − 𝑝𝑂2,𝑣𝑒𝑛)⏟            
dissolved gas
+ 𝑎 ∗ (𝜃𝑎𝑟𝑡 − 𝜃𝑣𝑒𝑛)⏟          
hemoglobin transport
] 
(2.5) 
 𝑎 = [𝐻𝑏] ∗ 𝛿⏟    
maximum mol O2/L in hemoglobin
∗ 𝐻𝑠𝑜𝑙,𝐻𝑏 (2.6) 
 
where 𝐵𝐹 describes the blood turn-over rate (closely related to the retinal blood flow rate), and 𝑎 
defines appropriate oxygen partial pressure in hemoglobin concentration. Venous oxygen tension is 
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set to match local tissue oxygen tension (𝑝𝑂2,𝑣𝑒𝑛 = 𝑝𝑂2), and arterial oxygen, 𝑝𝑂2,𝑎𝑟𝑡, is a parameter 
in the model. For the inner segment of the photoreceptors (IPS), the maximal consumption rate, 
𝑞𝑚𝑎𝑥, is different for light and dark adaptation.  
Ischemia is modeled by decreasing the blood turn-over rate, which reduces the oxygen available 
(source term) to the inner retina. Decreases in blood flow mimic oxygen loss downstream from 
occluded capillaries. Certainly, ocular blood flow in patients with diabetic retinopathy decreases 
from 42.7μL/min to 33μL/min [2.4]. This is simulated in COMSOL version 5.0 with a varied set of 
retinal blood flow values. Figure 2.2 plots the results for both the light and dark adapted retinas. 
 
Figure 2.2: Four-layer computational model of the retina with a uniformly distributed capillary 
network throughout the inner retina, and uniform oxygen consumption throughout the retina. Inner 
retinal blood flow is modeled by BF, describes blood flow per unit mass into the inner retina. 
Decreasing this number acts as a decreasing availability of oxygen for the inner retina. A healthy 
retina is defined as having BF=0.4 in this model [2.1]. Note the light and dark time oxygen tension 
at the photoreceptor depth (x>180μm) is different, with the inner segments dipping to below 
5mmHg in dark adaptation. Inner retinal blood flow reduces light adapted oxygen tension in the 
photoreceptors, but oxygen tension at dark-adapted photoreceptors are unaffected. 
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Now that the profile of oxygen in the retina is known, the impact of oxygen supplying devices 
(oxygen transporter and oxygen generator) on the retina can be modeled. The oxygen source of a 
device is modeled as a concentration boundary condition on one end of a silicone layer. The results 
for devices with O2 partial pressures of 100mmHg and of 250mmHg are plotted in Figure 2.3 and 
Figure 2.4. 
 
Figure 2.3: 4-layer computational model of the retina with 100mmHg device placed 1mm 
away from the retina. Healthy inner retinal blood flow is set to 0.4 [2.1], and the reduction to 0.3 
estimates a mild retinopathy. Oxygen penetrates the entire inner retina, but the oxygen 
tension remains above the healthy case only for the inner 35μm. This however is not a 
useful metric, as the level of VEGF suppression, and therefore efficacy of this 
oxygenation, is unclear. 
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Figure 2.4: 4-layer computational model of the retina with 150mmHg device placed 1mm 
away from the retina. Healthy inner retinal blood flow is set to 0.4 [2.1], and BF= 0.3 estimates 
mild retinopathy. The device raises retinal pO2 for dark-adapted retinas with a BF value 
of 0.3 above the dark-adapted healthy BF of 0.4 up for depths less than 75µm. 
 
When devices are placed near the retina, the oxygen levels near the vitreous approach those of the 
healthy retina, but quickly fall when approaching the outer retina. This means that the nerve fiber 
layer (NFL), the ganglion cell layer (GCL), and the inner plexiform layer (IPL) can be well 
oxygenated, but deeper tissue, such as the inner nuclear (INL) and the outer plexiform layers (OPL) 
cannot. It is difficult to draw conclusions from this, because the VEGF upregulation and the hypoxic 
levels for cells are not well understood. 
Two aspects stand out about this particular model: (a) the inner retina is unaffected by the increased 
oxygen consumption of the dark adapted outer retina, and (b) the inner retina has a fairly uniform 
oxygen tension throughout that depends on the availability of oxygen. The former is supported by 
literature: measurements of a cat’s inner retinal oxygen tension remained largely unaffected in light 
and dark adaptation, and mammalian photoreceptors are primarily supplied by the choroid [2.2], 
which in the model is defined as a fixed concentration boundary condition at 57mmHg of oxygen. 
However, literature disagrees with the latter: Cringle and Yu have found distinct peaks in a rat’s 
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intraretinal oxygen curve corresponding to capillary layers (Figure 2.5A) [2.5], [2.6], [2.7]. Indeed, 
optical coherence tomography (OCT) of human retinas defines several layers of capillaries (oxygen 
source): the superficial vascular plexus (SVP) in the nerve fiber layer, and the intermediary capillary 
plexus (ICP) and the deep capillary plexus (DCP) surrounding the inner nuclear layer [2.8]. Oxygen 
consumption in the inner retina occurs mostly in the ganglion cell layer, in the inner plexiform layer 
and in the outer plexiform layer [2.5]. Together these layers point to a more complex picture of the 
inner retina than captured by this model. The oxygen tension value at the oxygen consuming layers 
is important in determining the severity of the oxygen deficit, which determines the upregulation of 
VEGF. Figure 2.6 shows VEGF mRNA expression in those layers in a human retina. A multilayer 
model will better track oxygen tension in the human retina. 
 
Figure 2.5: Intraretinal oxygen profiles of mammals. For vascularized inner retinas (A,B,D), 
inner retinal capillaries result in distinct peaks. (A) Rat retina. Reprinted from [2.11]. (B) Rabbit 
retina, which has an avascular inner retina. Reprinted from [2.12].  (C) Cat retina with direction 
reversed. Reprinted from [2.13].  (D) Macaque retina. Reprinted from [2.14]. 
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Figure 2.6: VEGF mRNA expression in human eyes. From Pe’er et al, VEGF mRNA staining 
in retina of patients with diabetic retinopathy. Reprinted from [2.15]. VEGF expression is 
concentrated two bands of the inner retina: the ganglion cell/inner plexiform layers, and in the inner 
nuclear/outer plexiform layers. No expression is seen in the outer nuclear layer. 
2.2 CAPILLARY OCCLUSION, 8-LAYER MODEL 
An 8-layer model of the retina (3 layers for the outer retina, and 5 layers for the inner retina) zoomed 
into a 2 dimensional slice (100µm wide) with individual capillaries within each capillary network 
allows the effect of inner retinal capillary occlusions to be modeled with the minimum number of 
assumptions (Figure 2.1). These capillaries are 4.6μm in diameter (as found in Wang et al, 2011 
[2.16]), and match per layer the percentage area found in humans [2.8]. The capillary networks are 
the superficial vascular plexus, the intermediary vascular plexus, and the deep capillary plexus 
(Figure 2.7). Capillary density and retinal layer thicknesses are found in Table 2.1 and Table 2.2. 
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Table 2.1: Capillary Density as per Campbell et al., 2011 [2.8]  
LOCATION PARAFOVEAL PERIFOVEAL PERIPHERAL 
SVP 0.28 0.31 0.17 
ICP 0.22 0.21 0.22 
DCP 0.13 0.15 0.22 
 
Table 2.2: Retinal layer thickness. Periphery is taken to be similar to perifoveal. [2.8] [2.9], [2.10] 
LAYER FOVEAL PARAFOVEAL PERIFOVEAL 
NERVE FIBER LAYER 4 µm 34 µm 44 µm 
GANGLION CELL LAYER 28 µm 43 µm 27 µm 
INNER PLEXIFORM LAYER 28 µm 43 µm 27 µm 
INNER NUCLEAR LAYER 23 µm 38 µm 30 µm 
OUTER PLEXIFORM LAYER 38 µm 40 µm 29 µm 
OUTER NUCLEAR 77 µm 54 µm 54 µm 
INNER PHOTORECEPTOR LAYER 25 µm 25 µm 25 µm 
OUTER PHOTORECEPTOR LAYER 42 µm 37 µm 37 µm 
RETINAL PIGMENT EPITHELIUM 22 µm 22 µm 22 µm 
REGION RADIUS 0.6 mm 1.55 mm 3 mm 
 
 
Figure 2.7: OCT of human inner retinal vasculature; reprinted from Campbell et al., 2017 [2.9]. 
Note the 3 distinct retinal layers, superficial vascular plexus, intermediate capillary plexus, and 
deep capillary plexus. 
 
A symmetry boundary condition was placed at zero on the x-axis (retinal width). Capillaries were 
given a fixed oxygen concentration boundary condition and occlusions were modeled by removing 
said condition from the capillaries. Ischemia was increased by occluding capillaries moving away 
from zero at the x-axis (Figure 2.8 and Figure 2.9). A color graph of the concentration is plotted in 
Figure 2.8. 
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Figure 2.8: 8-layer computational model of the retina with individual capillaries for the dark 
adapted inner retina. The capillary spacing matches the capillary density in literature. The model 
has a symmetry boundary condition at x=0 (width). Capillaries are modeled as a concentration 
boundary condition set to 𝑝𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 = 30mmHg. Mild occlusions to severe occlusions are 
modeled by turning off this condition to ever more capillaries moving away from the x=0 line. 
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Figure 2.9: Oxygen profile along the depth of the 8 layer retinal model. Plotted oxygen tensions 
from x=0 line. Note the two distinct peaks from the SVP and ICP/DCP vessels. Looking at each 
progressive increase in occlusion, the peak height drops, and the peaks widen. As seen in the 
previous model, the inner photoreceptor segments are largely unaffected by the occlusions, but the 
ganglion cell and inner plexiform layers decrease. These layers are where VEGF has been found 
to express during diabetic retinopathy (Figure 2.6).  
 
Intuition suggests that the retina has lower oxygen tension in oxygen consuming layers than those 
layers with capillaries networks, and this trend is confirmed in the mammalian vascularized inner 
retinas seen in Figure 2.5A,B,D [2.5], [2.6], [2.7]. Figure 2.9 plots the dark-adapted retina with a 
dashed line, and the light-adapted retina with a solid line. Note that in the inner retina, in particular 
at the GCL and INL, the light and dark adapted oxygen curves are near identical. This would indicate 
that the effect of increased consumption in the photoreceptor layer does not impact the oxygen 
tension in the retina, even in severe occlusions. The effect occlusions have on the ganglion cell and 
inner plexiform layers indicates that this is where VEGF would be up-regulated. Indeed Figure 2.6 
shows VEGF mRNA expression in these layers in eyes affected by diabetic retinopathy [2.15]. 
Occlusions broaden and lessen peaks of oxygen tension, as oxygen diffuses from farther away. 
Intraretinal oxygen measurements will vary based on proximity to vessels. The distribution of 
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oxygen tension is seen to be non-uniform across a layer at this micro-level, and the model captures 
this fact in Figure 2.8. Intraretinal oxygen probes average measurements over a small but non-
infinitesimal area (30µm in diameter [2.12]). Consequently, the oxygen tension measurements in 
literature are affected by the proximity of the probe to the vessels. This explains the varied oxygen 
curves seen for mammalian inner retinas (Figure 2.5).  
Due to computational limitations this model cannot be extended to encompass the entirety of the 
retina, as there are many capillaries each with an individual boundary condition. 
2.3 AXISYMMETRIC (AXSY) MODEL OF THE MACULA AND 
SURROUNDING PERIPHERY 
The capillary oxygen supply rate will be averaged out into a source term similar to the first model. 
The model will be referred to as the AXSY model for clarity. This source term estimates the oxygen 
supply rate in the specific layers which contain the capillary networks (SVP, ICP, and DCP). As 
before, the source term is defined by the equation (2.5). As the choroid is expected to be mostly 
unaffected in retinopathy, the reduction in ocular blood flow was assumed to occur primarily in the 
inner retinal capillaries. Any deficit in blood flow was subtracted from the inner retina only: 
 𝐵𝐹𝐼𝑛𝑛𝑒𝑟𝑅𝑒𝑡𝑖𝑛𝑎 = 𝐵𝐹 − 𝐵𝐹𝑂𝑢𝑡𝑒𝑟𝑅𝑒𝑡𝑖𝑛𝑎 (2.7) 
where the blood flow of the outer retina was defined to be 65% of the total blood flow of a healthy 
retina [2.17]. As seen in Table 2.4, this results in the same ratio between oxygen consumption in 
proliferative retinopathy and a healthy retina, as calculated in Table 1.1. 
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Figure 2.10: Diagram of the retinal layers in the model. 
 
A 9-layer AXSY model of the retina (adding a retinal pigment epithelium layer) is implemented. 
The areas of each layer were made to differ across 4 distinct regions of the retina: the fovea, the 
parafovea, the perifovea, and the periphery. The oxygen consumption in the layers, GCL, IPL, OPL, 
and IPS, were taken from the values in literature. At the time of writing, the closest human analog 
whose intraretinal oxygen consumption has been measured was the macaque monkey, Birol et al. 
[2.18]. All model parameters are found in Table 2.3.  
Table 2.3: AXSY model parameters. 
PARAMETER DESCRIPTION VARIABLE 
𝑫𝒐𝒙,𝒗𝒊𝒕𝒓𝒆𝒐𝒖𝒔 Vitreous Diffusion coefficient [2.19] 4×10
-5 cm2/s 
𝑫𝒐𝒙,𝒓𝒆𝒕𝒊𝒏𝒂 Retinal Diffusion coefficient [2.2] 1.97×10
-5 cm2/s 
𝑫𝒐𝒙,𝑷𝑫𝑴𝑺 Silicone Diffusion coefficient [2.20] 7.88×10
-5 cm2/s 
𝑯𝒔𝒐𝒍,𝒗𝒊𝒕𝒓𝒆𝒐𝒖𝒔 Vitreous Solubility of Oxygen [2.3] 7.79×10
4 Pa·m3/mol 
𝑯𝒔𝒐𝒍,𝒓𝒆𝒕𝒊𝒏𝒂 Retinal Solubility of Oxygen [2.1] 1.41×10
5 Pa·m3/mol 
𝑯𝒔𝒐𝒍,𝑷𝑫𝑴𝑺 Silicone Solubility of Oxygen [2.1] 
600 Ba
𝐷𝑜𝑥,𝑃𝐷𝑀𝑆
=3.9×104 Pa·m3/mol 
𝑯𝒔𝒐𝒍,𝑯𝒃 Solubility of Oxygen in Blood [2.1] 8.89×10
4 Pa·m3/mol 
𝑲𝒐𝒙 Michaelis Constant for Retinal Consumption 
[2.1] 
2 mmHg 
𝑲𝒉𝒆𝒎 Hill half-concentration constant [2.1] 26 mmHg 
𝒏 Hill cooperativity coefficient [2.1] 2.7 
[𝑯𝒃] Concentration of hemoglobin in blood [2.1] 140 g/L 
𝜹 Oxygen carrying capacity of hemoglobin [2.1] 0.0616 mmol/g 
𝒑𝑶𝟐,𝒃𝒍𝒐𝒐𝒅 pO2 of Arterial Blood [2.1] 57 mmHg 
BF Healthy Retinal Blood flow [1.23] 42.7 µL/min 
𝒒𝒐𝒙,𝑶𝑹,𝒅𝒂𝒓𝒌 Macaque Dark-Adapted Outer Retinal 
Consumption [2.19] 
4.9 mL O2·100g
-1·min-1 
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𝒒𝒐𝒙,𝑶𝑹,𝒍𝒊𝒈𝒉𝒕 Macaque Light-Adapted Outer Retinal 
Consumption [2.19] 
0.72*𝑞𝑜𝑥,𝑂𝑅,𝑑𝑎𝑟𝑘 
𝒒𝒐𝒙,𝑰𝑹 Inner retinal consumption scaled from cat 
consumption [2.2] 
𝑞𝑜𝑥,𝑂𝑅,𝑑𝑎𝑟𝑘 ·
(3.91 mL O2·100g−1min−1)
(3.48 mL O2·100g−1min−1)
  
𝑨𝒓𝒆𝒕 Area of a human retinal 1094 mm
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The AXSY model implemented the effect of ascorbate in the vitreous as follows. It is well 
documented that ascorbate consumes oxygen in the vitreous as per the reaction: 
 AscH− + O2 + H
+ → DHA + H2O2 (2.8) 
which is beneficial in reducing the oxygen tension at the lens. Here reduced ascorbate acid is 
converted into dehydroascorbic acid (DHA) via a two-step process which consumes oxygen in the 
vitreous. Such a second order equation has a rate given by:  
 
𝑅 =
𝑑[O2]
𝑑𝑡
= −𝑘[AscH−]⏟    
𝑘′
[O2] = −𝑘
′[O2] (2.9) 
where 𝑘 is the rate for this process. The concentration of ascorbate in the posterior vitreous is 
0.376mM, and the rate is 1.61 M-1s-1[2.21]. Ascorbate acid is renewed by eye, meaning one can 
assume the rate to be relatively constant. To simplify, it is replaced by a rate incorporating ascorbate 
concentration in the posterior vitreous, 𝑘′ = 𝑘[AscH−] = 6.0536s−1.  
Table 2.4: Oxygen consumption and severity of DR in the simulation. AXSY model 
consumption integrated and scaled by the surface area of the AXSY model’s retina to the surface 
area of the retina. 
Source Parameter Light-Adapted Dark-Adapted DR Severity 
Blood  
Flow 
(µL/min) 
Flow 
Reduction 
(%) 
Total Retinal 
Consumption 
(nmol/s) 
Total Retinal 
Oxygen Deficit 
(%) 
Total Retinal 
Consumption 
(nmol/s) 
Total Retinal 
Oxygen Deficit 
(%) 
42.7 0% 2.10 0% 2.27 0%  
38.43 10% 2.05 2.3% 2.21 2.6%  
36.295 15% 1.98 5.7% 2.13 6.2% Mild NPDR 
33 22.7% 1.67 20.5% 1.78 21.5% Moderate NPDR 
29.89 30% 1.23 41.4% 1.33 41.4% Severe NPDR to PDR 
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Figure 2.11: 9-layer axisymmetric computational model of the retina; oxygen profile for a dark 
adapted retina. The color bar represents the oxygen tensions in mmHg. The device is represented 
by a white box is not active with no boundary condition. Note the elevated oxygen tension at GCL, 
and INL with the band of lower oxygen tension at IPL. 
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The effects of reduced blood flow are shown in Figure 2.11. The reduction in blood flow is based 
on 42.7µL/min being defined as healthy human blood flow [2.22]. The resultant oxygen 
consumption for different blood flows is found in Table 2.4. An ischemia of 30%, results in a 
reduction in oxygen consumption of 41.4% (similar to proliferative DR). Blood flow reductions of 
15% and 22.7% result, respectively, in 5.8% and 20.5% reduction in oxygen consumption (similar 
to mild and moderate non-proliferative DR). The AXSY model over estimates the total healthy 
oxygen consumption by 15% compared to healthy human retinas (see Table 1.1).  Remember that 
the model uses the retinal tissue consumption from macaque and cat retinas.  
 
Figure 2.12: Perifoveal oxygen profile for the 9 layer computational model; midway in the 
band of the perifovea. Here, LA stands for light-adapted, and DA for dark-adapted. A blood flow, 
BF, of 42.7µL/min is the healthy human blood flow. 38.43µL/min is a 10% reduction in blood 
flow, 36.295µL/min is a 15% reduction in blood flow, 33µL/min is a 22.7% reduction in blood 
flow, and 29.89µL/min is a 30% reduction in blood flow. 
 
Figure 2.11 shows a two dimensional color plot of the retinal oxygen tension. Note the minimum 
oxygen tension of the healthy retina is 8.58mmHg. Figure 2.12 is generated intersecting surfaces of 
Figure 2.11 at the same point in the x-axis (distance from center of fovea), and plotting the values 
on Figure 2.12; in this case the intersection was done at 2.275mm. In Figure 2.12, the black line 
represents healthy retinal blood flow, the blue line a 10% reduction in blood flow, the red line a 15% 
reduction in blood flow, the green line a 22.7% reduction in blood flow, and the brown a 30% 
reduction in blood flow. All lines have two dips in oxygen tension representing consumption: one at 
75µm of retinal depth and one at 145µm of retinal depth. The dip at 75µm represents the 
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consumption of the GCL and the IPL, and the dip at 145µm represents the consumption of the OPL. 
These dips match the ones seen in vascularized inner retinas of the rat, the cat, and the macaque. The 
deficit in the GCL and IPL may manifest as "cotton wool" spots.  
2.3.1 MODELING VEGF EXPRESSION IN THE RETINA 
Using grey scale and reducing the range in the AXST model’s output to 12mmHg, 15% blood flow 
deficit simulation shows agreement with VEGF staining in humans (Figure 2.13). Note that human 
VEGF expression is seen predominantly in the inner retina near the GCL and the IPL, these same 
regions exhibit decreased oxygen tension in the AXSY model. 
 
Figure 2.13: Low oxygen tension in simulation versus human VEGF expression. Simulation 
of light-adapted retina with a 15% reduction in retinal blood flow. Grey scale range was reduced 
to center on 9mmHg to 10mmHg leading to a sharp transition around those values. Human VEGF 
mRNA staining (Fig 2a of Pe’er et al [2.18) is scaled to match choroid to choroid and NFL to NFL. 
 
Based on the work of Chiarotto and Hill on cervical cancer cells [2.23], a sigmoid curve is used to 
model VEGF upregulation, equation (2.10): 
 VEGF(𝑝𝑂2) = 1 −
𝑝𝑂2
𝑝𝑂2 + 𝑝𝑂2,1/2
 (2.10) 
The oxygen partial pressure for 50% upregulation, 𝑝𝑂2,1/2, is set at the AXSY model’s minimum 
oxygen tension for a healthy eye of 8.6mmHg (Figure 2.11). The estimated percentage VEGF 
upregulation by retinal layer is plotted in the color map of Figure 2.14.  
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Figure 2.14: Simulation of VEGF upregulation in the retina. Percent VEGF Upregulation 
describes the rate of VEGF production with respect to the maximum percent. 
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Considering the maximal rate of VEGF expression of each layer is unknown, and not necessarily the 
same, one cannot average over different layers. Therefore, one must work with an independent 
average VEGF upregulation per layer. VEGF percentages of each retinal layer is normalized by 
dividing by the VEGF of the healthy retina, Table 2.5. In severe NPDR and PDR, the AXSY model’s 
VEGF production in the GCL is 2.5× to 3× that of healthy tissue. The values in the AXSY model 
(Table 2.5) conform to VEGF mRNA expression in Figure 2.6, meaning where there are white spots 
in the photograph, there is a corresponding high value of VEGF upregulation in GCL, IPL, INL, and 
OPL. The AXSY model of the retina shows decreased oxygen tension in the same regions that 
exhibit VEGF mRNA in human eyes.  
Table 2.5: VEGF upregulation by layer. Integrating VEGF Upregulation percentage over each 
layer and then dividing by the value of the healthy retina. The metric gives a comparison of the 
total change in VEGF expression by layer across different ischemic conditions.  
 
BLOOD FLOW 
(µL/min) NFL GCL IPL INL OPL ONL IPS OPS RPE 
L
IG
H
T
  
42.7 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
38.43 1.25 1.25 1.25 1.21 1.18 1.11 1.05 1.02 1.00 
36.295 1.54 1.55 1.55 1.44 1.37 1.20 1.09 1.04 1.01 
33 2.50 2.51 2.41 2.11 1.83 1.40 1.16 1.07 1.01 
29.89 3.23 3.20 2.98 2.70 2.18 1.51 1.20 1.08 1.02 
D
A
R
K
  
42.7 1.01 1.01 1.03 1.04 1.08 1.12 1.13 1.06 1.01 
38.43 1.27 1.28 1.30 1.28 1.30 1.26 1.19 1.09 1.02 
36.295 1.59 1.61 1.63 1.55 1.53 1.38 1.25 1.11 1.02 
33 2.55 2.56 2.50 2.25 2.04 1.60 1.33 1.13 1.03 
29.89 3.24 3.22 3.02 2.83 2.39 1.72 1.37 1.15 1.03 
 
2.3.2 MODELING AND OPTIMIZING THE DEVICE 
An oxygen containing ring is placed around the macula at the edge of the perifovea. The ring is 
comprised of 120µm thick silicone shell with hollow interior set at a fixed concentration. The ring 
prevents occlusions along the optical path of the macula, and reduces the risk of damage to the fovea 
if the ring were to contact the retina. The ring also provides an even oxygen distribution within the 
region of the macula compared to a point source (Figure 2.15). First, this section will confirm the 
device can improve oxygen tension, and reduce VEGF upregulation in the inner macula. The device 
will be swept across all parameters to determine the distance from the retina and the device oxygen 
tension required to treat DR. 
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Figure 2.15: 9-layer model with 200mmHg device. Retina with 33µL/min blood flow. 
 
 
Figure 2.16: Simulation with 33 µL/min and 200mmHg device (vitreous not plotted). 
 
The AXSY model estimates three ratios with respect to a healthy retina: VEGF upregulation, moles 
of oxygen in the retina, and oxygen consumption in the retina. Animal models will be needed to 
validate the estimates, since these are just a starting point. The device’s oxygen tension and position 
were independently swept for these ratios. The device’s position was fixed at 10µm above the nerve 
fiber layer at the perifovea, and the oxygen tension swept values are shown in Figure 2.17. Note that 
oxygen’s diffusion path length is much shorter in the retina than in the vitreous due to the lower 
diffusion and solubility constants. Furthermore, consumption in the GCL and IPL increases the 
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amount of oxygen deposited in those layers before it can diffuse deeper into the retina. This second 
effect efficiently deposits oxygen that enters the hypoxic tissue of the GCL and the IPL, where it is 
most needed (Figure 2.11). 
 
Figure 2.17: Ischemia model with varying device oxygen tension. Device placed 10µm from 
the perifovea and tested with a 15% reduction in retinal blood flow from the healthy 42.7µL/min. 
 
In the AXSY model, oxygen from the device is not transported through the vasculature. The 
vasculature normally transports oxygen along the layer. In the AXSY model, the vasculature does 
not shuttle oxygen, consequently the model overestimates the oxygen requirements from the device.  
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Figure 2.18: Simulation VEGF upregulation for different device oxygen tension. VEGF 
upregulation with 33µL/min retinal blood flow rate (22.7% reduction from the healthy 42.7µL/min 
flow rate) and a device with varied 𝑝𝑂2. 
 
The percentage of VEGF upregulation is plotted in Figure 2.18. VEGF upregulation starts to be 
suppressed at 100mmHg, and falls below 80% at 200mmHg. VEGF upregulation of 1.5× the healthy 
retina’s VEGF upregulation is considered unhealthy, considering that VEGF upregulation 1.4× that 
of healthy retinal VEGF was not observed to overexpress in the IPS layer in severe ischemia (refer 
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to the outer retina of Figure 2.6). Now that the device produces a favorable effect on the hypoxia in 
the inner retina, the device will be optimized for different severities of DR. 
Three contour plots are used to optimize the distance between the device and the macula, and to the 
device’s oxygen tension: moles of oxygen in the inner macula (Figure 2.19), oxygen consumption 
in the inner macula (Figure 2.20), and VEGF upregulation ratios in the combined GCL and IPL 
(Figure 2.21).  
For moles of oxygen and consumption in the inner macula, the positive slope of the contour line 
implies that reducing the oxygen tension from the device must also be followed with nearly linear 
reduction in distance between the device and the NFL. The values necessary for treatment depend 
on the level of ischemia. For a severe ischemia (30% reduction), which equates to PDR, either 
175mmHg at 0µm from the NFL or 250mmHg at 500µm fall within the treatable range for moles of 
oxygen and for retinal consumption. Lower oxygen tension devices or devices farther away from the 
retina, such as 100mmHg with a 1000µm separation, are adequate to treat mild to moderate NPDR.  
VEGF upregulation has an optimum distance around 200µm-400µm away from the NFL layer that 
is independent of oxygen tension. When the device is moved away from the retina, the thinner bottom 
membrane (the reason for thicker sidewalls can be found in section 6.3.1) has a more direct path 
length with tissue through vitreous, which is far more permeable than the retina. If the device is too 
close, oxygen is wasted oversupplying a smaller segment of the retina. As VEGF upregulation is 
more sensitive in the low oxygen tension, this effect is magnified in Figure 2.21. A 22.7% ischemia 
(moderate to severe non-proliferative DR) is best treated by a device of 150mmHg or greater oxygen 
tension at approximately 200µm. Since lower ischemia has a lower oxygen demand, such a device 
is adequate to treat those as well. PDR is best treated with a device of 250mmHg at 200µm from the 
nerve fiber layer.  
Note that these simulations assume very little cell death in the inner retina’s tissue; if sufficient 
oxygen could be supplied, retinal consumption would be the same as healthy. Therefore, the model 
overestimates the oxygen. The percentage of cell death is not modeled, as it would be a free 
parameter that is difficult to estimate correctly. Instead, the model sets an upper bound. As is seen in 
section 7.3.2, the provided oxygen tension may be modulated as desired. 
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Figure 2.19: Contour map of the ratio between moles of oxygen in the inner macula 
(integration of concentration in the NFL, GCL, IPL, OPL) for treated ischemic tissue compared to 
the untreated healthy case. A value less that 1 (blue) means the oxygen concentration is less than 
the healthy case. A value greater than 1 (red) means the net oxygen tension is higher than the 
healthy case. 
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Figure 2.20: Contour map of oxygen consumption in the inner macula. Ratio oxygen 
consumption in the dark adapted inner macula between the treated ischemic and untreated healthy 
cases. A consumption of 1 or higher (orange to yellow) will be considered healthy. 
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Figure 2.21: Contour map of VEGF upregulation in the GCL an IPL. Ratio between treated 
ischemic and untreated healthy case, for the integrated VEGF Upregulation in the GCL and IPL 
for a dark-adapted macula. The goal would be to minimize the amount of VEGF production in 
tissue to near the healthy value.  
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Finally, this device requires approximately 0.25nmol/s of oxygen to achieve treatment (Table 2.6). 
This requirement is only 3x the inner retinal deficit over the 6mm radius of the modeled retina (Table 
2.4). This is an efficiency of at worst 36.4%. The flux has little variation between 200µm and 1mm 
separation from the retina, so the target maximum flux is accurate.  
Table 2.6: Simulated oxygen flux from diffusor in nmol/s out of the device. The estimate was 
taken on the outer surface of the silicone wall. The top and bottom silicone walls are 120µm thick, 
and the device is 0.5mm from the NFL at perifovea. 
Diffusor Oxygen Flux at 0.5mm from Dark Adapted Perifovea (nmol/s) 
Blood Flow (µm) 42.7 38.43 36.295 33 29.89 
D
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25 0.004 0.008 0.012 0.017 0.020 
50 0.023 0.028 0.031 0.037 0.040 
100 0.063 0.067 0.069 0.075 0.080 
150 0.102 0.105 0.108 0.113 0.119 
200 0.140 0.143 0.146 0.150 0.156 
250 0.178 0.181 0.183 0.187 0.193 
300 0.215 0.218 0.220 0.223 0.228 
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CHAPTER 3 – HARVESTING OXYGEN: THE 
OXYTRANSPORTER 
Efforts are being made towards improving the underwhelming pharmacokinetics of most new drugs 
[3.1]. To that end, current research focuses on drug delivery mechanisms that promise selective 
delivery and zero-order or near zero-order kinetics: mechanisms such as biodegradable nanoparticle 
carriers, drug elution devices and refillable pumps [3.2]. These mechanisms are ingested, injected, 
or implanted. In chronic disease management, these mechanisms must be replaced. This chapter is 
about a design of a permanent mechanism to treat diabetic retinopathy. 
3.1 THE OXYTRANSPORTER 
 
Figure 3.1: Oxytransporter concept. (a) Diagram of shunt. An input side accumulator is placed 
near a high oxygen tension source, and an output is placed near the target tissue. A high 
permeability thin cannula connects the two.  The input and output have a larger area than the 
cannula to reduce the impedance through liquids and the silicone encapsulant used. (b) This shows 
the placement of the target device, where the input sits on the sclera, and the cannula penetrates at 
the pars plana to prevent tearing the retina. The output is a hook that surrounds the macula, to 
oxygenate it without occluding central vision. 
 
The oxytransporter harvests oxygen from a region (the input) with high concentration and shuttles it 
to a region (the output) with low concentration, acting like a shunt. This shunt must have a non-
occluding, non-fouling, and highly gas permeable pathway between the input and output (Figure 
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3.1a). There are several high oxygen concentration areas in the body, as seen in Table 3.1. Selection 
of the source depends on surgical considerations and on minimization of the conduit of the 
oxytransporter. Three factors must be determined: the location of the source, and the location output, 
and the path in between. 
Since this oxytransporter will treat DR, one must look at the sources of oxygen tension in the eye: 
the choroid and the atmosphere. The choroid is relatively difficult to access, and surgeries increase 
the chances of retinal detachment. Therefore, the oxytransporter’s input should be located in contact 
with the atmosphere. The input must be on the surface of the eye, and the oxytransporter must travel 
into the vitreous humor with an output in the vicinity of the macula of the retina. Animal studies by 
Abdallah et al. support the viability of oxygenating the vitreous to treat the inner retina [3.3]. 
Conferring with ophthalmologists at USC, the pars plana was chosen as it is a suitable and 
established region at which to transverse the sclera and can tolerate incisions of approximately 3mm.  
Table 3.1: Partial pressures of a healthy adult inspiring atmospheric oxygen. 
OXYGEN SOURCE OXYGEN PARTIAL PRESSURE [mmHg] 
ALVEOLAR [3.4] 107mmHg 
ARTERIAL BLOOD GAS [3.5] 75-100mmHg 
CHOROIDAL CAPILLARIES [3.6], [3.7] 57 mmHg 
SUBCUTANEOUS [3.8], [3.9] 86mmHg[3.8] or 65.7 mmHg [3.9] 
ATMOSPHERE 160mmHg 
 
Using the atmosphere as an input limits the treatment to mild to moderate NPDR that according to 
the AXSY model requires less than the 160mmHg provided by the atmosphere. The AXSY model 
(Section 2.3estimates the inner macula requires 0.72nmol/min for 15% ischemia on a ring shaped 
output. 
The permeability of the conduit material must be considered. The upper limit on the oxytransporter’s 
cross-sectional area, 𝐴, for the portion (i.e. cannula) penetrating the sclera is 3mm2. The conduit 
must traverse half the length, 𝐿, of the human eye, which is 12mm (Figure 3.1b). The permeability 
of the conduit material is found by an approximation using Fick’s first law 
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𝑄 = −𝐴𝑃
𝜕𝑝
𝜕𝑥
 (3.1) 
 
𝑃 =
𝑄𝐿
𝐴(𝑝𝑂2,𝑎𝑡𝑚 − 𝑝𝑂2,𝑟𝑒𝑡)
 (3.2) 
where 𝑝 is the partial pressure, 𝑃 is the permeation constant, and 𝑄 is the net flux. The oxygen 
tension 5mmHg, near the retina, 𝑝𝑂2,𝑟𝑒𝑡, [3.10], and 159mmHg in atmosphere, 𝑝𝑂2,𝑎𝑡𝑚. Therefore, 
the required permeability is 6.9x103 Barrer. From Table 3.2, silicone, the state-of-the-art, falls short 
with a permeability of 600 Barrer [3.11]. Only an air-filled channel will satisfy this requirement, 
potentially with a thin layer of silicone sealing both ends. 
Table 3.2: Oxygen Permeability of different materials. The permeability of a material is the 
product of the sorption equilibrium parameter and the diffusion constant. Permeation only occurs 
in solids, but one can represent the product of Henry’s solubility and the diffusion constant in a 
similar fashion of liquids. For air, the relationship between concentration 𝑐 = 𝑛/𝑉, and pressure 
is given by the ideal gas law as 𝑝 = 𝑐/𝑅𝑔𝑎𝑠𝑇, where 1/𝑅𝑔𝑎𝑠𝑇 is similar to Henry’s solubility and 
the sorption solubility constant. The “permeability” of air can be calculated by 𝐷𝑂2,𝑎𝑖𝑟/𝑅𝑔𝑎𝑠𝑇. 
MATERIAL PERMEABILITY [Barrer] 
PARYLENE-C [3.12] 0.042 
POLYIMIDE [3.13] 0.146 
WATER [3.14], [3.15] 127.6 
SILICONE [3.11] 600 
AIR [3.16] 2×107 
DESIRED 
MATERIAL 
6.9x103 
 
Following these basic principles, oxytransporters were built out of NuSil MED4-4210 silicone, 
Parylene-C, and stainless steel. Such devices had a square input, a bent cannula, and a hook shaped 
output (the diffusor). The hook shape of the diffusor allows a larger area to pass through the scleral 
incision than is permitted by a ring shape. Primary design of the input and cannula for this device 
was performed (D. Kang, 2015) [3.17]. This oxytransporter, referred as version 1, has a 3mm x 5mm 
input area with a 720μm tall cavity and an overall height of 1.44mm, top and bottom silicone is 
360μm thick (Figure 3.2). Refer to CHAPTER 6 explains the method used to mold silicone. The 
device uses a 10mm long, stainless steel 304, 25-gauge tube for the cannula that has a hook with an 
inner radius of 3mm. On one inside, the input faces the sclera, and on the other is covered by the 
conjunctiva or directly faces the atmosphere. The diffusor is implanted at the mid- vitreous. 
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Figure 3.2: Fabricated oxytransporter devices with bent cannula. Diffusor (output) is aligns 
parallel to the lens in rabbits. 
 
In early experiments, the oxytransporter was left uncovered by the conjunctiva. A simple finite 
element model (FEM) of oxygen transport can be constructed with stationary, Fickian diffusive 
transport: 
 
0 =
𝑑𝑐
𝑑𝑡
= 𝐷𝑜𝑥∇
2𝑐 (3.3) 
The eye was modeled as a sphere with a 20mmHg concentration boundary condition everywhere 
except at the lens. The retina is supplied with more oxygen the closer the diffusor is to the retina. 
According to the AXSY model, vitreal oxygen consumption has a minor impact on the device’s 
oxygen transport compared to the exact placement of the device; therefore vitreal oxygen 
consumption can be ignored. Figure 3.3 shows agreement between this model and in vivo animal 
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measurements. In particular, the data from the rabbit and this simple FEM have a difference of less 
than 2% in the oxygen tension of the diffusor. 
 
Figure 3.3: Simulation versus animal data for the oxytransporter. (A) A 3-dimensional 
COMSOL Multiphysics 5.0 model of oxygen transport through the device. No flux is assumed on 
the cannula (stainless steel), and bottom of the input side. The top of the input is assumed to be in 
contact with atmosphere. The diffusor is simplified to a 3mm disk with a 360μm top and bottom 
wall. (B) Oxygen tension in a line from the diffusor to the top of the eyeball as oriented in the 
model. This is compared to the oxygen profile in an acute rabbit experiment. In the rabbit, at 4mm 
the oxygen probe is near or touching the retina, but the dimensions of the human eyeball in the 
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model allow for a much longer profile. The two curves have a similar trend but a different slope. 
However, the value at the device’s diffusor, 0mm in (B), has good agreement between both (within 
2mmHg of each other). Therefore, the oxygen profile within the device is well modeled. 
 
From the estimates in section 2.3.2 (Figure 2.19, Figure 2.20, and Figure 2.21), this device may 
treat a 15% reduction in blood flow at 1mm or smaller separation from the retina when exposed to 
atmospheric oxygen tension during the day. During sleep the eyelid is closed and the oxygen tension 
of the diffusor drops significantly. Oxygen tension under the eyelid has been reported to be around 
58mmHg, which is approximate one-third that of atmospheric oxygen [3.37]. Nevertheless, this 
device may offer treatment for early mild diabetic retinopathies. The number of mild retinopathies 
identified will rise with new detection methods. Early treatment of mild retinopathies by 
photocoagulation reduces the rate of progress [3.38]; if early treatment can mitigate hypoxia as well, 
mild retinopathies may progress still slower if at all. 
For more severe ischemia where higher oxygen tension and flux is required and for treatment at 
night, the device will need to generate its own oxygen. 
3.2 CONDENSATION 
Oxytransporters implanted on rabbits’ mid vitreous resulted in elevated oxygen tension from the 
diffusor in acute experiments. However, one week follow-up experiments did not produce consistent 
results; some oxytransporters had no measureable response to oxygen, even with pure oxygen blown 
over the input. Water droplets observed in the device indicate that condensation may be affecting 
oxygen transport (Figure 3.4). 
 
Figure 3.4: in vivo condensation in the device. The white arrows point to condensation occurring 
in the (A) input after being implanted, and (B) diffusor after being explanted. The condensation on 
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the input side was been observed to occur in the timescale of minutes (within 5 minutes for this 
particular case). 
 
A thermal gradient between the surface of the eye and the vitreous humor is well documented [3.18], 
[3.19], [3.20]. The eye experiences, in the mm closest to its surface, the greatest deviation from body 
temperature [3.20]. In addition, the entire eye is a high humidity environment, with partial pressure 
of water near or at the saturation pressure for the given temperature (𝑝/𝑝𝑠𝑎𝑡,𝑏𝑢𝑙𝑘 ≈ 1). Bulk 
saturation pressure of water is highly temperature dependent, 𝑇 [3.21]: 
 𝑝𝑠𝑎𝑡,𝑏𝑢𝑙𝑘 = 0.61078exp (
17.27𝑇
𝑇+237.3
), (3.4) 
As water vapor diffuses from the body temperature of the vitreous through the oxytranporter, which 
is near the atmosphere, the saturation limit is surpassed (𝑝/𝑝𝑠𝑎𝑡,𝑏𝑢𝑙𝑘≥1) and water condenses. Given 
that the diffusion coefficient of oxygen in water is 9000 times slower than in air [3.16], even minimal 
condensation would occlude the oxytransporter. 
A model of condensation in the device was created to allow for rapid iteration of solutions. This 
model incorporates water vapor and heat transport, which are linked by equation (3.4). If 
𝑝/𝑝𝑠𝑎𝑡,𝑏𝑢𝑙𝑘 > 1, then the relative humidity in the air exceeds 100% and water will begin to condense 
locally. Heat transport is dominated by conduction: 
 𝜌𝐶𝑝𝜕𝑇
𝜕𝑡
= ∇ ∙ (𝑘∇T), (3.5) 
where 𝜌 is the density of the material, 𝐶𝑝 is the specific heat, 𝑘 is the conductivity of the material, 
and 𝑇 is the temperature. Equation (3.5) is solved in the time-dependent domain. Boundary 
conditions between materials are defined as continuous in temperature and heat flux: 
 𝑇1(𝒙0) = 𝑇2(𝒙0) (3.6) 
 𝑛 ∙ (𝑘∇𝑇1)|𝒙0 = 𝑛 ∙ (𝑘∇𝑇2)|𝒙0 (3.7) 
Table 3.3 and Table 3.4 include the parameters used in this model. The sections of the 
oxytransporter inside the eye (the diffusor and 5mm of the cannula closest to the diffusor) and those 
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in contact with the sclera (the lower half of the device) were kept at body temperature, 37⁰C. The 
remaining parts of the device was set to ambient temperature. Figure 3.5 shows the temperature 
distribution. Note the ambient and body temperature boundary conditions meet at the center of the 
cannula. 
Table 3.3: Parameters for heat transport simulation [3.22], [3.23] 
MATERIAL 𝝆 (g/cm3) 𝑪𝒑 (J/kg·K) 𝒌 (W/m·K) 𝛄 
SILICONE 0.965 1450 0.15 
 
SS304 8.03 530 16 
 
AIR 1.1315 1005.6 0.02624 1.4 
PERFLUOROCARBONS 1.908 446.8 0.067409 1 
Table 3.4: Parameters for water vapor transport. 
MATERIAL 𝑫 (cm2/s) 𝒌𝒉 (mol/kg·m
2) 
Silicone [3.23] 2E-5 8.9810E-6 
Air [3.30] 0.22 Ideal gas law 
Water [3.14], [3.31] 3E-5 1.2458E-5 
 
 
Figure 3.5: Simulation of temperature profile of the oxytransporter. The bent cannula is 
flattened out here to simplicity. While the model is fully 3-D with a cylindrical diffusor, the cross 
section where a symmetry line was placed to reduce mesh size is shown. 
 
The same physics of oxygen transport applies to water vapor transport. To simplify the model, the 
process of “consuming” water vapor by condensation is not considered (to model the exact dynamics 
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of water condensing into a droplet would need to include a model of the volume taken up by the 
water droplets, adding unnecessary complexity). 
The locations of the boundary conditions for water vapor transport match those of heat transport. 
Specifically, where the temperature was set to body temperature, the water vapor pressure is instead 
set to the saturation vapor pressure at body temperature, as defined by equation (3.4), and where the 
device had an ambient temperature boundary condition, the device now has a water vapor boundary 
condition that is a parameter in the simulation. The maximum value for the water vapor pressure in 
this region is defined by the saturation pressure of water vapor at the chosen ambient temperature. 
Figure 3.6 plots this water vapor distribution inside the device. 
 
Figure 3.6: Simulation of water vapor partial pressure (mmHg) in the oxytransporter. 10% 
of saturation pressure at the ambient side. Notice the smoother change in water vapor tension 
through the cannula than in the case of the heat transport. Heat transport sees a sharper change in 
values since the tube walls conducts heat, while no oxygen transport occurs radially through the 
stainless steel tube walls. 
 
Using the temperature and water vapor distributions, the relative humidity in the device is given by 
the ratio of water vapor pressure to saturation vapor pressure, 𝑝𝐻2𝑂/𝑝𝑠𝑎𝑡,𝑏𝑢𝑙𝑘 = 𝑅𝐻 (Figure 3.7). In 
the case of 20⁰C at both 10% and 100% ambient relative humidity, condensation occurs in the topside 
of the input. This agrees with observations in implants in rabbits. Figure 3.8 shows that it takes 90 
seconds for the relative humidity in the top side of the input to surpass 1. The order of magnitude of 
the time for this effect agrees with observation. However, the condensation of the input membrane 
is insufficient to account for the complete blockage of oxygen. The simulation points to condensation 
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in the cannula as the culprit for decreased oxygen transport (Figure 3.9). Figure 3.7 has a relative 
humidity >1 midway up the cannula.  
 
Figure 3.7: Simulation of relative humidity inside the oxytransporter. Note, in all 4 cases, the 
relative humidity on the top input side of the air chamber exceeds 1. This means that in nearly all 
conditions, the device will have condensation occur in that region (Figure 3.4). The definition for 
relative humidity only holds for air, and therefore these plots only include the region of the device 
filled with air. 
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Figure 3.8: Simulation of time progression for relative humidity in the oxytranporter. Note 
the scale parts differ in each plot. Within 90 seconds, the critical value, 𝑅𝐻 > 1 is reached. 
 
 
 
Figure 3.9: Simulation of condensation in the cannula. The left plot shows an un-occluded 
device. The right plot demonstrates the effect of a 1mm cylinder of water in the cannula. As 
predicted earlier, the significantly lower permeation coefficient of water greatly hinders oxygen 
transport. 
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Water vapor pressure at body temperature enters either from the bottom of the input side or from the 
diffusor, which is transported through the entirety of the cannula. As the path through the cannula is 
longer, and the diffusor’s area is smaller than that of the input chamber, the lower side of the input 
chamber (the side in contact with the sclera) accounts for the majority of the water vapor entering 
the device. Replacing the silicone membrane of the lower section of the device, that was at a water 
vapor transmission rate of 1.73-3.11g·mm·m-2·day-1 with Parylene-C that has a water vapor 
transmission rate of 0.08g·mm·m-2·day-1, reduces the influx of water vapor into the device [3.24], 
[3.25]. Adding a no flux boundary condition on the bottom side of the input (meaning a sufficiently 
thick section of Parylene that little water vapor enters through that surface) results in a greatly 
reduced relative humidity in the device (Figure 3.10). This device will be called oxytransporter 
version 2. 
 
Figure 3.10: Simulation of Parylene coating on the lower half of the input. No flux boundary 
condition results lowered relative humidity throughout the device. 
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However, in the case of 100% relative humidity at the input (such as when the conjunctiva covers 
the device), the oxytransporter version 2 has an internal 𝑅𝐻 of 1; regardless condensation can still 
occlude, given a low enough temperature. A simulation of relative humidity with the proper 
geometry for a bent cannula, Figure 3.11, shows condensation in the cannula will reach 𝑝/𝑝𝑠𝑎𝑡 =
1.3; explaining the occlusions of the devices in vivo (the devices worked after being dried, 
confirming the occlusion was only due to condensation). 
 
Figure 3.11: COMSOL simulation humidity in bent oxytransporter with 100% humidity on 
the top surface of the reservoir and on the diffusor. The vertical part is at body temperature, with 
the horizontal part having body temperature on the lower surface and ambient temperature, 20ºC, 
on the upper surface. The lower surface of the diffusor is taken to be impermeable to gas transport. 
Note that on the horizontal portion of the cannula, the relative humidity exceeds 1. 
 
3.3 A NANOSCALE FILLER MATERIAL 
What is needed is a material to fill the area were condensation is likely to occur, thus preventing 
occlusion. Unfortunately, most materials have oxygen permeabilities that fall short of the required 
6.9x103 Barrer (Table 3.2). Consequently, a novel filler material was developed.  
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If porous materials have sufficiently small pores, the equilibrium vapor pressure deviates from that 
of bulk material. This effect is governed by the Kelvin equation: 
 
 𝑝
𝑝𝑠𝑎𝑡,𝑏𝑢𝑙𝑘
= exp(
2𝛾𝑉𝑚
𝑟𝑅𝑔𝑎𝑠𝑇
) (3.8) 
where 𝑝𝑠𝑎𝑡,𝑏𝑢𝑙𝑘 is the saturation pressure of bulk water, 𝛾 is the surface energy, 𝑉𝑚 is the liquid molar 
volume, 𝑟 is the droplet radius, 𝑅𝑔𝑎𝑠 is the universal gas constant, and  𝑇 is the temperature. If a 
droplet is sufficiently small, the surface energy of the droplet exceeds the energy released by 
condensation and it becomes thermodynamically unfavorable to condensation. A pore with a convex 
curvature (hydrophobic) would constrain a droplet such that the equilibrium vapor pressure is above 
that of bulk, thereby increasing the vapor pressure at which condensation would occur.  Figure 3.12 
plots equilibrium vapor pressure versus bulk equilibrium vapor pressure for different sizes of pores. 
This suggests that a hydrophobic material with pores ≤8.2nm is capable of withstanding 
condensation up to 𝑝/𝑝𝑏𝑢𝑙𝑘 = 1.3 (Figure 3.11). 
 
Figure 3.12: Kelvin equation plotted across multiple temperatures. From Figure 3.11, the 
material must tolerate 𝑝/𝑝𝑏𝑢𝑙𝑘,𝑠𝑎𝑡 > 1.3 without condensing (black horizontal line) at 
physiological temperatures. This intersects the Kelvin curves at 8.2nm at 37ºC. 
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Porous glasses are commonly used in confined liquid physics [3.26]. These materials have open 
celled pores which are ideal for gas transport as they provide for continuous path for gaseous 
diffusion, despite the impermeability of the glass-phase. Furthermore, glass is generally inert in the 
human body and has a long history of use in implants [3.27], [3.28]. Both of these properties make 
porous glasses an ideal filler for the oxytransporter. Vycor 7930 in particular has pores averaging on 
the order of 44Å in diameter, making it ideal for this application [3.26 An SEM image of the surface 
of a Vycor 7930 sample is shown Figure 3.13. The image cannot resolve for pores down to 5nm, 
but 22% of the surface in the image is shown to be porous, with most of those pores being 
approximately 12nm or larger. This is in agreement with literature citing Vycor to be 28% porous 
[3.29]. However, glass is hydrophilic, and condense far too readily. To take advantage of the physics 
described by the Kelvin equation, the glass must first be hydrophobized. 
 
Figure 3.13: SEM image of treated Vycor 2930 nanoporous glass. Image acquired with the 
generous help of Dr. Matthew Hunt and the Kavli Nanoscience Institute. Pores comprise 22.6% of 
this image, with the smallest resolvable pores approaching 12nm in width. The porosity may be 
higher still, but pores down at 5nm are visible here. 
 
3.3.1 HYDROPHOBIZATION OF NANOPOROUS GLASS 
Hydrophobization of the glass is done by silanization with hexamethyldisilazane (HMDS). First, the 
nanoporous glass is piranha cleaned using 3:1 Nitric Acid to 30% Hydrogen Peroxide at 90ºC for 2 
hours or until the glass is no longer reacting with the mixture. Then, the glass is submerged into 
deionized water to rinse away any piranha. It is then heated to 80ºC in a nitrogen environment to 
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drive off any moisture within the pores. Once dry, the glass is placed in a round bottom flask 
connected to a second flask where 3mL of HMDS (Shin-Etsu MicroSi, Inc. MicroPrime HP Primer) 
is placed. This is heated in a dry bead bath to 120ºC for 6 hours. Then the flask with glass is separated 
and heated for 24 hours at 120ºC. At this point, the glass has been made hydrophobic. The contact 
angle was measured and a float test was performed, both documented in Figure 3.14. Water fully 
wets untreated Vycor making it difficult to acquire a reading, while treated Vycor exhibits 105º 
indicating the material is hydrophobic on the surface. During the float test, the hydrophobized Vycor 
indents the surface of the water and does not take in liquid. These tests are a strong indicator of 
proper silanization in the material.  
 
Figure 3.14: Hydrophobicity of silanizated Vycor 2930. (a) Water droplet on untreated Vycor 
2930 has no measureable contact angle. Untreated, Vycor 2930 is hydrophilic. (b) Silanized glass 
rod has a contact angle of 90º. (c) Silanized and machined Vycor 2930 tack has a contact angle of 
105º. (d) Silanized Vycor 2930 floating on water, while unsilanized Vycor 2930 sinks (black 
circle). (e) Silanized Vycor 2930 tack floating on water. 
 
3.3.2 VALIDATING THE NANOPOROUS ANTI-CONDENSATION FILLER 
A treated Vycor sample were then tested for oxygen permeability (Figure 3.15). The sample was 
placed in a heated water bath. To reduce axial oxygen transport out of the sample, it was tightly 
jacketed by a polyolefin heat shrink tube. The top of the sample was left above the water bath and 
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exposed to a step function of gas which goes from atmosphere to 100% humidified oxygen. The 
oxygen was humidified by passing it through a 20ºC bubbler between the oxygen source and the 
sample. An AL-300 AP-coat Fluorometrics Instruments oxygen probe and NeoFox reader were used 
to measure the response curve. This experiment was compared to an oxygen transport simulation in 
COMSOL. 
 
Figure 3.15: Oxygen permeability of hydrophobic Vycor 2930. (a) Diagram of test setup. 
Humidified oxygen is blown over silanized Vycor 2930. A polyolefin sheath surrounds the Vycor 
to prevent radial oxygen diffusion. The Vycor is placed inside a vial of water with ambient oxygen 
content. That vial is placed in a water bath on a hotplate which is agitated with a magnetic stirrer 
to maintain a constant temperature. Doing so assures an accurate temperature without introducing 
convective transport to the experiment. An AP coated oxygen probe (Fluorometrics Instruments) 
is placed against the Vycor’s base to measure oxygen. This was run at several temperatures. (b) 
The resultant curve at 37ºC was used to fit for the permeation constant of the material, which was 
found to be 3×104 Barrer, with a reduced-χ2 of 1.14. 
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Simulation began with a time dependent transport equation without convection. Both the tank of 
water and sample begin at ambient concentration. The boundary condition for the top of the sample 
is a constant oxygen concentration at the top surface with 760mmHg of oxygen tension. The 
boundary with water is calculated such that the flux is continuous, ∇c1|x1=x = ∇c2|x2=x, and the 
partial pressures are continuous across the boundary. Concentration is converted to partial pressure 
by Henry’s law, c = Hp, where H is the solubility constant. The permeability is the product of the 
diffusivity and solubility. Parameters for the model can be found in Table 3.5. The solubility of 
Vycor is assumed to be the product of air, 1/RgasT and its porosity, 0.28 [3.29]. The diffusivity is 
approximated by scaling the diffusivity of air by a factor, a [3.30]: 
 
𝐷𝑜𝑥,𝑣𝑦𝑐 = 𝑎𝐷𝑜𝑥,𝑣𝑦𝑐 = 𝑎 (1.13 × 10
−9 [
m2
s
] (
𝑇
1[K]
)
1.724
) (3.9) 
This accounts for the change in permeability over a wide range of temperatures. The exact division 
of solubility and diffusivity does not change the result of the simulation, only their product, the 
permeability, is relevant. The permeability of the material was swept until the curve matched the 
experiment at 37ºC (Figure 3.15c), which was 3x104 Barrer at 37ºC.  
Table 3.5: Parameters used in the COMSOL simulation of Vycor. Most parameters are sourced 
from literature. The diffusion coefficient for Vycor was scaled from the diffusion coefficient from 
air. The scaling factor, a, was determined by the simulation to the experiment at 37ºC. The 
solubility coefficient was taken from the equivalency for air to Henry’s law, 𝑝 = 𝑐/𝑅𝑔𝑎𝑠𝑇, where 
it was scaled by the open pore percentage. Since Fick’s law can be written in terms of permeation, 
𝜕𝑝
𝜕𝑡
= 𝑃𝛻2𝑝, the exact division between the solubility coefficient and diffusivity is unimportant; 
only their product affects the simulation. 
PARAMETER VALUE 
POROSITY OF VYCOR 2930 
[3.29] 
0.28 
DIFFUSION COEFFICIENT OF 
O2 IN AIR [3.30] 1.13 × 10
−9 [
m2
s
] (
𝑇
1[K]
)
1.724
 
DIFFUSION COEFFICIENT OF 
O2 IN VYCOR 𝑎 (1.13 × 10
−9 [
m2
s
] (
𝑇
1[K]
)
1.724
) 
DIFFUSION COEFFICIENT OF 
O2 IN WATER [3.31] 
3.33×105 [cm2/s] 
SOLUBILITY OF O2 IN WATER 
[3.14] 
1.3×10-3 [mol∙L-1∙atm-1] 
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SOLUBILITY OF O2 IN VYCOR 0.28
𝑅𝑔𝑎𝑠𝑇
 
VYCOR 2930 MEAN PORE SIZE 
[3.26] 
44 [Å] 
VYCOR 2930 STANDARD DEV. 
PORE SIZE [3.26] 
4 [Å] 
CONDUCTIVITY OF VYCOR 
2930 [3.32] 
1.4 [W∙m-1∙K-1] 
CONDUCTIVITY OF 
POLYOLEFIN [3.33] 
0.2 [W∙m-1∙K-1] 
POLYOLEFIN THICKNESS 350 [µm] 
VYCOR 2930 SHAFT RADIUS 1 [mm] 
VYCOR 2930 SHAFT LENGTH 4 [mm] 
 
 
As the water bath is heated, the water vapor inside the Vycor sample will surpass the saturation 
pressure predicted by the Kelvin equation, at which point water would condense inside the pores 
(Figure 3.16). The time constant was determined by fitting the function: 
 𝑝 = 𝐴𝑒−𝑡/𝜏 + 𝐵 (3.10) 
where τ represents the time constant. A smaller time constant is indicative of greater permeability as 
τ ∝ 1/P. As the water bath temperature increases the time constant is expected to drop, the pore 
saturation pressure is reached, at which point some pores will become occluded. 
A multi-part COMSOL simulation calculated temperature, water vapor partial pressure, bulk 
saturation pressure, and p/psat,bulk. If p/psat,bulk surpasses the ratio determined by the Kelvin 
equation, the diffusivity of the region is switched from that of hydrophobic Vycor to that of water. 
Heat transport is given by the equation: 
 ∇ ∙ (k∇T) = 0, (3.11) 
where k is the thermal conductivity of the material. The water bath is at uniform temperature. Contact 
between the Vycor and polyolefin coating is assumed to be continuous in temperature and thermal 
flux. Parameters for the model can be found in Table 3.5. Water vapor transport is calculated similar 
to oxygen transport with the boundaries in contact with water and fixed at concentrations given by 
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the saturation partial pressure of water vapor at their respective temperatures [3.21]. The results of 
these simulations are used to calculate p/psat,bulk.  
Using the Kelvin equation, the critical pore radius above which condensation would occur can be 
found by: 
 
rpore =
2γVm
RgasT log(p/pbulk)
 (3.12) 
Note that the pores of Vycor are not all uniform in size, and tend to be normally distributed with a 
mean diameter, μpore, of 44Å and a standard deviation, σ, of 4Å [3.26]. Since any section of the 
FEM mesh includes a large number of pores, the cumulative function for a normal distribution can 
be used to determine the percentage of pores above or below the critical pore diameter. The diffusion 
constant of un-occluded Vycor is scaled to the percent of pores that remain below the critical 
diameter. The percent of pores above this critical diameter is multiplied by the diffusivity of water. 
Therefore, for every mesh tetrahedral, there is a diffusion coefficient given by: 
Dvyc = {
Dox,vyc(T), p/psat,bulk < 1
Dox,vyc(T)
2
[1 + erf (
2rpore − μpore
σ√2
)] +
DH2O
2
[1 − erf (
2rpore − μpore
σ√2
)] , p/psat,bulk ≥ 1
 
(3.13) 
This diffusivity was then used on a simulation of the oxygen permeability of the Vycor sample. The 
time constant was found by fitting equation (3.10) to the simulated data (Figure 3.16). The 
experimental time constant increases sooner than the simulated one; suggesting the pore size may be 
10Å to 20Å larger than expected from literature. Regardless, experiment and simulation agree that 
the nanoporous glass is resistant to condensation under typical physiological conditions.  
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Figure 3.16: Hydrophobic Vycor’s resistance to occlusion under high humidity. (a) The water 
bath was heated to various temperatures, and a step function of 100% oxygen was applied. The 
oxygen tension at the probe (Figure 3.15a) was measured over time. The time constant of the 
resultant curve, similar to Figure 3.15c, was fitted. The same procedure was done for the 
simulation. (b) The oxygen tension at 100s in 87ºC water bath, and the ratio of pore equilibrium 
partial pressure to bulk partial pressure in 87ºC water bath are shown. These time constants were 
then plotted. Below the equilibrium partial pressure of the pores, no condensation would be 
expected. Therefore, as temperature increases the time constant decreases or remains relatively 
flat. As the pores being to condense, fewer high permeation paths through the material are left open 
and the net permeation decreases, thereby increasing the time constant. Both simulation and 
experiment demonstrate that hydrophobic Vycor is robust in physiological conditions. 
 
3.3.3 DESIGNING THE IMPLANT 
Glass can be brittle. However, concerns of breakage are minimized by encapsulating the material in 
a shell. Vycor is utilized in the outermost 5mm of the eye, where the majority of the temperature 
gradient occurs [3.20].  The nanoporous glass is encapsulated in medical grade silicone to give the 
device shape and suture points (Figure 3.17). Taking guidance from earlier work [3.34], [3.35], a 
mold was constructed to cast the silicone parts. The molds were made using DuPont WBR2120 dry 
film photoresist which was laminated onto a silicon wafer substrate at 95ºC at a travel speed of 
3.8mm/s on a General Binding Corporation Model No. Eagle 35 laminator. The wafer was soft baked 
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in a convection oven at 65ºC for 20 minutes, before exposing the mask pattern as per specification 
in the datasheet [3.36]. The molds utilized two separate masks to cast half of a part, and so the dry 
film was laminated again over the mold, soft baked and exposed. Next, the mold was post-exposure 
baked at 95ºC for 2 minutes, and developed for 20 minutes in 1:4 AZ Chemicals AZ340:DI water. 
The finished mold was coated with 5µm of Parylene-C to ease silicone release and reduce 
contamination from dry film debris. 
 
Figure 3.17: Exploded computer rendering of nanoporous-filled oxytransporter (a). The 
Vycor tack is encapsulated in an oblong silicone shell with 2 suture points on at the extremes and 
a stainless steel tube. The tube also acts to reduce radial permeation of oxygen from the device 
before reaching the output. (b) Computer rendering of the device. 
 
NuSil MED4-4210 silicone is mixed at the specified 1:10 part A to part B ratio, and thoroughly 
mixed for 5 minutes before pouring onto the mold. The silicone is degassed in a vacuum chamber 
until bubble free, and then a flat object such as a glass slide is used to squeegee any excess. The mold 
is then partially cured for 5 minutes at 100ºC in a convection oven to firm the silicone. Parts can then 
be peeled for device assembly. 
For integration into the final device, the Vycor is machined by a CNC lathe (Specialty Glass Products 
Inc, PA, USA) into a tack with a 1mm diameter by 3mm long shaft, and a 3.4mm diameter by 0.5mm 
thick head. The tack shape allows the input accumulator to be much larger in area than that tolerated 
by the scleral incision, thereby reducing the input resistance. All cleaning and silanization was 
performed after machining. To support the tack, a 1.42mm outer diameter by 1.17mm inner diameter 
stainless steel tubing (McMaster Carr #8988K39) was machined into a support. As shown in Figure 
3.18c, a slot was cut into the tube which formed wings supporting the head of the tack. To properly 
reach mid-vitreous from the pars plana, the tube was notched to allow it to be bent at 45º. 
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Figure 3.18: Nanoporous-filled oxytransporter fabrication. (a) Completed wafer mold. (b) 
NuSil MED4-4210 silicone parts after demolding. (c) The metal cannula and sections re assembled 
onto this custom spindle to allow them to be glued and cured together. The spindle has the same 
dimensions as the Vycor tack. (d) The resultant silicone device ready for assembly. The Vycor tack 
is inserted into the shape, and a top silicone film is applied. The entire device is then fully cured in 
an oven. (e) Device as seen from below. (f) Device as seen from above’ note the 4 metal flaps 
supporting the Vycor tack. (g) Side profile; input is on the left side and output is the hook on the 
right. (h) The device’s curve allows it to bend around the rabbit’s lens. 
 
Using a precision machined aluminum jig, the silicone parts (Figure 3.18b) were integrated onto the 
tube. The parts were adhered using uncured silicone, which was applied by spreading a thin layer of 
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degassed and uncured NuSil MED4-4210 onto a glass slide, where the parts were pressed against 
prior to integration. 
The device output is shaped like a hook to increase the distribution area while allowing a surgeon to 
insert it through a thin incision in the pars plana. The shape was made by joining two mirrored parts 
under a microscope and the parts weree then partially cured. This cannula is then slid over the 
stainless steel tube and adhered to other silicone parts. This lower half of the device was then partially 
cured for 5 minutes at 100ºC in a convection oven before being removed from the jig. The tack was 
then inserted into the now completed bottom half, and a 120µm top section was adhered to the Vycor. 
The device was then cured for 2 hours at 150ºC to fully crosslink the silicone. A brief soak in 
isopropyl alcohol cleaned the surface of the device. The device was sterilized using ethylene oxide 
(ETO). 
3.3.4 IMPLANT TESTING: IN VIVO AND IN VITRO 
The device was tested on benchtop for stability of the silanization, to assure that it would not exhibit 
any meaningful change over the implant period. To this end, a plate kept the head of the tack above 
the water level and the rest of the device below, insulating the rest of the device from the oxygen 
blown over the tack head (Figure 3.19). Oxygen was blown over the device daily and the oxygen 
response was measured using an AL-300 AP-coat Fluorometrics Instruments oxygen probe and a 
NeoFox reader. The water was maintained at body temperature by a hotplate. The measured time 
constant can be found in Figure 3.19b. When linear regression is applied to the time constants over 
30 days of soaking, no meaningful slope is found ((0.0667±0.1108)s/day) since the standard error 
greatly exceeds the slope. Therefore, with no statistically significant trend during the experiment, 
the device is considered to be stable.  
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Figure 3.19: Soaking stability of device. (A) Soaking setup. The diffusor tip is indicated by the 
red hour. (B) Time constants of a 30 day soaking data, where each time constant was found by 
fitting equation (3.10) to the oxygen response curve measured at the diffusor of each device. Linear 
regression fits, 𝑦 = (0.0667 ± 0.1108s/day)𝑥 + (22.80 ± 1.94s), with R2=0.01234; meaning 
there is no discernably trend over the 30 day soaking period. 
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Finally, the device was implanted three times in live rabbits for an acute experiment on permeability. 
For each rabbit, the oxygen profile surrounding the diffusor was recorded by moving a micrometer 
stage toward the retina and back, and then toward the incision (sclera) and back. The averaged data 
is presented in Figure 3.20. Comparing to the performance of oxytransporter version 1, this device 
is far more permeable. 
 
Figure 3.20: In vivo oxygen profile surrounding the device. An oxygen probe was placed against 
the diffusor and then moved away from that point using a micrometer stage toward the retina and 
back in live rabbits. This was repeated towards the incision point. An astute observer will note that 
the value and error towards the retina are both lower than the sweep towards the sclera. This is 
explained by the fact the diffusor is no more than 5mm from the optic nerve (the vascularized 
portion of the rabbit retina). Therefore, the oxygen tension tends to approach the retinal oxygen 
value, since it acts like a sink. On the other hand, the pars planar incision is farther away, and there 
is less consumption near that point. Therefore the oxygen tension exhibit a slower decline with 
greater variation in measurement, which is dependent on the proximity sweep path to the rabbit 
lens and the peripheral rabbit retina (which is mostly avascular). 
 
By estimating the diffusion coefficient of the rabbit vitreous humor, and approximating the equal 
oxygen tension lines to be an oblate spheroid, the total flux from this device can be calculated: 
 
𝐽 = 𝐴𝑃𝑂2,𝐻2𝑂
∆𝑝𝑂2
∆𝑟
= 𝐴𝑃𝑂2,𝐻2𝑂
𝑝𝑂2,𝑖+1 − 𝑝𝑂2,𝑖
𝑟𝑖+1 − 𝑟𝑖
 (3.14) 
 𝐴 = 2𝜋𝑟2 + 𝜋
ℎ2
𝑒
ln (
1+𝑒
1−𝑒
),  𝑒 = √1 − ℎ2/𝑟2 (3.15) 
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with the thickness of the device, ℎ, being 0.7mm, and the radius of the oblate spheroid, r, being 
2.5mm. Averaging through each data point in Figure 3.20, the flux, 𝐽, is 15±3nmol/s. 
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CHAPTER 4 – GENERATING OXYGEN: THE 
OXYGENERATOR  
The goal of this thesis would be to provide therapeutic options at every stage of DR. The 
oxytransporter’s input is taken from the atmosphere, consequently this device is limited to treatments 
of mild to moderate DR, that require an oxygen tension lower than the atmospheric of 160mmHg. 
The treatment of severe DR requires a device that generates oxygen at higher tension: the oxygenator 
meets that requirement 
4.1 OXYGENERATOR DESIGN 
There are two methods to generate oxygen are by chemical decomposition, or through electrolysis 
of water.  
Chemical decomposition requires the usage of reactive chemicals, such as peroxides, which tend to 
be toxic. Their use would require encapsulation and mechanical metering to control the rate. As any 
final device is expected to operate on the order of years, some method of refilling these chemicals 
would need to be devised. Assuring these substances do not make contact with the eye and assuring 
that no leaks occur after refill is a challenging issue, especially when the decomposition process 
generates excess pressure (see section 6.3.2). 
Instead, this device uses electrolysis. Electrolysis requires an external power source (discussed in 
CHAPTER 5), but consumed water can be replenished safely with a needle, as it is non-toxic, or by 
osmosis. The amount of oxygen produced could be controlled by controlling the amount on time of 
the primary side (where power is being provided). Therefore, this chapter will characterize the 
electrodes used, justify their usage, and convert the desired oxygen flux, 0.25nmol/s, into an 
electrical specification 
The oxygenerator has two parts: an implant and an external power source with a controller, the 
primary side (Figure 4.1). The primary side can be built into a pair of glasses or into a sleeping 
mask. This primary side controls the duty cycle and frequency of the electrolysis. Methods of 
powering the implant are briefly discussed in CHAPTER 5. Only the design of the device is 
discussed here, see Figure 4.1.  
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Figure 4.1: System diagram of the oxygen generating device. Power generation and transfer is 
discussed in CHAPTER 5. Power from the electronics in the implant drive electrolysis of water 
into gas. Any permeation out of the device (dependent on the difference in oxygen concentration 
and membrane permeations) contributes to supplying the retina with oxygen. This outflow of 
oxygen must be matched with an equal inflow of water through osmosis to prevent depleting the 
reservoir. Recombination of oxygen and hydrogen into water (dependent on oxygen and hydrogen 
concentrations) works to counteract gas generation in electrolysis. 
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4.2 ELECTROLYSIS 
When the implant receives electrical power, the voltage is rectified and sent to the electrodes housed 
in a cell with a membrane that is permeable to gases, but impermeable to electrolyte salts. The 
electrochemical process releases oxygen and hydrogen as described by the half-reactions: 
 2H2O(l) → O2(g) + 4Haq
+ + 4e− (4.1) 
 4H(aq)
+ + 4e− → 2H2(g) (4.2) 
This process depends on protons, H(aq)
+ , and electrons, e−, to act as charge carriers. If pure water 
used, the cell’s power efficiency would be very low and the overpotential quite high. Pure water has 
a low concentration of charge carriers, 10−7M H(aq)
+  and 10−7M OH(aq)
−  ions (implying low 
conductivity of 18MΩ·cm), and would result in a high overpotential and a low current density. 
Therefore, electrolysis of pure water would have a high faradic efficiency (percent of electrons going 
towards electrolysis of water); current entering the electrolytic cell primarily used to split water and 
to produce hydrogen peroxide. 
To reduce the over potential an electrolyte is added to the solution. The electrolyte must satisfy the 
following criteria: 
a. Safe and non-toxic. 
b. Reduction potentials of the cation must be lower than those of hydrogen, and oxidation 
potentials of the anion must be greater than those of hydroxide [4.1]; any redox reaction 
occurring in the electrolyte reduce the faradic efficiency of the system. 
c. No gaseous redox products must be produced (e.g. electrolytes with chlorine ions that 
produce chlorine gas), because membrane is only permeable to gas phase transport. Aqueous 
and solid phase products are safely encapsulated. 
Magnesium sulfate, commonly sold as “Epsom salt”, was chosen. The sulfate anion is difficult to 
oxidize, and its products, S2O8
2−, SO2 and S, are not gases. Magnesium, Mg
2+, is a suitable cation as 
its potential is lower than that of a proton [4.1].  
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The overpotential of the system depends on the electrode material, the resistance, and the 
concentration of the electrolyte. The resistance is dependent on bubble formation at the electrodes 
and affects the current density at a given voltage. The Tafel equation, 𝐼 ∝ 𝑒𝜂/𝐴, describes an 
exponential relationship between the current density and the overpotential, with 𝐴 being the Tafel 
slope. The choice of electrode material and electrolyte concentration affects the overpotential and 
power efficiency of the system, see section 4.2.2. The rate of recombination and the rate of 
replenishment must be taken into consideration. 
The rate of recombination needs to be significantly slower than the flux of oxygen, see section 4.3, 
because recombination of hydrogen and oxygen into water adds consumption on the oxygen flux out 
of the device. 
The rate of replenishment of the device must match the rate of consumption of water.  
4.2.1 A TEST PLATFORM 
To test the electrode material and electrolyte concentration, a silicone microfluidic channel with 
markings every 0.2mm was designed (Figure 4.2). Figure 4.3 describes the manufacturing process 
used to build the device.  Different microelectrodes patterns were evaporated onto a glass substrate 
(the base of the microchannel). Electrolyte with green food coloring was injected into both chambers. 
The silicone was poured greater than 3mm thick to reduce the outward permeation. The 
microelectrodes were powered on for a predetermined amount of time, with continuous voltage and 
current recording using two HP 34401A. The power supply, Korad KA3005P, was controlled by 
python code. A microscope with an OMAX A3590U recorded video of the fluid. The setup is 
described in Figure 4.4. Analysis of the video determined the displacement, which is dependent on 
the gas volume. To measure recombination, the silicone and glass device was coated with Parylene-
C to reduce outward permeation even further. Any shrinkage of the water column was then 
associated with recombination. 
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Figure 4.2: Electrolysis test chip. (A) Single Layer SU-8 100 mold design. The large dashes 
represent 1mm spacing. (B) Fabricated device with 30Ga needle glued in place using silicone. 
 
 
Figure 4.3: Electrolysis test chip fabrication. (A) Spin MicroChem Su-8 100 at 1krpm, expose 
mask, and develop (recipe in Section 6.2.1). (B) Parylene coat water to act as a mold release for 
the silicone. (C) Wrap aluminum foil around the sides to hold the silicone after pouring. (D) Pour 
NuSil MED4-4210 silicone into mold and degas in vacuum chamber until all bubbles are gone. 
Cure in oven at 100ºC for 10 minutes. (E) Peel and cut silicone device. Place silicone upside down 
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(channel exposed) and a clean glass slide in the Technics PEII-A plasma etcher at 300mT of O2 at 
50W for 10s. Immediately vent and flip silicone piece over onto glass, bonding the two. The glass 
slide can be replaced by any desired microelectrode pattern (Figure 4.5). 
 
 
Figure 4.4: Electrolysis test setup. A 1000Ω resistor on a relay allows the voltage to be set on the 
power supply accurately before applying a voltage to the microelectrodes. The relay is triggered 
by python code using an Arduino UNO R3 as an intermediary. Two HP 34401A multimeters 
perform the voltage and current measurements. Simultaneous video recording allowed movement 
of the water column in the microchannel to be measured. 
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4.2.2 ELECTROLYSIS EFFICIENCY 
Three different electrodes were tested: platinum-iridium (Pt-Ir) micro-patterned electrodes, gold 
micro-patterned electrodes, and platinum wire electrodes. The microelectrodes were fabricated using 
the lift-off process (Microchemicals AZ1518 photoresist and MicroChem LOR3B) to pattern the 
interdigital design onto a soda lime wafer (Figure 4.5). Afterwards, 200Å titanium and 3000Å gold 
was evaporated using an e-beam evaporator. A bath in ST-22 positive resist stripper removed 
photoresist and metal from everywhere except on the electrodes. In the case of platinum-iridium, the 
electrodes were electroplated. Both were diced and bonded silicone flow cell with the oxygen 
plasma.  
 
Figure 4.5: Microelectrodes boded to test chip. (A) Microelectrode pattern. (B) Electrodes 
patterned with Ti-Au and bonded to flow cell. (C) Electrodes electroplated with Pt-Ir and bonded 
to flow cell. (D) Microscope image of flow cell’s microchannel with green dye to color the 
electrolyte. 
 
Electrolysis tests were performed as described above. From Table 4.1 and Table 4.2, gold performed 
better than the Pt-Ir, because gold does not exhibit significant recombination. However, significant 
degradation of the gold microelectrodes was observed, leading to concerns about longevity. The Pt-
Ir coating survived well, but the underlying Au and Ti were etched through the pinholes. 
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Table 4.1: Power efficiency of Au and Pt-Ir microelectrodes. 
POWER 
EFFICIENCY (%) 2.0V 2.2V 2.5V 3.0V 3.2V 3.39V 
A
u
 0.5M   5 13 18 27 
1.0M   8 8 11 11 
1.2M    1 19 32 
P
t-
Ir
 
0.5M 3 2 10 14 17 11 
1.0M 9 2 12 14   
 
Table 4.2: Faradic efficiency of Au and Pt-Ir microelectrodes. 
FARADIC 
EFFICIENCY (%) 2.0V 2.2V 2.5V 3.0V 3.2V 3.39V 
A
u
 0.5M   11 31 48 75 
1.0M   17 20 29 31 
1.2M    3 51 88 
P
t-
Ir
 
0.5M 4 3 20 35 45 30 
1.0M 16 3 25 34   
 
Table 4.3: Power efficiency of Pt microwires. Electrolyte was injected into the chamber with 
care to prevent bubbles from being trapped in the chamber. The platinum electrodes were 4mm in 
length and separated by a gap of 2mm. Voltage and current were integrated and the theoretical 
amount of gas produced was compared to the actual volume displacement. 
 
POWER 
EFFICIENCY 
(%) 
 
1.8V 
 
2.0V 
 
2.2V 
 
2.5V 
 
2.75V 
 
3.0V 
 
3.2V 
 
3.5V 
 
3.75V 
 
4.5V 
 
5.0V 
0.2M 0.0 5.3 0.0 13.3 12.4 14.2 23.7 23.6 15.9 19.1 15.2 
0.5M 60.9 6.2 34.8 9.7 29.5 28.7 22.0 23.0 13.8 17.7 17.9 
0.8M 0.0 3.4 11.1 45.3 21.6 31.2 25.3 25.8 26.4 18.2 20.3 
1.0M 0.0 1.3 0.0 15.1 40.3 24.3 25.3 22.9 15.6 23.0 18.8 
1.2M 0.0 0.0 0.0 3.3 19.0 25.4 15.2 12.9 13.7 25.4 13.6 
1.5M 3.2 3.2 10.6 17.5 15.1 23.4 33.8 16.8 21.6 17.1 15.4 
1.8M 20.7 0.0 7.8 8.5 14.5 33.7 30.0 24.6 27.6 19.3 23.3 
2.0M 37.6 12.4 8.9 12.6 25.5 16.5 22.5 11.8 23.7 25.5 13.3 
 
Table 4.4: Faradic efficiency of Pt microwires. Electrolyte was injected into the chamber with 
care to prevent bubbles from being trapped in the chamber. The platinum electrodes were 4mm in 
length and separated by a gap of 2mm. Current was integrated and the theoretical amount of gas 
produced with that amount of current was compared to the actual volume displacement. 
FARADIC 
EFFICIENCY 
(%) 
 
1.8V 
 
2.0V 
 
2.2V 
 
2.5V 
 
2.75V 
 
3.0V 
 
3.2V 
 
3.5V 
 
3.75V 
 
4.5V 
 
5.0V 
0.2M 0.0 8.6 0.0 27.1 27.7 34.6 61.8 67.2 48.4 70.0 61.8 
0.5M 89.0 10.1 62.3 19.8 65.9 70.1 57.2 65.5 42.1 64.7 72.6 
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0.8M 0.0 5.6 19.9 92.1 48.4 76.3 65.8 73.4 80.6 66.6 82.5 
1.0M 0.0 2.2 0.0 30.7 90.2 59.4 65.9 65.0 47.6 84.3 76.7 
1.2M 0.0 0.0 0.0 6.7 42.5 62.0 39.6 36.6 41.7 93.2 55.5 
1.5M 4.6 5.2 19.0 35.7 33.7 57.2 87.8 47.9 65.7 62.7 62.4 
1.8M 30.3 0.0 13.9 17.5 32.3 82.2 77.9 70.1 84.2 70.6 94.7 
2.0M 54.9 20.2 16.0 25.9 56.9 40.2 58.5 33.7 72.3 93.4 54.2 
 
Resorting to 0.004in (101.6µm) platinum wire (California Fine Wire Model No. M447640) resolved 
the electro-etching issue. Two wires were inserted into a flow cell bonded to a glass. The length of 
the electrodes was set by the length of the chamber in the flow cell, which was 4mm. Measurements 
are shown in Table 4.3 and Table 4.4. The power efficiency for most concentrations is around 
20%.  The faradic efficiency (2.5V to 5.0V) is 59%, which is higher than the other microelectrodes; 
likely because of the lack of redox reactions etching the Pt electrodes. An overpotential of 1.2V 
(2.5V applied across electrodes) seems to be the turning point of the relationship between voltage 
and current in Figure 4.6. 
 
Figure 4.6: I-V curve for Pt microwires with respect to MgSO4 concentration. Two platinum 
wires were submerged in a 15mL tube filled with 10mL of MgSO4 solution. Voltage was swept 
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using a Korad KA3005P power supply and voltage and current were measured using HP 34401A 
digital multimeters. 
 
Figure 4.6 shows a voltage sweep applied to two 2cm (submerged) platinum wires in a 15mL 
centrifuge tube. Current and voltage were measured using HP 34401A in a similar setup to the one 
previously described. The Tafel equation was curve fitted, Table 4.5, over the region 1.23V to 3.2V 
to remove the effects of heavy bubble formation on the electrodes that occur at higher overpotentials. 
When scaled by the wire length, the current requirements at 2.5V and 1M MgSO4 solution is 
0.576mA/mm (2.3mA for 4mm long Pt wires). 
Table 4.5: The Tafel Equation fitted against the different solution concentrations with the 
voltages, 1.23V to 3.2V (overpotential of 𝜂=0V to 1.97V). 
MgSO4 SOLUTION CURRENT (mA) TAFEL SLOPE (V) 
0.2M 4.29E-02 0.335 
0.5M 4.15E-02 0.338 
0.8M 6.90E-02 0.355 
1.0M 5.36E-02 0.338 
1.2M 2.21E-02 0.302 
1.5M 4.67E-02 0.352 
1.8M 5.30E-02 0.377 
2.0M 1.05E-02 0.293 
2.4M 6.70E-03 0.286 
DI 1.14E-02 0.528 
AVERAGE SLOPE  0.331±0.01 
 
All curves in Figure 4.6 deviate from the Tafel equation at higher voltages, implying a decay in the 
current density that limits electrolysis. This happens for any electrode configuration, in part because 
bubble occlusions decrease the area of platinum wire in contact with the electrolyte. The decay in 
current density can be estimated by an exponential.  
A theoretical understanding of the bubble mechanism needs modeling based upon the nucleation 
points in the electrode and upon the imbalances of supersaturated gas. This is a chaotic system hard 
to formulate.  
One is now ready to calculate the oxygenerator’s electrical power to supply a maximum 0.25nmol/s 
of oxygen to treat severe NPDR or PDR corresponding to 30% ischemia in the AXSY model. At the 
theoretical maximum power efficiency, the continuous power needed is 0.12mW, and 0.6mW at 
20% power efficiency. According to the turning point of Figure 4.6, the circuit requires a minimum 
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of 2.5V, resulting in a continuous current of 0.24mA. If the circuit pulse-width modulated (powered 
on periodically), the current requirements scale as the ratio of the period to the on time. Pulsed power 
delivery also requires the device to be able to store sufficient oxygen to supply the off-state (𝑛𝑂2 =
𝑡𝑜𝑓𝑓 ∙ 0.25nmol/s for 30% ischemia). This primary side pulse-width modulation can be tailored to 
different disease severities up to 30% ischemia with the same implant, see section 7.3.2. 
4.3 RECOMBINATION RATE 
The use of platinum raises concerns regarding recombination. Therefore, a flow cell was coated with 
12um Parylene-C using the Specialty Coating Systems PDS. The Parylene coating reduces the 
permeation time constant of oxygen from 1.1×103s to 1.4×104s (𝐷𝐻2𝑂,𝑃𝑎𝐶 = 1.12 × 10
10cm2/s) 
[4.2], [4.3]. This way, any shrinkage in water column can be attributed to recombination and not to 
permeation. 
Electrolysis was performed in the column and video recorded. The reaction was measured from the 
point where the water column stopped moving forward. The distance traveled backwards by the 
water column was recorded as recombination. 
Table 4.6: Recombination rate measurements for Pt microwires (0.004in thick and 4mm long) 
TIME (s) RATE (mm3/s) RATE (nmol/s) 
420 9.4821E-05 3.852E-3 
420 6.0000E-06 2.4375E-4 
120 3.4125E-05 1.3863E-3 
121 4.0909E-05 1.6619E-3 
AVERAGE (1.8±0.8)E-3 
 
Experiments with excess gas in the chamber after electrolysis were chosen for the recombination 
measurement (Table 4.6). The molar rate of recombination is 0.72% of the estimated oxygen 
consumption rate (0.25nmol/s) required for the eye. Therefore, recombination can be ignored. 
4.4 REPLENISHMENT 
Two methods of replenishment—injections and osmosis—are explored in this section, each leading 
to very different designs of the device.  
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4.4.1 INJECTIONS INTO AN ELECTROLYTE RESERVOIR 
The implant involves injecting 1.5M MgSO4 electrolyte into the electrolyte reservoir after Ethylene 
Oxide sterilization and immediately before implant. This design has 3 sections (Figure 4.7): the 
reservoir, the cannula, and the diffusor. The reservoir and the cannula are both impermeable to 
oxygen on all their outward surfaces, while the diffusor is semipermeable. All electronics for this 
design are located in the reservoir segment of the device sharing space with the liquid reservoir. 
 
Figure 4.7: Oxygen generator device diagram. Device is split into 3 sections. The reservoir 
contains the electronics the power the device, the electrolyte reservoir and the input to the gas 
conduit, which passes unbroken through the cannula into the diffusor. A stainless steel cannula 
acts as a permeation barrier for oxygen and helps retain the position of the diffusor. The bottom of 
the liquid reservoir is made to be either a 50µm to 120µm thick silicone sheet (depending on 
iteration), with the lower conduit being only 120µm. The gas conduit is filled with air. 
 
As this device is intended to be refilled infrequently by a physician, the liquid reservoir must provide 
sufficient electrolyte to operate continuously between refills. The minimum interval for such refills 
is one month with 3-monthsl preferred (the maximum time between visits to the ophthalmologist for 
patients receiving anti-VEGF injections [4.4]). Such a large reservoir may only be situated in the 
temporal side of subconjunctival space between the two rectus muscles of the eye. Electrolysis 
occurs in this reservoir on the sclera to simplify design, because moving the electrolysis into the 
vitreous would require a pump to draw fluid over the electrodes. 
The maximum footprint of the device on the sclera is 12mm×12mm×3mm (thick), as established by 
other implants (SecondSight’s Argus II and Ahmed Glaucoma Valve). The maximum liquid volume 
of this footprint is 250µL (14millimoles of water); allowing for a 3-month interval between refills. 
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Converting 250µL of water to oxygen at a consumption rate of 0.25nmol/s (30% ischemia) allows 
for 324 days of continuous operation of the device. In 3 months, 28% of the liquid volume would be 
consumed.  
 
Figure 4.8: Needle fill of oxygen generator device. (A) Diagram of version 1 of the device. Note 
the thick silicone backside that acts as a septum. (B) Location of the reservoir on the eyeball. 
Injecting electrolyte into a silicone bag. (C) Version 5 of the active device with a septum layer 
(circled red). This separate layer reduced the chance of puncturing through the thin semipermeable 
membrane between the electrolyte and air chambers. (D) Two needles inserted to inject electrolyte 
before implant in live animal. (E) Diagram of septum layer. One needle acts as input for electrolyte, 
while the other acts as a vent. Electrolyte is added until it is seen exiting from the vent needle. (F) 
Having the two ports close together made it difficult to add both needles. Here each needle is 
inserted on an opposing end.  
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Needles of 32Ga (0.235mm outer diameter) or 31Ga (0.2604mm outer diameter) were chosen to 
minimize holes that do not seal in the material. The electrolyte is injected directly into the reservoir 
through a thick silicone septum (Figure 4.8). After filling, residual air is sucked out using the same 
needle. The chamber’s side wall thickness is typically 300µm and the septum thickness is between 
1mm to 5mm. Injections should enter at a shallow angle, so as to not penetrate the membrane. Any 
hole in that thin membrane will lead to device failure, because electrolysis will pump liquid into the 
gas conduit and occlude it. 
Later versions of the device have a dedicated layer with a channel to the liquid reservoir to prevent 
the needle from damaging the membrane (Figure 4.8E). In these newer designs, two needles are 
used to allow all trapped gas to be pushed out by the incoming liquid. However, the location of the 
implant made it difficult to refill. For all current animal studies, the device was filled only at the start 
of the experiment. This difficulty calls for an alternative method of replenishment: osmosis 
 
Figure 4.9: Silicone septum and leakage. (A) PDMS Only. Black line on top left cross section 
represents the needle’s entry point. On the top view this damaged area is roughly circular. When 
pressure is applied from the inside the silicone (Young’s modulus of 1.4MPa [4.5]), the material 
stretches and is prone to open along entry hole. Thickening the silicone here reduces the amount 
of stretching and makes the resultant microchannel longer as well. The hydraulic resistance of the 
microchannel is proportional to 𝑡/𝑎4, therefore reducing the radius of the hole, 𝑎, increases the 
resistance greatly. The deflection of a plate is proportional to the inverse cube of the thickness 
[4.6]. As this deflection is reduced, the strain on the entry point is also reduced. Therefore, the 
radius remains small. The leak follows the relationship, 𝑄 = ∆𝑃/𝑅. (B) Coating Parylene-C 
(Young’s Modulus of 2.7GPa [4.7]) reduces the deformation of the outer surface immensely. The 
hole can be treated as having a fixed radius on the surface. Any applied pressure would therefore 
deform this microchannel inwards. This effect depends on the compressibility of silicone, and can 
be treated as small. Therefore the hydraulic resistance through a Parylene coated port will remain 
equivalent to the maximum dictated by the size of the tear regardless of the pressure. The leak rate 
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increases linearly with the applied pressure. For these reasons the injection ports for the devices 
featured long silicone coated regions with a parylene coat. 
 
The perforation of the septum by the needle is prone to leak by the pressure of electrolysis gases. 
This risk is reduced by the Parylene coat over the chamber (Figure 4.9). 
 
Figure 4.10: Leak in version 5 of the oxygenerator after electrolysis in rabbit when under 
pressure (after electrolysis). 
 
Even with a Parylene coating, damage from needles still resulted in microchannels in the septum 
(Figure 4.10). Regular needles were replaced with 30Ga non-coring (Huber) needles, which do not 
remove material upon puncturing silicone. However, a 63µm channel was observed from using a 
non-coring needle (Figure 4.11). A one way valve solution would be required to prevent openings 
in the septum. 
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Figure 4.11: Microchannel formed by non-coring needle in silicone. (A) Leak (red circle) in 
version 7 of the device through the syringe plate. Note the channel formed by the non-coring needle 
(red ellipse), which has fluid moving through it (B) when under pressure. (C) Microchannel (63µm 
in diameter) formed by non-coring (Huber) needle in the silicone-PaC syringe plate. (D) The 
geometry of a Huber point needle is supposed to prevent extensive damage, as it does not cut out 
a cylindrical core of material when injected. 
 
4.4.2 REPLENISHMENT BY OSMOSIS 
Replenishment by osmosis seems to the solution to the above mentioned problems: the difficulty to 
inject in vivo, and the septum integrity. Water for electrolysis can be replenished from the vitreous. 
The oxygenerator changes as follows: the diffusor contains the electrodes and the electrolyte, the 
reservoir contains the electronics, and the cannula provides an electrical connection through the 
sclera. This design reduces the footprint in the subconjunctival space. 
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If there is a gradient in concentration of a solution across a semipermeable membrane, water will 
flow from the low concentration to the high concentration. This is called osmosis, and the pressure 
is defined as: 
 Π = 𝑖𝑐𝑅𝑇 (4.3) 
where 𝑖 is the van t’ Hoff factor, 𝑐 is the concentration of the solute, 𝑅 is the universal gas constant, 
and 𝑇 is the temperature. The water flux across a membrane is approximated by: 
 𝐽𝐻2𝑂 = 𝐾∆Π (4.4) 
 𝐾 = 𝑃𝐻2𝑂𝐴/𝐿 (4.5) 
where 𝐾 is the hydraulic permeability of the membrane, given by the area, 𝐴, thickness, 𝐿, and 
permeability of the membrane to water, 𝑃𝐻2𝑂. 
Assuming NaCl in the vitreous humor and MgSO4 in the diffusor, the water flux can be calculated 
using equation (4.4). For a device placed in the eye, the osmotic pressure difference must account 
for the two main salts in the system: NaCl in the vitreous humor, and MgSO4 in the diffusor. The 
van t’ Hoff factors are 1.9 for NaCl and 1.4 for MgSO4 [4.8]. The salinity of the vitreous is that of 
saline at 0.154M NaCl. The permeability of silicone to water is about 36kBarrer [4.9]. For the body, 
𝑅𝑇 is 2.577×106 Pa·L/mol. The area of the human device’s diffusor is estimated to be 17.3mm2. 
Given a thickness of 50µm for the membrane, the water flux is estimated as:  
 
𝐽𝐻2𝑂 =
𝑃𝐻2𝑂𝐴
𝐿
(1.4 × 𝑐𝑀𝑔𝑆𝑂4 − 1.9 × 0.154M)𝑅𝑇 
(4.6) 
Assuming the desired salt concentration in the diffusor is 1M MgSO4, the water flux is approximately 
12µmol/s, which exceeds the oxygen consumption rate. The equilibrium salt concentration (where 
𝐽𝐻2𝑂 = 0) is 0.209M MgSO4, meaning the salt will never dilute further than this concentration. The 
rate of oxygen consumption (0.25nmol/s) matches the rate of water intake when the salt 
concentration is 0.210M MgSO4. 
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As the diffusor is initially dry before ETO sterilization (which includes a vacuum step), the salt must 
absorb moisture from a solution. As MgSO4 is hydroscopic, water vapor in contact with the surface 
of the salt will be absorbed up to the equilibrium point. This creates a concentration gradient with 
the outside of the diffusor. If the diffusor is fully submerged in water, the relative humidity at the 
silicone membrane is 100%. Evidence presented later shows liquid water in the diffusor after soaking 
the silicone diffusor filled with MgSO4 salt. The maximum solubility of MgSO4 in water is 2.92M. 
Therefore, the inside of this diffusor has a concentration of at most 2.92M. Any higher value would 
involve water absorbed onto the surface of the salt, instead of dissolved, and would mean that no 
liquid would form. 
A simple experiment confirms these estimation of the total flux of water. A silicone bag shaped like 
the diffusor, a 12mm disc with 0.24mm sidewalls, was constructed out of NuSiL MED4-4210, and 
filled with a 1.5mL of 2.4M MgSO4. The bag with the solution was dried in an oven. This bag was 
submerged in deionized water and weighed periodically to determine the rate of osmotic flux. The 
consequent osmosis can be explained by Darcy’s law, where the molar flow rate of water is given 
by: 
 𝑑𝑛
𝑑𝑡
= 𝐴𝑃
∆𝑝
𝐿
 (4.7) 
being 𝐴 the area of the bag, 𝑃 the permeation constant, 𝐿 the wall thickness, and ∆𝑝 the pressure 
differential across the walls of the bag. Since there is no pressure differential through the bag walls, 
only the osmotic pressure determines the water flux: 
 ∆𝑝 = Π = 𝑖𝑐𝑅𝑇 (4.8) 
 𝑑𝑛
𝑑𝑡
= 𝐴𝑃
𝑖𝑐𝑅𝑇
𝐿
 (4.9) 
The concentration of the solution is given by 𝑐 =
𝑛𝑀𝑔𝑆𝑂4
𝑉𝐻2𝑂𝑛𝐻2𝑂
. Since there is no water in the device to 
begin with, 𝑛(0) = 0, which results in: 
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𝑛(𝑡) = √
2𝑃
𝐿
(
𝑛𝑀𝑔𝑆𝑂4
𝑉𝐻2𝑂
) 𝑖𝑅𝑇𝑡 (4.10) 
Therefore, the concentration becomes: 
 
𝑐 = √
𝑛𝑀𝑔𝑆𝑂4
𝑉𝐻2𝑂
(
𝐿
2𝑖𝑅𝑇𝐴𝑃
)√𝑡 (4.11) 
In a log-log plot, this becomes: 
 
log(𝑐) = −
1
2
log(𝑡) + log(√
𝑛𝑀𝑔𝑆𝑂4
𝑉𝐻2𝑂
(
𝐿
2𝑖𝑅𝑇𝐴𝑃
)) (4.12) 
Three bags were weighed using an analytical balance and the results are plotted in Figure 4.12. Each 
bag’s concentration data was fitted by linear regression, R2>0.99. Table 4.7 contains the parameters 
of each regression. Note that the slopes are near f -1/2, but statistically different, implying other 
variables had an effect on the results. This is particularly true when the salt is not in solution, as that 
process is technically not the result of osmosis. Knowing the membrane thickness and the total area 
of bag, one can solve the parameter, 𝑖𝑃, which is inherent to the silicone membrane and the salt. 
With this result, the rate of osmosis for any other device can be calculated by simply knowing its 
dimensions. For the dimensions of the diffusor, the flow rate using equation (4.9)  is estimated to be 
5×10-7L/s·𝑐. With an internal concentration of 1.2M, the diffusor would have a flow rate of 8.8×10-
7 mol/s of water inward. The flow rate is certainly sufficient. 
97 
 
 
Figure 4.12: Osmosis through silicone. Linear regression of data for 3 test devices in log-log. 
The salt was not fully dissolved at first, so the model does not perfectly fit the data on the low end, 
menaing the slope is not -1/2. However, the R2 values of 0.993, 0.995, 0.994 show that devices 1, 
2, and 3 have good agreement with the linear fit. 
 
Table 4.7: Fit parameters for osmosis through a silicone membrane. 
TEST 
DEVICE 
SLOPE Y-INTERCEPT MGSO4 
(mmol)  
𝒊𝑷 
 [𝐦𝐨𝐥 ∙ 𝐬−𝟏 ∙ 𝐏𝐚−𝟏 ∙ 𝐦−𝟏] 
1 -0.524±0.0066 1.672±0.013 0.10 5.33×10-13 
2 -0.609±0.0064 2.047±0.013 0.21 1.99×10-13 
3 -0.590±0.0097 2.123±0.018 0.43 2.87×10-13 
AVG    3.4×10-13 
 
To allow for osmotic replenishment a new diffusor is constructed (Figure 4.13). The platinum wire 
electrodes connect from the reservoir to the diffusor through the cannula. This cannula is thinner, 
because it does not require a gas conduit. By having the electrodes run along the entire length of the 
diffusor, this electrolyte filled diffusor generates oxygen uniformly throughout its shape. Providing 
a uniform oxygen gradient throughout.  The diffusor is filled with 1.5M MgSO4, and dried in the 
oven. The top half of the silicone diffusor is glued over the dried salt, sealing it in. The platinum 
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wires run around the entire length of the diffusor, therefore electrolysis occurs evenly throughout the 
diffusor, and more oxygen can be generated before gas fully occludes the electrodes. The diffusor’s 
top and bottom membranes were thinned to 50µm from 120µm to increase permeation and osmosis. 
This thinning reduces the fill time by 2.4×, since water flux scales as the inverse of the thickness. 
 
Figure 4.13: Osmotically refilled device. (A) Mask files for the diffusor. Purple represents the 
lower layer, and magenta represents the upper layer. This was fabricated using MicroChem Su8-
100 spun at 1krpm for the lower layer, and Su8-50 spun at 1.5krpm for the upper layer; resulting 
in a 150µm lower layer and 50µm upper layer. This mold was coated in 5µm Parylene-C and then 
parts were cast using NuSil MED4-4210 silicone. The two platinum electrodes from the electronics 
(reservoir) were laid in their respective channels (second pattern from the left) and bent along the 
diffusor, being held in place by silicone tabs. (B) The assembled cannula and diffusor with the 
dried MgSO4 salt can be seen attached to the complete device. 
 
The diffusor was submerged in deionized water at room temperature (Figure 4.14). In 4 hours, the 
diffusor was significantly filled with water, and within 10 hours, it was mostly filled with water, 
confirming the functionality of the design. 
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Figure 4.14: Time lapse images of diffusor filling up with water. Time lapse images of 
submerged diffusor in deionized water at 20ºC. As the salt dissolves the underlying platinum wire 
electrodes become clear. Note that after 11 hours the diffusor is nearly completed filled with water. 
It is estimated to take 14.8hours for the salt to reach 0.5M MgSO4 concentration using the above 
estimate for 𝑖𝑃. 
 
A video of the diffusor was taken while the electrodes were energized. Snapshots are presented in 
Figure 4.15. Note that gas formation occurs throughout the extent of the diffusor. As time passes 
gas builds up uniformly along the top of the diffusor with significant volumetric expansion occurring 
in under 1 second.  
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Figure 4.15: Snapshot of diffusor during electrolysis when energized with 3.5V. Note that gas 
bubbles are uniformly spread through the diffusor and within 0.778s a significant volume of the 
diffusor is filled with gas. 
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CHAPTER 5 – ELECTRICAL POWER 
Power autonomy is essential for any device permanently implanted. The implant cannot recharge 
through electric contacts. In the previous chapter it was determined that 0.6mW (0.24mA at 2.5v) 
are required to drive the electrodes of the oxygenator. Assuming a checkup period of 1 month, 
180mAh would be required from a 3.7V nominal lithium ion battery. Given a volumetric energy 
density of 693Wh/L [5.1], the minimum volume of the battery would be 1.9cm3. The battery needs 
to be sealed to prevent water ingress. Quallion Medical grade batteries are sealed as required but do 
not hold sufficient charge in the constrained volume of 0.25 cm3 allowed by the eye. 
Approaches to electrical power other than lithium ion are needed. There are four to consider: optical 
(solar cells), kinetic harvesters, inductive coupling for power transfer, and thermoelectric energy 
harvesters. Thermoelectric systems, according to literature, have very low power densities of 
1.0µW/cm-2, for small temperature differentials, ∆𝑇 = 5℃, making their power output far too low 
for this application [5.2]. 
5.1 OPTICAL POWER DELIVERY 
Optical power delivery is an attractive approach. Photovoltaics have made great advances in recent 
decades achieving up to 44.7% efficiency [5.3]. The eye regularly washes away particulates; leaving 
a clear path for light, thereby reducing the effect of dust on the maximum power point of solar cells 
[5.4]. Most optical power transfer for implants occurs in near-infrared (IR), since visible light has 
low transmittance through tissue [5.5].  Transmittance through 2mm of human skin in near-IR is 10-
20% [5.6]. It is common for such devices to rely on irradiation around 810nm. However, this 
wavelength can elevate tissue temperature, which should be maintained to less than 1.4ºC [5.7]. 
Fortunately, the conjunctiva is transparent in the visible region with a transmittance of 19% at 400nm 
to 65% at 800nm [5.8]. Implants underneath the conjunctiva would be sufficiently exposed to solar 
radiation to make optical energy harvesting viable. 
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Figure 5.1: Optical transmittance of the conjunctiva as well as several biocompatible materials. 
Reprinted from K. Murali et al.’s paper [5.8]. Note that borosilicate glass, silicone, and parylene 
are highly transmissive over the region of interest, and therefore are ideal encapsulants for such an 
array. 
 
 
Figure 5.2: Photovoltaic energy harvesting circuit. Reprinted from K. Murali et al.’s paper [5.8]. 
 
With the help of Dr. Karthik Murali at USC, the viability of photovoltaic (PV) energy harvesting 
was explored [5.8]. On benchtop, the subconjunctival photovoltaic implant, produced 3.13mW, 
2.13mW, and 1.26mW with 1000W/m2, 667W/m2, and 333W/m2, respectively [5.8]. In the circuit, 
eight OSIoptoelectronics photovoltaic cells were wired in 2 sets of 4 parallel cells in series (Figure 
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5.2) [5.8]. With the Texas Instruments BQ25504 energy harvesting IC acting as a boost converter, 
the circuit managed a suitable 3.2V with 0.38mA, 0.28mA, and 0.14mA for 1000W/m2, 667W/m2, 
and 333W/m2, respectively [5.8]. Such a circuit utilized only 7.8mm2 of the ocular surface; 
equivalent to 49µA/mm2, 36µA/mm2, and 18µA/mm2 per unit area of solar cell, respectively. 
Given that humans tend to not stare directly at the sun, the actual incident illumination is much lower 
than the solar maximum. Scattered light provides a more accurate irradiance of the PV circuit. A 
perusal of common building materials shows a wide range of albedos from 0.05 up to 0.8 [5.9]. For 
a common material, concrete, ranges from 0.2 to 0.4. Given that solar irradiance onto the ground is 
between 1kW/m2 to 1.3kW/m2, and light reflected off of the ground is on the order of 200W/m2 to 
520W/m2; the lower value of 18µA/mm2 is likely the most accurate. Given the oxgyenerator’s 
requirement of 0.25mA, a collection area of 14mm2 is needed. 
Table 5.1: Lumens from standard household bulbs [5.10] 
OLD 
INCANDESCENT 
BULB (WATTS) 
ENERGY STAR BULB 
BRIGHTNESS (MINIMUM 
LUMENS) 
40 450 
60 800 
75 1100 
100 1600 
150 2600 
 
This collection area needed is larger when indoor illumination is considered.  Elderly patients likely 
spend most of their time indoors. From Table 5.1, the luminous energy for 100W (1600Lumens) 
equivalent bulbs is: 
 1600 (
1
683
W × Steradian) = 2.34W × Steradian (5.1) 
assuming all energy is transmitted at 555nm [5.10]. If a human were to stand 2m away from and 
staring at the bulb, the human eye will receive: 
 (2.34W × Steradian)/ (
Steradian
4𝜋(1m)2
) = 0.186W/m2 (5.2) 
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This result matches previously reported values of indoor light being 10-4 less than solar intensity 
[5.11]. The circuit’s efficiency is found to be: 
 
3.2V × 0.14mA
0.33mW/mm2 × 4.1mm × 1.9mm
= 17.3% (5.3) 
Therefore, the photovoltaic cells would provide 3.2×10-2µW/mm2, and would need to cover 500cm2 
of area to supply the retina. Given that the eyeball can be approximated by a 24mm diameter sphere, 
this solar cell array would cover 13.5 times the surface of the eye, which is clearly unachievable. 
 
Figure 5.3: Location for implantable photovoltaic cells. 
 
Patients wearing such a solar harvesting devices would, therefore, need to spend a significant portion 
of time outside. Indeed a large implant covering a 4mm ring around the cornea would have a surface 
area given by [5.12]: 
 𝐴 = 2𝜋(12mm)2∫ sin 𝜃 𝑑𝜃
𝜃𝑑=39°
𝜃𝑐=29°
= 88.2mm2 (5.4) 
where 𝜃𝑐 is the angle for the corneal radius, 11.7mm, Figure 2.1, and 𝜃𝑑 is the angle for the device 
end (Figure 5.3). This device would harvest 1.59mA on a sunny day. Given that daily power 
requirements were found to be 0.25mA, the user would need to spend 3.8 hours outside on a sunny 
day to generate sufficient oxygen. This is likely a large lifestyle change for most patients, and may 
result in low compliance. 
A further flaw of this approach is that no oxygen generation would occur at night when oxygen 
demand is highest due to rod stimulation. Solar cell oxygen harvesting would therefore be reliant on 
a rechargeable battery or would need to increase vitreal oxygen tension sufficiently to act as a source 
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for nocturnal oxygen demands of the retina. The Quallion QL0003I, 3mAh with an 11.8mm height 
and 2.9mm diameter, is appropriate [5.13]. The battery would be fully charged in 1.88 hours of 
sunlight. A single battery would power electrolysis for 12 hours. 
 
Figure 5.4: Exposed conjunctiva on the rabbit eye. Reprinted from [5.14].  
 
In addition, this approach is problematic in animal models, especially in a rabbit (Figure 5.4), where 
the sclera is fully covered by the eyelid. In such a scenario, the cells would only receive near-IR. 
Since surgical experiments would be done indoors, this would necessitate a near-IR source to power 
the device. 
5.2 KINETIC ENERGY HARVESTING 
Kinetic energy harvesters made their way into commercial devices since 1989 with the Seiko’s 
Kinetic Quartz wristwatch [5.15]. Seiko tested a pacemaker in a dog which harvests 13µJ per 
heartbeat [5.16]. Such devices relied on a rotating or an oscillating weight, whose motion induces a 
voltage on a coil which in turn charges an energy storage device such as a battery or capacitor.  
Miao et. al. demonstrated a MEMS inertial power generator, which utilizes a proof mass attached to 
one plate of a variable capacitor [5.17]. As the device underwent acceleration, the proof mass would 
lag, causing the two plates to separate, which lowered the capacitance and therefore increased the 
voltage. Such a device produced 120nJ for an 11mm x 11mm device [5.17]. In the literature are 
found for values of 60µW in a 1cm2 footprint for piezoelectric harvesters based on aluminum nitride 
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[5.18]. The principle of kinetic harvesting is generally similar in all these cases: a proof mass forms 
an oscillator with the device, and the energy generation mechanism acts as a damper. Work done by 
dampening the oscillation is converted into electricity.  
In the case of the eye, a small energy harvester would have a footprint with a maximum length of 
10mm, and sit on the side of the eye. Taking inspiration from literature, the harvester could be 
modeled as a proof mass, 𝑚, traveling in a tube on the surface of the eye, with a restoring force, 
𝑘∆𝑥, and a viscous damping force, 𝑐∆?̇?. The saccades of the eye occur incredibly rapidly, and reach 
10º-30º of movement at up to 300º/s to 500º/s, or 30Hz to 16Hz, respectively [5.19]. These major 
saccades are infrequent, and therefore are an inconsistent source of power. Microsaccades of up to 
1.2º in amplitude are common and have frequencies between 40Hz-150Hz, with frequency 
decreasing with increasing amplitude [5.20]. Their recurrence makes them are a more reliable source 
of power generation. These microsaccades can be modeled as an oscillatory angular motion, 
𝜃𝑒𝑦𝑒(𝑡) = 𝐴 sin(𝜔𝑡). The difference between the mass position and the eyeball’s rotation 
determines the elongation of the spring, 𝑘(𝑥 − 𝑟𝜃𝑒𝑦𝑒), where 𝑟 is the radius of the eye. Likewise, 
the relative motion of the mass and the eye is described as 𝑐(?̇? − 𝑟?̇?𝑒𝑦𝑒). Putting this together: 
 𝑚?̈? + 𝑐 (?̇? − 𝑟?̇?𝑒𝑦𝑒(𝑡)) +  𝑘(𝑥 − 𝑟𝜃𝑒𝑦𝑒(𝑡)) = 0 (5.5) 
The driving force can be found by separating the ocular motion: 
 𝐹𝑑𝑟𝑖𝑣𝑖𝑛𝑔 = 𝑘𝑟𝜃𝑒𝑦𝑒(𝑡) + 𝑐𝑟?̇?𝑒𝑦𝑒(𝑡) (5.6) 
 𝑚?̈? + 𝑐?̇? +  𝑘𝑥 = 𝑘𝑟𝜃𝑒𝑦𝑒(𝑡) + 𝑐𝑟?̇?𝑒𝑦𝑒(𝑡) (5.7) 
Let 𝑐/𝑚 = 𝛾, and 𝑘/𝑚 = 𝜔0
2, the undamped resonant frequency is: 
 ?̈? + 𝛾?̇? + 𝜔0
2𝑥 = 𝜔0
2𝑟𝜃𝑒𝑦𝑒(𝑡) + 𝛾𝑟?̇?𝑒𝑦𝑒(𝑡) (5.8) 
since ocular motion was defined as 𝜃𝑒𝑦𝑒(𝑡) = 𝐴 sin(𝜔𝑡). The terms for the driving force are defined 
as 𝐹0 = 𝜔0
2𝑟𝐴 and 𝑓1 = 𝛾𝑟𝐴, resulting in: 
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 ?̈? + 𝛾?̇? + 𝜔0
2𝑥 = 𝐹0 sin(𝜔𝑡) + 𝜔𝑓1 cos(𝜔𝑡) (5.9) 
Testing the solution of 𝑥 = 𝐵0 sin(𝜔𝑡) + 𝐵1 cos(𝜔𝑡): 
 
−𝐵0𝜔
2 sin(𝜔𝑡) − 𝐵1𝜔
2 cos(𝜔𝑡) + 𝛾(𝐵0𝜔 cos(𝜔𝑡) − 𝐵1𝜔 sin(𝜔𝑡))
+ 𝜔0
2(𝐵0 sin(𝜔𝑡) + 𝐵1 cos(𝜔𝑡)) = 𝐹0 sin(𝜔𝑡) + 𝜔𝑓1 cos(𝜔𝑡) 
(5.10) 
Separating all sine and cosine terms, as that is the only solution for which the equation is true for all 
values: 
 −𝐵0𝜔
2 sin(𝜔𝑡) − 𝐵1𝛾𝜔 sin(𝜔𝑡) + 𝐵0𝜔0
2 sin(𝜔𝑡) = 𝐹0 sin(𝜔𝑡) (5.11) 
 −𝐵1𝜔
2 cos(𝜔𝑡) + 𝐵0𝛾𝜔 cos(𝜔𝑡) + 𝐵1𝜔0
2 cos(𝜔𝑡) = 𝜔𝑓1 cos(𝜔𝑡) (5.12) 
The solution is found to be: 
 𝑥(𝑡) =
𝛾𝜔2𝑓1 + (𝜔0
2 − 𝜔2)𝐹0
(𝜔0
2 − 𝜔2)2 + 𝛾2𝜔2
sin(𝜔𝑡) +
(𝜔0
2 − 𝜔2)𝑓1 − 𝛾𝐹0
(𝜔0
2 − 𝜔2)2 + 𝛾2𝜔2
𝜔 cos(𝜔𝑡) (5.13) 
The force exerted by the eye is given by: 
 𝐹𝑑𝑟𝑖𝑣𝑖𝑛𝑔 = 𝐹0 sin(𝜔𝑡) + 𝑓1𝜔 cos(𝜔𝑡) (5.14) 
The device will reach steady state over time, and instantaneous power absorbed by the device from 
the eye is given by the force the eye is driving into the device: 
 𝑃𝑖𝑛𝑠𝑡 = 𝐹?̇? = 𝑚 ∗ (𝐹0 sin(𝜔𝑡) + 𝑓1𝜔 cos(𝜔𝑡))?̇? (5.15) 
Averaging over a cycle, (0,2𝜋/𝜔) gives a more useful power equation: 
 𝑃𝑎𝑣𝑔 =
𝑚𝜔
2𝜋
∫ 𝐹?̇?𝑑𝑡
2𝜋/𝜔
0
=
𝑚𝜔
2𝜋
∫ (𝐹0 sin(𝜔𝑡) + 𝑓1𝜔 cos(𝜔𝑡))?̇?𝑑𝑡
2𝜋/𝜔
0
 (5.16) 
which solves to: 
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 𝑃𝑎𝑣𝑔 =
𝛾𝜔2
2
(
𝜔2𝑓1
2 + 𝐹0
2
(𝜔0
2 − 𝜔2)2 + 𝛾2𝜔2
) (5.17) 
Plugging in 𝐹0 = 𝜔0
2𝑟𝐴 and 𝑓1 = 𝛾𝑟𝐴: 
 𝑃𝑎𝑣𝑔 =
𝛾𝑚𝜔2𝑟2𝐴2
2
(
𝜔2𝛾2 + 𝜔0
4
(𝜔0
2 − 𝜔2)2 + 𝛾2𝜔2
) (5.18) 
Power is maximized when the harvester’s resonant frequency matches the driving frequency, 𝜔0 =
𝜔, resulting in the simplified expression:  
 𝑃𝑎𝑣𝑔 =
𝛾𝑚𝜔0
2𝑟2𝐴2
2
(
𝛾2 + 𝜔0
2
𝛾2
) (5.19) 
 Table 5.2: Parameters for estimation of energy extracted by a kinetic energy harvester. 
PARAMETER VALUE [UNIT] 
SACCADE AMPLITUDE (𝑨) [5.20] 1.2ᵒ/2 = 0.6ᵒ 
SACCADE DRIVING FREQUENCY (𝝎𝟎) [5.20] 40[Hz] 
STAINLESS STEEL PROOF MASS (10MM × 5MM × 2MM) 0.77[g] 
RADIUS OF THE EYE 12[mm] 
DAMPING FACTOR 6.31854[s−1] 
 
 
Figure 5.5: Amplitude for a proof mass. Plot of 𝑥(𝑡), equation (5.13), when driven at resonance. 
This sweeps the amplitude of the motion of the proof mass over all values of 𝛾. The amplitude is 
less than 5mm when 𝛾 ≥ 6.31854s−1. 
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Figure 5.6: Average power over a cycle for different damping factors. This plots the average 
power, equation (5.19), versus the damping factor under resonance, 𝜔 = 𝜔0, with the eye having 
a 40Hz, 0.6º microsaccade. For low damping factors, the power added by the eye in steady state 
increases a the damping factor decreases, therefore the maximum that satisfies the amplitude 
requirement of |𝑥(𝑡)| ≤ 5mm is 𝛾 = 6.31854s−1. The time average power of 3.84mW is 
associated with that damping factor. 
 
The parameters are listed in Table 5.2. The mass, 0.77g, is assumed to be a stainless steel weight 
10mm × 5mm × 2mm, to keep the entire device footprint within 10mm × 10mm × 3mm. The 
damping factor, 𝛾 = 𝑐/𝑚, is determined from the value which maximizes 𝑃𝑎𝑣𝑔, while keeping the 
amplitude below 5mm (1/2 the total travel distance), since anything above that would be wasted by 
slamming into the limits of the device (Figure 5.5). Damping values of 𝛾 ≥ 6.31854s−1, keep the 
amplitude below 5mm. Figure 5.6 plots the average power at resonance, equation (5.19), over all 
values of 𝛾. For low damping factors, power increases as the damping factor is reduced. Therefore, 
the maximum that satisfies the amplitude requirement is 𝛾 = 6.31854s−1, which yields an average 
power of 3.84mW over a cycle. This value assumes complete conversion of energy from mechanical 
to electrical. Power supply conversion losses boosting the voltage to a suitable 2.5V normally would 
range in the range of 5%-10%. Electrical energy harvesting techniques, such as piezoelectricity or a 
linear alternator, have power losses as well. Furthermore, such a design expects the entirety of the 
damping force to be energy harvesting. In actuality, mechanical losses would account for a 
substantial fraction of the “damping” force calculated here; meaning 𝛾 = 𝛾𝑙𝑜𝑠𝑠 + 𝛾𝑒. Other energy 
harvesting devices for biomedical applications from literature have 0.778mW/cm3 (35Hz) to 
8.24mW/cm3 (149.3Hz) for electromagnetic energy harvesting devices, and 0.76µW/cm3 to 
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6mW/cm3 for piezoelectric devices; resulting in a maximum of 2.472mW/cm3 for a 150Hz operating 
frequency, or 1.8mW at 50Hz [5.2]. There is little margin for such a device, and it would only achieve 
this power during the REM portion of the sleep cycle, and during saccades. The time averaged power 
harvested is likely to be much lower. For these reasons, though enticing for its power autonomy, 
kinetic energy harvesting was not pursued as power source for the oxygenerator. 
5.3 INDUCTIVE POWER COUPLING 
Inductive power coupling is the most promising approach. While it does not offer the same power 
autonomy as kinetic energy harvesting or solar cells, it works well in a rabbit eye, can penetrate an 
eye lid, and provides a high power density for the implant size. Furthermore, other devices, such as 
SecondSight’s Argus II, have demonstrated the technology is viable in humans.  
The basic concept of inductively coupled power transfer is to provide a radio frequency signal from 
an oscillator to a primary coil. That primary coil induces an electromotive force on a secondary coil, 
and the received power is rectified to DC.  
A sleep mask could contain the primary coil and driver circuitry, and power the oxygenator 
throughout the night when oxygen demand is highest and the disease is believed to progress 
(CHAPTER 1 and CHAPTER 2). During the day, the sleep mask can easily be recharged. The 
engineering of such a sleep mask is rather simple, is not tackled here, nor such mask was tried in 
humans. 
Resonant inductive power coupling relies on the primary and secondary side to be in resonance with 
each other (Figure 5.7). The signal is then rectified, and utilized to power electronics, which can be 
thought of as an equivalent load, 𝑅. 
 
Figure 5.7: Concept of the inductive power transfer circuit. 
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5.3.1 THEORY 
The primary side consists of an RF generator, whose signal is passed through a power amplifier 
before going to the resonant primary coil, usually configured as an LC tank (Figure 5.8). Mutual 
inductance, 𝑀, between the primary and secondary coils induces the electromotive force onto the 
secondary coil. The mutual inductance can be written as: 
 𝑀 = 𝑘√𝐿1𝐿2 (5.20) 
where 𝑘, is the coupling coefficient, and 𝐿1 and 𝐿2 are the primary and secondary coil inductances, 
respectively. The primary coil experiences an impedance, 𝑍𝑚, from the presence of the secondary, 
which in the frequency domain can be written as:  
 𝑉1 = 𝑍1𝐼1 + 𝑍𝑚𝐼2 (5.21) 
where 𝑍1 represents the primary side without the secondary coil. 
 
Figure 5.8: Circuits for inductively coupled power transfer. (A) Complete circuit. The 
resistances, 𝑅1 and 𝑅2, represent the resistances of the inductors, 𝐿1 and 𝐿2, while 𝐶1 and 𝐶2 are 
the coupling capacitors.  (B) The rectifying circuit and load, 𝑅𝐿𝑜𝑎𝑑 can be combined into an 
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approximate A.C. load 𝑅𝐿. (C) The parallel capacitance and parallel resistance form an equivalent 
circuit to (B). 
 
The secondary side contains an LC tank circuit with a connected load, 𝑅 = 𝑅𝐿. There is no external 
driving voltage, 𝑉2 = 0, since all power is generated from mutual inductance with the primary side: 
 𝑍2𝐼2 − 𝑍𝑚𝐼1 = 0 (5.22) 
where the secondary side impedance, 𝑍2. Mutual inductance generates an electromotive force from 
the current of the partner coil, 𝑣 = 𝑀𝑑𝐼/𝑑𝑡. When transformed into the frequency domain, 𝑉 =
𝑖𝜔𝑀𝐼, the impedance from the mutual inductance is found to be 𝑍𝑚 = 𝑉/𝐼 = 𝑖𝜔𝑀. Using this in 
equation (5.22), one finds a relationship between 𝐼1 and 𝐼2: 
 𝐼2 = 𝑍𝑚2𝐼1/𝑍2 = 𝑖𝜔𝑀𝐼1/𝑍2 (5.23) 
Combining with equation (5.21), 
 𝑉1
𝐼1
= 𝑍1 + 𝜔
2𝑀2/𝑍2 
(5.24) 
the impedance reflected on the primary side is found to be 𝑍𝑟𝑒𝑓𝑙 = 𝜔
2𝑀2/𝑍2. Before proceeding, 
however, the secondary side must be dealt with. Assuming that the voltage drop from the diode is 
minor, the rectifying circuit and load can be replaced with an A.C. load, 𝑅𝐿 (Figure 5.8b). A purely 
series circuit is easier to deal with, and so the parallel capacitance, 𝐶2, and resistance, 𝑅𝐿, of the 
secondary side can be converted to a series resistance, 𝑅𝐿𝑆 and capacitance, 𝐶2𝑆: 
 
𝑅𝐿𝑆 +
1
𝑖𝜔𝐶2𝑆
= 𝑅𝐿||
1
𝑖𝜔𝐶2
 (5.25) 
 
𝑅𝐿𝑆 +
1
𝑖𝜔𝐶2𝑆
=
𝑅𝐿
1 + 𝜔2𝑅𝐿
2𝐶2
2 −
𝑖𝜔𝑅𝐿
2𝐶2
1 + 𝜔2𝑅𝐿
2𝐶2
2 (5.26) 
So the series resistance becomes: 
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𝑅𝐿𝑆 =
𝑅𝐿
1 + 𝜔2𝑅𝐿
2𝐶2
2 (5.27) 
The series capacitance can be further solved to be: 
 1
𝐶2𝑆
=
𝜔2𝑅𝐿
2𝐶2
1 + 𝜔2𝑅𝐿
2𝐶2
2 (5.28) 
 
𝐶2𝑆 =
1 + 𝜔2𝑅𝐿
2𝐶2
2
𝜔2𝑅𝐿
2𝐶2
 (5.29) 
The series capacitance is dependent on the load. If the load is well defined and in a range such that 
1 ≪ 𝜔2𝑅𝐿
2𝐶2
2, the series capacitance approaches the value of the parallel capacitance, 𝐶2 ≈ 𝐶2𝑆. The 
secondary circuit will have values in the range of 𝜔 ≈ 6𝜋[MHz], 𝐶2 ≈ 1[nF], and 𝑅𝐿 ≈ 1[kΩ], such 
that  
 𝜔2𝑅𝐿
2𝐶2
2 ≈ 355 ≫ 1 (5.30) 
Therefore, the resonant frequency for the series capacitance, 𝜔0 = 1/√𝐿2𝐶2𝑆, is approximately 
equal to that of the original,  𝜔0 = 1/√𝐿2𝐶2 ≈ 1/√𝐿2𝐶2𝑆. The same estimation results in an 
approximation of the series load to be, 𝑅𝐿𝑆 ≈ 1/𝜔
2𝑅𝐿𝐶2
2 = 𝐿2/𝑅𝐿𝐶2. The series resistance, 𝑅𝐿𝑆, 
and capacitance, 𝐶𝑆, determine the impedance of the secondary circuit: 
 
𝑍2 = 𝑅2 + 𝑅𝐿𝑆 + 𝑖𝜔𝐿2 +
1
𝑖𝜔𝐶2𝑆
 (5.31) 
 
𝑍2 = 𝑅2 + 𝑅𝐿𝑆 +
1 − 𝜔2𝐿2𝐶2𝑆
𝑖𝜔𝐶2𝑆
 (5.32) 
At resonance, 𝜔 = 𝜔0 the impedance of the secondary becomes: 
 𝑍2 = 𝑅2 + 𝑅𝐿𝑆 (5.33) 
Meaning that at resonance, assuming the diode voltage drop, 𝑉𝐷, is small compared to the induced 
voltage,  the efficiency of power conversion is given by: 
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 𝜂2−𝑙𝑜𝑎𝑑 =
𝑅𝐿
𝑅2 + 𝑅𝐿𝑆
 (5.34) 
 𝜂2−𝑙𝑜𝑎𝑑 =
𝑅𝐿
𝑅2 + 𝐿2/𝑅𝐿𝐶2
 (5.35) 
The input power into the secondary side can be found by finding the power input into the reflected 
impedance of the secondary side from the primary side. The configuration in figure Figure 5.8a is 
similar to a parallel RLC circuit, meaning the impedance increases at resonance (Figure 5.9). 
Driving such a circuit with a voltage amplifier would result in a reduction in the current passing 
through the inductor, and therefore a reduction in the resultant magnetic field. A current amplifier, 
on the other hand, would result in a constant amplitude through the inductor, and therefore such a 
circuit (Figure 5.10) was chosen. 
 
Figure 5.9: Plot of the total impedance of the primary without the secondary. Plot of the total 
impedance of the primary when there is no coupling with the secondary, 𝑀(𝑘 = 0) = 0. Note that 
at resonance, the impedance rises sharply. Such a circuit benefits from a current A.C. source to 
maximize power delivery. 
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Figure 5.10: LT1206 amplifier. (Top) LT1206 schematic. (Bottom) LT1206 diagram (PCB). 
 
To determine the steady state current through the inductor and the reflected mutual inductance, the 
voltage, 𝑉1 = 𝑍1𝐼, and impedance of the inductor’s branch, 𝑍𝐿 = 𝑖𝜔𝐿1 + 𝑅1 + 𝜔
2𝑀2/𝑍2, are 
combined: 
 
𝐼1 =
𝑉1
𝑍𝐿
= 𝐼
𝑍1
𝑍𝐿
 (5.36) 
The impedance, 𝑍1, is calculated to be: 
 
𝑍1 =
1
𝑖𝜔𝐶1
||𝑍𝐿 =
𝑍𝐿 (
1
𝑖𝜔𝐶1
)
(
1
𝑖𝜔𝐶1
) + 𝑍𝐿
=
𝑍𝐿
1 + 𝑖𝜔𝐶1𝑍𝐿
 (5.37) 
The ratio, 𝑍1/𝑍𝐿, is paramount to finding the current through the inductor, 𝐼1, therefore equation 
(5.37) is used to find: 
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 𝑍1
𝑍𝐿
=
1
(1 − 𝜔2𝐿1𝐶1) + 𝑖𝜔𝐶1(𝑅1 + 𝜔2𝑀2/𝑍2)
 (5.38) 
Which at the parallel resonance, 𝜔0𝑃 = 1/√𝐿1𝐶1, increases to: 
 𝑍1
𝑍𝐿
=
𝑍2
𝑖𝜔0(𝑅1𝑍2𝐶1 +𝑀2/𝐿1)
 (5.39) 
The magnitude of the current is, therefore, using equation (5.33), calculated: 
 
|𝐼1| = |𝐼| |
𝑍1
𝑍𝐿
| =
|𝐼|
𝜔0
(
𝑅2 + 𝑅𝐿𝑆
𝑅1(𝑅2 + 𝑅𝐿𝑆)𝐶1 +𝑀2/𝐿1
) (5.40) 
The power onto the secondary side from equation (5.22) at resonance is: 
 
𝑃2 = 𝜔0𝑀|𝐼1|
2 = 𝑀(
𝑅2 + 𝑅𝐿𝑆
𝑅1(𝑅2 + 𝑅𝐿𝑆)𝐶1 +𝑀2/𝐿1
)
2
|𝐼|2 (5.41) 
whichm given that 𝑀 = 𝑘√𝐿1𝐿2, is: 
 
𝑃2 = 𝜔0𝑀|𝐼1|
2 = |𝑘|√𝐿1𝐿2 (
𝑅2 + 𝑅𝐿𝑆
𝑅1(𝑅2 + 𝑅𝐿𝑆)𝐶1 + 𝑘2𝐿2
)
2
|𝐼|2 (5.42) 
Therefore the power available to the load is given by the product of the power incident on the 
secondary from the primary side, equation (5.41), and the efficiency of the power conversion to the 
load, equation (5.34): 
 
𝑃𝐿𝑜𝑎𝑑 = 𝑃2𝜂2−𝑙𝑜𝑎𝑑 = |𝑘|√𝐿1𝐿2 (
𝑅2 + 𝑅𝐿𝑆
𝑅1(𝑅2 + 𝑅𝐿𝑆)𝐶1 + 𝑘2𝐿2
)
2
(
𝑅𝐿
𝑅2 + 𝑅𝐿𝑆
) |𝐼|2 (5.43) 
 
𝑃𝐿𝑜𝑎𝑑 = |𝑘|√𝐿1𝐿2
𝑅𝐿(𝑅2 + 𝑅𝐿𝑆)
(𝑅1(𝑅2 + 𝑅𝐿𝑆)𝐶1 + 𝑘2𝐿2)2
|𝐼|2 (5.44) 
This implies that the power into the secondary side is proportional to the square of the current. Given 
previous estimates, one can write 𝑅2𝑅𝐿𝐶2 ≪ 𝐿2 for the approximate values chosen. This means an 
approximation of the power available to the load can be approximated as: 
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𝑃𝐿𝑜𝑎𝑑 ≈
|𝑘||𝐼|2√𝐿1𝐿2
𝐿2𝐶2(𝑅1𝐶1 + 𝑘2𝑅𝐿𝐶2)2
=
|𝑘||𝐼|2
(𝑅1𝐶1 + 𝑘2𝑅𝐿𝐶2)2√𝐶1𝐶2
 (5.45) 
Note that decreasing 𝑅𝐿𝐶2 compared to 𝑅1𝐶1 will increase the power on the secondary side. Since 
𝑅1 and 𝑅𝐿 are difficult to modify, decreasing 𝐶2 compared to 𝐶1 will increase the transmitted power. 
However, as the frequency is set, the inductor must increase in size proportional to the decrease in 
capacitance. Therefore, as the secondary inductor increases in size compared to the primary inductor, 
the power transfer efficiency improves.  
 
Figure 5.11: Primary side device. To shift the impedance at resonance to |𝑍1| = 50[Ω], a series 
capacitor was added to the circuit. Circuit was built on a PCB with solder points for different 
capacitors, to find the optimum. Tape helps protect the fragile Litz wires. 
 
Actually, the current amplifier (Figure 5.10) provides maximum power when impedance was 
matched to 50Ω. A second series capacitor is added to the circuit to shift the impedance at resonance 
(Figure 5.11). The addition of the series capacitor gives a circuit with a series resonance and parallel 
resonance, where the impedance reaches a minimum at approximately, 𝜔0,𝑆 ≈ 1/√𝐿1𝐶1𝑆, and a 
maximum at approximately, 𝜔0,𝑃 ≈ 1/√𝐿1𝐶1𝑃 (Figure 5.12). Such a circuit can be modeled as: 
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𝑍1 =
1
𝑖𝜔𝐶1𝑆
+ (
1
𝑖𝜔𝐶1𝑃
|| (𝑖𝜔𝐿1 + 𝑅1 +
𝜔2𝑀2
𝑍2
)) (5.46) 
 
Figure 5.12: Primary side impedance with a series capacitor. Using the coil parameters in 
Table 5.3 
 
A 5 turn, 38mm diameter solenoid coil was wound from 40/44 Litz wire (40 insulated strands of 
44AWG copper wire) to reduce impedance due to the skin effect at 3MHz. Using the HP 4192A, the 
inductance was measured to be 4.527µH at the circuit’s operating frequency of 2.94MHz (Table 
5.3).  The capacitors 𝐶1𝑃 (0.5875nF) and 𝐶1𝑆  (81.6pF) were chosen to achieve 50Ω at approximately 
3MHz. Their values were also measured using the HP 4192A (Table 5.3). The impedance of the 
assembled circuit was measured over a range of frequencies and plotted into Figure 5.13. Note the 
model matches the data closely. 
Table 5.3: Components in primary coil measured with the HP 4192A 
PART VALUE SERIES RESISTANCE 
COIL 4.524µH 0.86Ω 
SERIES CAPACITOR 81.6pF 1 Ω 
PARALLEL CAPACITOR 0.5875nF 1 Ω 
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Figure 5.13: Measured impedance and phase for primary circuit versus the calculated curve 
from measuring the component values. 
 
Given that the load |𝑍1| ≈ 50[Ω], the transmitted power onto the secondary side can be calculated. 
The magnitude of the current is therefore: 
 
|𝐼1| = |
𝑍1
𝑍𝐿
| |𝐼| =
|𝑍1||𝑍2||𝐼|
√𝜔2𝐿1
2𝑍2
2 + (𝑅1𝑍2 + 𝜔2𝑀2)2
 (5.47) 
This current into the primary coil (inductor) can be used to find the power into the secondary side, 
as per equation (5.40): 
 
𝑃2 =
𝜔|𝑘||𝑍1|
2|𝑍2|
2|𝐼|2√𝐿1𝐿2
𝜔2𝐿1
2𝑍2
2 + (𝑅1𝑍2 + 𝜔2𝑘2𝐿1𝐿2)2
 (5.48) 
If the secondary side is driven at its resonance, the power available to the load is then given by: 
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𝑃𝐿𝑜𝑎𝑑 = 𝑃2𝜂2−𝐿𝑜𝑎𝑑 =
𝜔0|𝑘||𝑍1|
2𝑅𝐿(𝑅2 + 𝑅𝐿𝑆)|𝐼|
2√𝐿1𝐿2
𝜔0
2𝐿1
2(𝑅2 + 𝑅𝐿𝑆)2 + (𝑅1(𝑅2 + 𝑅𝐿𝑆) + 𝜔02𝑘2𝐿1𝐿2)2
 (5.49) 
The power in the primary is based on the current into the circuit, and the impedance, 𝑃1 = |𝑍1||𝐼|
2, 
which gives a total efficiency of: 
 
𝜂 =
𝑃𝐿𝑜𝑎𝑑
𝑃1
=
𝜔0|𝑘||𝑍1|𝑅𝐿(𝑅2 + 𝑅𝐿𝑆)√𝐿1𝐿2
𝜔0
2𝐿1
2(𝑅2 + 𝑅𝐿𝑆)2 + (𝑅1(𝑅2 + 𝑅𝐿𝑆) + 𝜔02𝑘2𝐿1𝐿2)2
 (5.50) 
This is a useful result, as the coupling constant, 𝑘, can be determined by measuring the voltage and 
current on the load and input into the primary circuit. Since all other parameters have been measured, 
the equation can be numerically solved for the coupling constant. As the coupling constant and, 
therefore, efficiency depend on the separation and angle between the coils, this can be plotted with 
respect to the separation between the two centers. 
5.3.2 SECONDARY COIL FABRICATION 
This section will discuss coil manufacturing methods. The secondary coil will be implanted under 
the conjunctiva. Therefore, it must be biocompatible and resist degradation so as to function over the 
lifetime of the oxygenerator. For animal trials, that period maybe measured in months, but a human 
implant would require years of service. The coil was therefore built out of solid core gold wire. To 
reduce the size of the coil, the cross section would ideally be small, but power losses in the resistance 
of the coil should be minimized. The skin depth at 3MHz is calculated to be 𝛿 = √2𝜌/(𝜔𝜇𝑟𝜇0) =
44.6μm [5.21]. Since the A.C. current density at any given depth is an exponential equation, 𝐽 =
𝐽𝑠𝑒
−(1+𝑖)𝑑/𝛿, the first 𝛿 in depth would contain 63% of the charge. Therefore, a wire with a radius 
equal to the skin depth would have only 1.58× the resistance of bulk material at 3MHz; A-M Systems 
Catalog #75100 PFA (perfluoroalkoxy alkane) coated wire with a gold wire diameter of 76.2µm is 
suitable.  
Coil size and design depends on the entire device. To batch out devices, coil properties would need 
to be repeatable. The manufacturing processes are discuess below. 
122 
 
5.3.2.1 ETCHED SILICON MOLDS 
Early oxygenerator utilized a flat coil laid on top of a liquid reservoir (Figure 5.14). In this 
configuration, the injections occurred in the plane of the reservoir. The coil was 2 layers deep. To 
create the coil, a silicon mold was etched using the Deep Reactive Ion Etcher (DRIE). The design 
spiraled inward 8 times starting with a diameter of 8mm and ending in a diameter of 5.6mm with 
0.15mm trenches and 0.15mm grooves. The silicone molds were broken off of the silicon wafer and 
coated in Parylene-C. 
The coil was formed by pressing the PFA-coated gold wire into the mold grooves. NuSil MED4-
4210 silicone was then poured over the mold, degassed and partially cured in the oven. The spiral 
was then peeled from the mold, and the second half of the coil was created by repeating the process. 
With the second spiral peeled from the mold, both spirals were loosely held together by the gold 
wire. This wire was tucked into the middle as the two spirals were bonded together with more 
silicone. The mold was then ready to be soldered to the coupling capacitor, 𝐶2, the rectifying diode, 
and the smoothing capacitor, 𝐶𝑟. The circuit, Figure 5.14, is 9mm in diameter, and 1.5mm tall. The 
coil was bonded with silicone onto the top of the reservoir, and the platinum electrodes were soldered 
onto the smoothing capacitor. The whole reservoir is then coated in Parylene-C to protect the 
electronics from water ingress, and reduce oxygen loss at the reservoir. 
This approach is slow, and had a low yield. Wires frequently broke during the peeling process. Out 
of a batch of five coils, only two would be useable when they needed to be soldered. 
 
Figure 5.14: DRIE etched silicon mold for coil. The silicon mold is a 10mmx10mm square with 
the pattern for a flat coil (left). The right image shots the final electronics next to a penny (right). 
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5.3.2.2 TWO PART SPINDLE 
A more traditional approach replaced the etched mold, with greater success. An aluminum spindle 
was machined in two parts with the desired inner diameter (8mm) and thickness (0.3mm) (Figure 
5.15). The surface was polished to a mirror finish to reduce the adhesion of cured silicone to the 
mold. To create a coil, firstly, NuSiL MED4-4210 silicone was painted onto the surface of the mold 
where the coil was to be wound. Then, wire was taped onto the side of the spindle, and wound 10 
times. The spindle was then allowed to partially cure in the oven for 5 minutes at 100⁰C such that 
the silicone would no longer be tacky. The spindle was then submerged in isopropyl alcohol to swell 
the silicone, and the screw holding both halves of the spindle was removed. The spindle was carefully 
separated, leaving the coil and its silicone flashing on one side of the aluminum cylinder (Figure 
5.15). The excess silicone was removed with a razor blade. Finally, the coil was removed from the 
aluminum. The 3 components were then soldered and adhered with further silicone to the inner side 
of the coil. The remaining opening was filled with silicone. The result is a thin disk containing the 
electronics. The package was glued using silicone to the reservoir. Such a design was relatively 
successful and was used for the oxygenerator versions 3-4 (see section 6.4). 
 
Figure 5.15: An aluminum spindle (left image) was turned on a lathe to allow the gold coil 
(middle image) to be 2 wires deep. The large open space in the center and flat design means the 
device (right image) can be filled up from the sides and the chamber can be seen clearly from 
above, which is used to confirm function after implant. Note that some turns are separate from the 
rest due to the difficulty of maintain consistent tension on the gold wire. 
 
5.3.2.3 AUTOMATED COIL WINDER 
The reliability of manufacturing the coil was further improved by automating the winding process 
(Figure 5.16). Using a 200-step stepper motor, the spindle could be turned an arbitrary number of 
rotations with 1.8⁰ accuracy leading to highly repeatable coils. The process of creating the coils 
followed the earlier approach. The stepper was connected to an EasyStepper driver board, with the 
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A3967 microstepping driver, which was controlled by an Arduino. Once the stepper wound the coil 
the appropriate number of turns, the spindle was detached and placed in the oven to partially cure. 
The coil would then be removed and integrated as before with the remaining electronics. This 
approach was used for coils in oxygenerator versions 5-8 (see section 6.4). 
 
Figure 5.16: Automatic coil winder. (Left) Coil winder device. (Right) Active device electronics, 
V5. Coil surrounds the outside of the device. The coil is far more consistent in shape. 
 
5.3.3 QUANTIFYING THE COILS 
Here, the coil used in the oxygenator version 8 was placed on a linear track from Thor Labs, which 
is bolted onto an optical bench. Both the primary and secondary coils were held by plastic fixtures 
away from the table and track. The coils were zeroed so that the primary and secondary coils’ nearest 
face were on the same plane. The secondary coil was centered onto the primary coil. 
 
Figure 5.17: 20 Turn coil with 5.4mm in diameter. The circuit is as shown in the diagram on 
Figure 5.8a 
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Figure 5.18: Coil test setup. Complete test diagram on top. Actual setup below. Angles and 
distance are both swept. 𝑉𝑅𝑀𝑆 on either side of the sense resistor, as well as the current and voltage 
through the load resistor, 𝑅𝐿𝑜𝑎𝑑, are also measured. 
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The final version of the secondary coil was a 20 turn device using A-M Systems Catalog #75100 
PFA-coated gold coil with 5.4mm outer and 2.5mm inner diameter, and 0.94mm thickness (Figure 
5.17). A 1600pF coupling capacitor (GRM188SC1H162JA01D) was chosen to maximize power 
delivered at 2.94MHz. A shottky diode and a 1µF smoothing capacitor formed the rectifying circuit. 
Two wire leads outputted the rectified D.C. signal to be measured by HP 34401A multimeters 
(Figure 5.18). A variable resistor box set the load across the secondary side’s output. 
The primary side was driven by an Agilent 33120A waveform generator at 2.94MHz and 2.8Vpp, 
which was fed into a current amplifier circuit based on the LT1206 IC (Figure 5.10). The current 
amplifier provides a maximum power of 250mA at 50Ω. The amplifier was supplied by a 30V D.C. 
power supply. The output was sent through a 1.061Ω (actual) non-inductive sense resistor (MP91S-
1.00-1%) before going to the 5-turn primary (Figure 5.11). The waveforms on both sides of the 
sense resistor were connected to a Tektronix TBS 1072B oscilloscope, which measured the root 
mean squared signal of both sides of the resistor (Figure 5.18). The system swept all combinations 
of 0mm to 70mm, and 0⁰ to 45⁰. The results are presented below in Figure 5.19, Figure 5.20, Figure 
5.21, Figure 5.22, Figure 5.23, and Figure 5.24. 
 
Figure 5.19: Polar plot of secondary side rectified voltage. Mirrored along the 0⁰ line. 
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Figure 5.20: Rectified secondary coil voltage at angle of 0º.  Secondary coil was moved away 
from primary 1mm at a time. Both voltage and current were measured together. The loads in the 
index refer to the load resistor from the resistor box used. 
 
 
Figure 5.21: Rectified coil voltage with 1kΩ load. The 0mm distance for any given angle was 
chosen as the point where the secondary coil touched the plane of primary coil. This was 
accomplished by placing a paper against the primary and finding the point where the secondary 
coil touched the paper. This offset was then subtracted from the value on the linear rail. 
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Figure 5.22: Received power on secondary coil with 1kΩ load. 
 
Figure 5.23: Power efficiency at 0º. The primary side root mean square voltage on either side of 
the sense resistor was measured using an oscilloscope. The power in the secondary was then 
divided by the power in the primary to get the efficiency. Propagation of errors was performed. 
Measurements of the primary side voltages were far noisier than the secondary and dominates the 
errors in the efficiency sweep. 
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Figure 5.24: Power efficiency with 1kΩ load. Similar to Figure 5.23, but here the sweep depends 
on voltage. 
 
With a 1kΩ load on the secondary, the power transfer efficiency peaks at over 12%. Even at 25mm 
the efficiency remains around 1%. The primary and secondary coil coupling was sufficient to drive 
electrolysis at up to 25mm away. 
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CHAPTER 6 – FABRICATION 
Fabrication techniques and materials used to make the devises are discussed, along with the different 
versions of the oxygenator. 
6.1 BIOCOMPATIBLE MATERIALS 
6.1.1 SILICONE 
Silicones are a series of siloxane backed polymers with a functional group attached. They are 
elastomers with good heat resistance, and low chemical reactivity. Silicones begin as a highly 
viscous liquid, which cures into a solid. There are three methods to polymerize silicone: platinum-
based, condensation, and peroxide cures. The acetoxy cure system is common in silicone caulking. 
Most medical grade silicones are based on a platinum cure, since the process produces no byproducts. 
Platinum cure silicones are two component silicones: a part A that contains silicones with vinyl 
groups and a platinum catalyst, and a part B with similar vinyl grouped silicones and a hydrogen 
cross-linker [6.1]. The process is an addition chemistry, where the cross-linker and vinyl groups 
result in an ethylene bridge (double carbon bond). The resultant silicone is biocompatible because 
the process does not produce byproducts and pure silicone is relatively chemically inert. Silicone has 
a high elasticity and a low Young’s modulus, which makes silicone a good material for medical 
applications. The compliance of silicone approaches that of the human body better than harder 
materials such as steel or glass. For these reason, silicone has made its way into all sorts of medical 
implants, where mechanical compliance is important. Cochlear implant uses silicone to sheath its 
platinum electrodes, cables and transmitter coil [6.2]. Silicones also have high gas and water vapor 
permeability, making them ideal for the semipermeable membrane used in this thesis.  
Processing silicone is a well understood process with soft lithography of poly(dimethylsiloxane) 
(also called PDMS) being a common process in microfluidics. The techniques involve pouring and 
curing PDMS over a mold (pattern) and peeling it afterwards. The PDMS part can then be bonded 
to another PDMS part or to a substrate. Bonding to itself is generally done by using different mixtures 
of part A and part B, where each piece would have an excess of a different part. PDMS can also be 
bonded to substrates like glass using oxygen plasma to make both the glass and the PDMS 
hydrophilic. Manufacturing techniques for silicone parts will be discussed further below. 
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Silicone NuSil MED4-4210 was predominantly used in the devices, as it is considered a medical 
grade material and was used successfully in animal implants. These facts reduced biocompatibility 
concerns in the experiments with rabbits. 
Manufacturing techniques for silicone parts will be discussed further below. 
6.1.2 PARYLENE 
Parylene is a name for polymer called poly(p-xylylene). There are several different Parylene 
polymers (Figure 6.1), all of which contain a phenyl (6 carbon) ring connected to a carbon atom as 
the monomer. Each Parylene type contains different elements attached to the basic carbon structure. 
 
Figure 6.1: Poly(p-xylylene) chemical structures. Parylene-C is the most commonly deposited 
polymer with low gas and moisture impermeability. Parylene D has better barrier properties but 
general has worse film uniformity. Parylene Ht is a fluorinated parylene with good high 
temperature properties. Parylene A and AM contain an amine group making them slightly 
hydrophilic and more reactive than other parylenes. 
 
Parylene is applied to substances by chemical vapor deposition, in which the Parylene dimer is 
decomposed into a monomer in a Pyrolysis tube at high temperature (690ºC for Parylene-C) and 
then deposited onto a substrate downstream. The polymer is coated at vacuum in specialized CVD 
machines, such as the ubiquitous Specialty Coating SystemsTM PDS2010, and the Specialty Coating 
SystemsTM PDS2035. These machines have 4 parts: a vaporizer chamber, where the dimer 
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sublimates at temperatures between 120ºC and 180ºC, a pyrolysis tube, where the dimer is cleaved 
into a polymer, a deposition chamber, where the monomer polymerizes at ambient temperature onto 
the target device, and a cold trap that collects any remaining monomer to protect the downstream 
mechanical vacuum pump (Figure 6.2).  
 
Figure 6.2: Parylene deposition process; reprinted from PDS 2010 Owner’s Manual.[6.3]. 
 
This vacuum process conformally coats the polymer onto surfaces with very few, if any, defects. 
The resultant defect-free polymer coat is used as a barrier material for electronics due to its low gas 
permeability (0.042Ba for O2 for Parylene-C) and low moisture (WTVR 0.08g·mm·m
-2·day-1) 
permeability [6.4], [6.5], [6.6].  The polymer is very chemically inert and biocompatible (USP rating 
class VI [6.7]). These properties make the material ideal for medical use and for the oxygenator. 
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6.1.3 USE OF PARYLENE AND SILICONE IN A DEVICE 
In the devices, Parylene was used to protect electronics from water ingress and to restrict oxygen 
permeation. Silicone was used for the semipermeable membrane to allow for transport of oxygen 
while leaving the salts in solution. Figure 6.3 shows that a 5µm Parylene-C coat on one side of a 
diffusor greatly reduces the oxygen readings on that side.  
 
Figure 6.3: Oxygen tension on opposite sides of a device coated with parylene on one side. 
5µm Parylene-C coated on side 2 of the device. Side 1 is only comprised of silicone. An oxygen 
probe was placed against the device in anoxic deionized water. 
 
However, Parylene is difficult to bond to given its chemical inertness. The fact that silicone does not 
bond to Parylene allows to use it as a mold release on micropatterned molds for silicone. However, 
when Parylene is deposited on silicone, it forms a strong bond (see below). It is reported that 
Parylene-C penetrates several microns into PDMS, with a peel force of 1.4N for an 8mm wide 
Parylene-C film [6.8]. This mechanical bond in which Parylene “caulks” silicone lowers silicone’s 
gas permeability. 
6.2 MOLD FABRICATION 
6.2.1 NEGATIVE EPOXIDE PHOTORESIST: MICROCHEM SU-8 
Su-8 is an epoxy-based negative photoresist. The material is made of a base chain with an average 
of 8 epoxy groups. When exposed to ultraviolet light (I-line 365nm), the triarysulfonium salt in the 
Su-8 resin produces an acid, which under the heat, catalyzes the cross linking reaction between Su-
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8 molecules. To make a mold with it, the photoresist must be spun, soft baked, exposed, post 
exposure baked (PEB), and finally developed. 
 
Figure 6.4: Su-8 Spin curve. Pour Su-8 over two-thirds of the area of the wafer. This spin curve 
results in 150µm for Su-8 100 and approximately 50µm for Su-8 50. 
 
Before spinning SU-8 50 or Su-8 100, which are quite viscous, the photoresist must be poured on 
the wafer, and allowed to spread to over two-thirds of the wafer’s surface area. This is done to prevent 
streaking. The spin curve for Su-8 100 results in a 150µm thick layer, and for Su-8 50, it results in a 
50µm thick layer (Figure 6.4). Su-8 may be spun twice with a partial soft bake in between to achieve 
up to 300 micron thickness; if much thicker than this leaves the material is susceptible to cracking 
due to thermal expansion differences with the underlying silicon substrate. 
 
Figure 6.5: Hotplate temperature curve for Su-8 soft baking and post-exposure baking. The 
soak times at 65ºC and 95ºC in the curve are soft baking for 2x150µm layers. The post-exposure 
bake for the same thickness is 30 minutes at 65ºC and 30 minutes at 95ºC. 
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The ramp-up in heating processes for both soft and hard baking must be sufficiently slow that the 
entire thickness equilibrates to reduce the stress build up in the material. This is even more important 
in the hard baking stage, as there is significantly less solvent present than in soft baking. The ramp 
curve is given in Figure 6.5, noting that the dwell times at 65ºC and 95ºC are dependent on layer 
thickness. Baking times increase with the square of the increase in thickness. 
For a 300µm thick Su-8 layer, the exposure time is 140 seconds (3.4mW/cm2 at 400nm, and 
1.5mW/cm2 at 365nm). However, this exposure imparts significant heat to the photoresist, which 
can result in cracking. For this reason, the exposure is split into 40 second intervals with 1 minute 
rests between exposures to allow the Su-8 photoresist to cool. 
Wafer development is done with MicroChem’s Su-8 developer, and takes 20 minutes with heavy 
agitation. Within the last minute, the wafer should be placed into fresh solution to rinse out any 
partially dissolved Su-8 gunk. The wafer should then be soaked in isopropyl alcohol, before a rinsing 
in deionized water. 
Multilayer patterns can be made through repetition of spinning, soft backing, developing and PEB 
(skipping the development step). In doing so, care must be taken with the patterns such that each 
subsequent mask does not expose an area that was previously left unexposed. The dimensions of the 
oxygenerator’s reservoir exceeded the thickness limit of less than 500µm that can be easily achieved 
with the Su-8 process. 
6.2.2 DRY-FILM PHOTORESIST PATTERNING: DUPONT WBR2120 
DuPont’s WBRTM 200 series of microlithographic polymer films were the solution to the mold 
limitations. These films were manufactured to be deformable to allow patterning over device bumps 
and vias, while minimizing the air trapped beneath them. This mean that the material was soft enough 
to not crack, when laminated over a non-flat surface. This flexibility of the material means it may 
allow for much thicker laminations with reduced stress build up and cracking. 
The material was developed for in-via and mushroom electroplating bumping, photo stenciling, and 
etching applications. It is available in 50µm, 75µm, 100µm, and 120µm thicknesses, the 120µm is 
the most amenable for 1mm thick molds with the fewest layers. 
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Optimization of this polymer film lithography was conducted with Dr. Jun Park. Using a General 
Binding Corporation Model No. Eagle 35 laminator, the optimal settings were found to be a travel 
speed of 3.8mm/s (speed of 1), with a roller temperature of 95ºC. For a silicon wafer, a roller 
separation of 1 (as marked by the machine) gave the best adherence. For best adhesion, the wafer 
should be cleaned with piranha solution to remove any organic contaminants from the surface. 
However, the polymer film adheres better to itself than to silicon. The substrate for any lithography 
should be a blank layer of the film, which is exposed and post-exposure baked. To prevent the 
photoresist from sticking to the masks, all masks were pre-coated with 5µm of Parylene-C before 
being used. This allows the wafers to separate from the masks with ease and maintain a glassy surface 
finish on the polymer. Using the protective polyester cover film to prevent adhesion between wafers 
and masks results in a matte surface finish. 
To act as a mold, this polymer film must be coated with a layer that isolates it from the silicone. The 
platinum catalyzed silicones does not cure properly on the photoresist. A layer of Parylene-C, which 
is very chemically inert, acted as a separating layer and aided demolding any patterns. 
In the following procedure, the lithographic polymer film will be referred to as dry-film photoresist 
1. Laminate 1 layer of the dry-film photoresist onto a clean wafer. Using a razor blade parallel 
to the edge of the wafer, cut away all excess film adhering the wafer to the paper substrate 
used to feed through the laminator. 
2. Expose this first layer using a blank mask to create a substrate for all subsequent patterns. 
After exposing, the polyester film covering the resist must now be removed before heating. 
Failure to do so will cause ripples to form on the photoresist and the coefficients of thermal 
expansion between the polyester and photoresist are different. 
3. Laminate subsequent layers of photoresist, comprising the first mask. Multiple layers can be 
exposed at once. This was successfully tested with up 6 layers (720µm) at the same time. 
4. The layers are exposed together, with the optimal exposure time being tabulated in Table 
6.1. 
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5. The wafer is post-exposure baked on a hotplate at 95ºC for 1 minute. This allows crosslinking 
to occur in the exposed polymer. 
6. If the device requires more masks, lamination is repeated once again. After the polyester film 
is removed, and before alignment and exposure, Sodium hydroxide developer, such as 
AZ340, is applied with an eye dropper over the alignment patterns. Doing so increases the 
contrast of any alignment patterns. 
7. The wafer can then be aligned to the mask and exposed. 
8. This procedure can be repeated for any set of masks required, though if the process exceeds 
1mm in height, the bowing of the silicon wafer becomes significant. As the dry-film 
photoresist is laminated at an elevated temperature, when cooled to room temperature, the 
film applies a stress to the underlying silicone which has a different coefficient of thermal 
expansion. Two solutions are to include stress release lines between devices, or use a thick 
pane of glass as a substrate in place of a wafer for thick laminations. 
9. After all exposures are complete, the wafer can be baked as a hybrid post-exposure baking 
and soft baking process at 65ºC for 20 minutes to 1 hour in a convection oven, depending on 
the number of layers. This is then allowed to cool slowly to room temperature at a slower 
than 5ºC/min. 
10. The wafer can then be developed in a dilute sodium hydroxide solution, 1 part AZ340 to 4 
parts deionized water, with constant agitation. This development process can take up to 30 
minutes. 
11. The molds then receive a 5µm coat of Parylene-C. This coat both allows silicone to properly 
cure within the mold, by isolating the silicone form the dry film, and allows the silicone to 
de-adhere easily from the mold. For fine features the coating must considered in the masks, 
which should be made larger to account for it. 
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Table 6.1: Exposure time for DuPont WBR2120 under 6.47mW/cm2 at 365nm and 
13.8mW/cm2 at 400nm 
NUMBER OF LAYERS EXPOSED EXPOSURE TIME (S) 
1 LAYER 60 
2 LAYER 80 
3 LAYER 100 
 
 
Figure 6.6: DuPont WBR2120 dry film fabrication process. (A) Laminate WBR2120 to the 
desired thickness and expose. (B) Repeat and expose the second layer. (C) Develop using 1:4 
AZ340:DI water. (D) Parylene Coat. (E) Pour and degas silicone. (F) Example of a completed 
mold for version 0 of the device. (G) Three sections are demolded. (H) They are joined by uncured 
silicone. (I) The cured shape is coated in Parylene-C. 
 
6.3 SILICONE CASTING 
Negative photoresists require exposure to light to cure. If a pattern has two layers, and the top mask 
exposes a region that is unexposed on the lower layer, that region on the lower layer will be cured as 
well, and will not dissolve in the developer. However, if the top mask exposes a region in the lower 
layer, there is no change to that lower region. Therefore, to preserve the patterns exposed into the 
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lower layer, the upper layer can only expose regions that have already been exposed in the lower 
layer. Any enclosed shape will have exposed areas in the middle layer that are unexposed in the 
bottom layer. As this cannot occur with a negative photoresist, any enclosed shape must be built in 
two parts (Figure 6.6). 
With completed molds, the next process is silicone casting. The silicone is thoroughly mixed for 5 
minutes at a 10 to 1 mixture of part A to part B of NuSil MED4-4210. The silicone is then poured 
and spread over the entirety of the wafer. It is important to make sure that every device is completely 
covered with the silicone. As the mixing process traps bubbles, the mold is placed in a vacuum 
chamber to degas fully. After no bubbles were visible, the mold is removed from the vacuum 
chamber and a fresh razor blade is dragged across the surface to remove excess silicone. If performed 
properly, no cleanup of the flashing should be required after during. The mold is placed into the 
vacuum chamber for another 15 minutes to allow the silicone to settle and remove any air that was 
trapped during scraping process. Finally, the mold is cured in a convection oven at 110ºC for 5 
minutes, which only partially cures the silicone to the point at which it can be handled. 
 
Figure 6.7: Silicone molding process using dry film mold. (A) WBR-2120 mold after silicone 
is cured into shape. (B) Demolding with a tweezer. (C) Uncured silicone spread over a clean glass 
slide with silicone part pressed against slide. (D) Peeling silicone part from uncured silicone. (E) 
Assembled diffusor. 
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The silicone parts can be demolded by grabbing their cast handles with tweezers and peeling with 
care, as shown in Figure 6.7. These shapes can be glued together using uncured silicone to construct 
more complex devices and enclosed pieces. 
6.3.1 MAKING AN ENCLOSED SHAPE 
The demolded silicone parts do not enclose anything due to limitations of the negative photoresist 
process. Therefore, the silicone parts must be bonded to a substrate or another part to make enclosed 
structures such as bags, microchannels, or other complex shapes. 
A common approach is to treat the silicone surface with oxygen plasma and bond two treated 
surfaces together. If the two pieces are brought in contact quickly after the treatment, the bond is 
resilient. This approach was used to create the electrolysis test device of section 4.2. There are two 
drawbacks with this technique. The first is that it offers a limited alignment time, meaning complex 
devices are difficult to reliability assemble. The parts bond soon after being brought into contact, so 
repositioning is not possible without hurting bond strength. The second drawback is thatg the bond 
is weaker than the silicone itself and generally separates before the silicone tears. Furthermore, the 
bond strength is dependent on the time exposed to atmosphere between plasma treatment and 
bonding. Therefore the bond strength can be very variable. 
Uncured silicone was used to bond parts together. Silicone would be mixed as per specification and 
thoroughly degassed. Once degassed, the silicone would be spread thin over a glass slide using a 
razor blade. The partially cured silicone parts would then be pressed against this thin layer of uncured 
silicone. After this the wetted sides can be aligned under a microscope until satisfied and then 
partially cured for 5 minutes at 110ºC in a convection oven. This procedure can be repeated for an 
arbitrary number of parts allowing complex shapes to be built up.  
There is a concern with any enclosed shapes. As a part is cured at a high temperature, any trapped 
air in between silicone pieces that have yet to cure will attempt to escape through the seam. This can 
cause unpredictable holes in any part. There are two solutions to this: to lower the temperature and 
increase the duration of the curing process, or, if the design permits, to add a vent hole to be filled in 
at a later time. The vent hole gives the design a predictable flaw that can be remedied afterwards by 
adding silicone onto a preheated part. Heating the part on a hot plate reduces the temperature 
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difference between it and the oven, meaning the uncured silicone sealing over the part will not get 
pushed out by the internal pressure. 
Concerns about the strength of this bond (partially cured silicone glued with uncured silicone) was 
tested two ways. The first involved spinning a thin sheet of silicone on a wafer (1krpm on a spinner 
for 1 minute with a ramp rate of 300rpm/s), and partially curing it for 3 minutes at 110ºC in a 
convection oven. The silicone was then removed from the oven and a 5mm wide section was 
removed from the sheet. Uncured silicone was poured in its place, degassed, and then the entire sheet 
was fully cured at 150ºC for 90 minutes. Samples were cut from the sheet such that they were 
centered on the 5mm wide new silicone. The stress-strain curves for the samples were measured on 
a TA Instruments DMA Q800 (Figure 6.8). The slope over different strains was extracted and 
compared to a control sample which had no silicone replaced from it. The statistic over 10%-20% 
strain was 1.4, falling short of the two-tailed critical value, 2.7, for α = 0.05, and over 40%-60% 
strain it was 0.88 falling short of 3.18 for the same alpha. This means the control and test populations 
are not statistically different. 
 
Figure 6.8: NuSil MED4-4210 silicone curing test. Uncured silicone was spun at 1krpm on a 
Parylene-C coated wafer. The silicone was cured for 3 minutes, after which point a section was 
removed from the now partially cured silicone sheet and uncured silicone was put in its place. 
Table 6.2 contains the slopes of the curves plotted here over two strain regions (10%-20%, and 
40%-60%). 
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Table 6.2: Slopes for silicone curing test. Three samples are stretched for each group. The bold 
values are the test statistic for each sections in the curve. Both test statistics are smaller than their 
two-tailed critical value. 
SLOPE (MPA/%) FROM 
10%-20% STRAIN 
SLOPE (MPA/%) FROM 
40%- 60% STRAIN 
CONTROL 3 MIN CURING CONTROL 3 MIN CURING 
0.9282 0.9011  0.559 
0.9528 0.8478 0.5299 0.5876 
0.8505 0.804 0.4958 0.4929 
1.427761424 0.877012037 
 
The second test checked how air tight the samples are, by inflating a flat disk of silicone. The silicone 
was cast in two halves and joined along the edge. A 30Ga needle was then epoxied onto the bag, 
which was then inflated using Nitrogen gas. As the bag was inflated, both the pressure and size of 
the bag where measured (Figure 6.9). As the seam along the edge makes difficult the calculation of 
the exact strain on the joint, the test demonstrates that only air tight designs can be built, which can 
withstand 100kPa. A conservative estimate on the force on the seam can be attained by: 
 𝐹 = 𝜋𝑟2𝑃 (6.1) 
where 𝑟 is the initial radius along the seam. At 100kPa, the force is 0.38N along the seam. No failures 
were observed along the seam. The stress averaged across the area of the seam is given by: 
 
𝜎 =
𝜋𝑟2𝑃
((𝑟 + 𝑡)2 − 𝑟2)𝜋
 (6.2) 
which results in a stress of 300kPa. The bond strength is therefore at least a tenth the breaking 
strength of cast silicone, and such a shape is air-tight and can withstand a pressure of 1atm above 
atmosphere. 
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Figure 6.9: Silicone bag resilience. A 3mm in diameter silicone disk shaped diffusor is epoxied 
to a 23Ga needle. The diffusor has an inner diameter of 2.2mm with a 0.4mm wide sidewall. The 
seam lies midway along the sidewall. (A-B) Calipers were used to measure the inflated height of 
the disk. The disk was inflated with nitrogen gas, whose pressure was recorded. (C) Plot of pressure 
versus height of the diffusor. This test was repeated for two separate diffusors. 
 
6.3.2 PARYLENE ON SILICONE RESERVOIR 
While the earlier inflation test demonstrates the strength of the seam, a large change in reservoir 
volume would subject the eye to increased intraocular pressure. To reduce the expansion of the 
reservoir under the pressure of electrolysis, Parylene-C may be coated. This has the added benefit of 
reducing gas permeability of the reservoir, so increasing the efficiency of the diffusor. To test this 
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idea a device reservoir was coated with parylene and inflated nitrogen gas through an epoxied needle. 
This was done for both the reservoir and the diffusor, and compared to an uncoated device (Figure 
6.10). 
 
Figure 6.10: Parylene coated silicone bag resilience. Points (A) and (B) show the inflation of 
the Parylene coated device at 37kPa above atmosphere and 72kPA above atmosphere. After 
inflating the device, above 65kPA bubbles are observed exiting the silicone, which are the result 
of the Parylene coating cracking. 
 
From the plot in Figure 6.10, it is clear that Parylene does have the desired effect. With a central 
pillar anchoring both surfaces, the initial volume change is reduced even further. Here the coating is 
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seen to work until 65kPa, at which point Parylene-C has been strained beyond its breaking point. 
After this the curve rises steeply as the Parylene coating is no longer restricting the silicone from 
expanding. Given that 65kPa above atmosphere equates to 421mmHg O2, far above the desired 
oxygen tension in the device, this limit on maximum pressure is acceptable. Note, the diffusor did 
not experience any meaningful expansion whether coated or uncoated, even though it had an open 
gas channel connecting it to the reservoir. As expansion of the diffusor is unlikely to occur and to 
cause a significant rise in intraocular pressure.  
The test also demonstrates that a Parylene coating on silicone is resilient, as the Parylene cracks 
before it delaminates from the silicone. 
6.3.3 FUSED DEPOSITION PRINTING OF RESERVOIR MOLDS 
The reservoir of the device sits on the sclera, which is a curved surface approximating a sphere of 
24mm in diameter. Therefore, a curved reservoir would conform better to the sclera and make it 
easier for the conjunctiva to cover the device. However, while lithography allows tall, high accuracy 
molds to be fabricated with ease, they are planar. It is difficult to induce a curve into a lithographic 
mold, and lithography over a 3 dimensional surface is challenging. 
It is much easier to use 3D printing technology to design an out enclosure for the reservoir electronics 
that has smooth curves. A stainless steel ball bearing with the same diameter as the eye provides the 
appropriate shape for the back surface. 
 
Figure 6.11: FDM 3-D printing molds. (A) Monoprice MP Mini Delta printer. (B) SolidWorks 
model of the reservoir mold. (C) Cross section of the mold. (D) 3D printed mold out of ABS plastic 
with a 0.05mm z-layer height. 
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The molds were designed with SolidWorks CAD software, and printed with Monoprice MP Mini 
Delta fused deposition modeling (FDM) 3D printer (Figure 6.11). The mold was printed at 100% 
infill, and 0.05mm z-layer height out of clear acrylonitrile butadiene styrene (ABS). To prevent loss 
of features, no smoothing was done to the mold. To release the silicone from the mold, Mann Release 
Technologies Ease Release 200 was applied to both the mold and steel ball bearing before casting 
silicone.  
 
Figure 6.12: 3D molded silicone device. (A) Stainless steel ball pressing against mold to form 
lower side of the device. (B) The curvature from this ball is visible on the underside of the device 
(version 8). (C) Top side of the device. 
 
A thin layer of silicone was painted onto the surface of the mold, vacuum degassed, and cured at 
85ºC for 20 minutes. The electronics can then be placed into the mold with care to make sure the 
electrodes are fed through the groove in the mold. The mold is filled to the brim with silicone and 
degassed fully. Once no more air bubbles appear, the ball bearing is pressed into the mold until it 
seats properly against the mold (Figure 6.12). Any squeeze out is wiped off with a Texwipe paper 
towel, before the mold is fully cured at 85ºC for 3 hours.  
Once the mold is taken out from the oven, the ball is carefully removed, and a tweezer is used to peel 
the oxygenerator from the mold. Dipping the oxygenerator in 2 parts hexane to 1 part silicone, 
smooths the visible grooves from the 3D printed layers. This is left at atmospheric temperature and 
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pressure for 2 hours after the dip coat to allow the hexane to fully evaporate. The device can then be 
fully cured at 150ºC for 2 hours. The final result is a complex 3D shape as seen in Figure 6.12bc. 
6.4 DEVICE ITERATIONS AND CONSIDERATIONS 
The device has gone through 9 iterations. Each iteration shrunk the footprint and increased reliability 
or made the device more amenable to implant. The diffusor and the reservoir are built separately and 
combined after the reservoir was coated with Parylene. Differences between each iteration are 
covered in Figure 6.13.  
 
Figure 6.13: Different versions of the oxygen generating device. Changes across different 
versions of the device. Note from the scale part, the device has shrunken to 25% of its size: from a 
14mm diameter by 3mm tall, planar device (V1) to a 7mm wide by 8mm long by 2mm tall, curved 
device (V8). 
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Version 0 of the Oxygenerator was a prototype using a copper 44 Litz wire and a Parylene PCB. The 
reservoir and diffusor were filled with electrolyte. The electrodes activated in the diffusor. This 
oxygenerator had issues transporting electrolyte from the reservoir to the diffusor, and suffered 
adhesion issues where the Parylene PCB entered the cannula. Subsequent designs, versions 1-7, had 
the electrolyte separated from the diffusor. The air conduit referred in section 4.4.1 shuttled oxygen 
from the liquid reservoir to the diffusor. In versions 1-5 this air conduit contained a set of pillars to 
maintain the shape of the chamber (Figure 6.14) and prevent collapse—under pressure from 
electrolysis—of the membrane that separates the conduit from the liquid reservoir.  
The coil changed along with the oxygenerator design and different fabrication methods. Versions 1 
and 2 used a planar coil, whose fabrication is discussed in section 5.3.2.1. Version 3 and 4 used a 
hand spun coil and a metal spindle. This flat coil remained above the device but opened a window 
for injecting electrolyte from above. Versions 5-8 used an automatically wound coil as described in 
section 5.3.2.3. In versions 5 and 6, the coil surrounds the electronics pocket and the reservoir. These 
versions of the oxygenator are covered in a cast shell of silicone to give the device an appropriate 
shape. 
Version 6 replaced the air conduit with nanoporous, hydrophobized Vycor glass. However, the 
nanoporous tack pushed the location of the cannula 2 mm back, which was problematic for implant, 
since the cannula needed to enter through the 3mm to 4mm wide pars plana. Version 7 reverted to 
an air conduit and moved the cannula to the very front. 
Version 8 is a departure from the approach in earlier versions, as the reservoir region contains only 
the electronics. The diffusor contains the electrodes and performs electrolysis. This change was 
brought about by changing the method of replenishment from injections to osmosis. In doing so the 
liquid reservoir could shrink. 
The fabrication steps for versions 1 through 7 are fairly similar. The description below is for version 
1 of the device, but applicable for every version. Only one fabrication procedure is presented to avoid 
repetition. 
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Figure 6.14: Fabrication of version 1 of the oxygen generating device. The silicone for the 
reservoir was cast in dry-film photoresist molds, while the (D) diffusor was made by dip-coating a 
Parylene-coated wire in silicone. Subsequent models contained a cast diffusor made using dry-film 
molds. (B) Note in that there is a small conduit in the lower right side of the diagram where the 
cannula sits. Such a feature exists in versions 1 through 7 as the cannula is much larger than the 
120µm height of the (A) air chamber. The final product can be found in Figure 6.13-V1. 
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Figure 6.15: Computer rendering of parts of version 5 of the device. Notice the commonality 
in the design process with version 1. Here placing the coil and electronics around the reservoir 
helps reduce its footprint to 10mm in diameter. 
 
The reservoir was cast in silicone using MEMS fabricated molds. It was made in 3 sections, as seen 
in Figure 6.14a-c; each with a separate mold made by laminating negative dry film photoresist 
(DuPontTM WBR2120). To fabricate a mold, first, the dry film is laminated onto a silicon wafer at 
95ᵒC. With all necessary layers for a given pattern applied, the dry film is baked for 20 minutes at 
65ᵒC, and followed by UV patterning (~250-600mJ/cm2, depending on number of layers). The film 
is then post exposure baked to cure the pattern at 95ᵒC for 1 minute. Further layers can be applied, 
and the process repeated. When all patterns have been defined, the wafer is developed in an AZ340 
develop-water solution (1:4) for approximately 40 minutes. The resultant mold is coated in Parylene-
C as a release agent. The electrolyte chamber has a 5-layer lamination (600µm tall) for the walls of 
the chamber, and a 2-layer lamination (240µm tall) for the membrane separation from the air 
chamber. The air chamber, Figure 6.14a, has pillars to prevent its collapse when pressure builds in 
the adjacent electrolyte chamber. The final mold defines the top of the electrolyte chamber. Each of 
these molds is filled with a mixed two-part medical-grade silicone (MED4-4210 from NuSil 
Technologies, LLC) and degassed. After degassing, the excess silicone is wiped from the mold using 
a fresh razor blade, and placed in the oven at 100ᵒC for 3 minutes to partially cure. The three sections 
are released from their molds and bonded together using uncured silicone as a glue under a 
microscope. The assembled sections are cured in an oven at 100ᵒC for 3 minutes. Two platinum 
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wires (0.004in from California Fine Wire) are then inserted through the sidewall of the silicone into 
the electrolyte chamber to act as the electrodes. The 304 stainless steel cannula is glued to the 
opening in the air chamber using uncured silicone. The other side of the cannula is temporarily 
plugged with silicone, and then the oxygenerator is placed in an oven at 100ᵒC for 4 hours to fully 
cure. The oxygenerator is CVD (Chemical Vapor Deposition) coated with Parylene-C to reduce 
oxygen permeation through the reservoir into the conjunctiva. 
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CHAPTER 7 – OXYGEN DISTRIBUTION 
The performance of the completed oxygenerator is validated along several criteria: 
 Longevity of the soft polymer packaging the electronics 
 Device response time, and duration and spatial distribution of stored oxygen 
 Ability to modulate oxygen tension 
 Distribution of oxygen in an animal 
 Metabolic changes in an animal with retinal ischemia 
 
7.1 LONGEVITY OF THE OXYGENERATOR: ACCELERATED LIFETIME 
TEST 
Medical implants have to contend with the natural salinity (0.9% by weight NaCl. The difference in 
the anodic index between two dissimilar metals in contact with a salt solution generates galvanic 
corrosion. The corrosion is exacerbated in the presence of an electrical potential. To prevent this, the 
rate of water ingress into the electronics’ compartment must be reduced. The earliest version of the 
oxygenerator relied on a silicone coat over the Parylene circuit board and a titanium film to insulate 
the electronics (Figure 7.1). However, the film could not entirely encapsulate the electronics, and 
significant corrosion was observed after 2 days of soaking at 90°C in saline. The titanium adhesion 
layer in the Parylene circuit board, which lies between the gold traces and the Parylene, was 
significantly damaged (Figure 7.2). 
 
Figure 7.1: Soak testing Parylene PCB. (A) Parylene PCB circuit. (B) Version 0 of the device, 
with titanium film encapsulation of electronics. (C) After two days of soaking at 90°C in saline. 
Externally, there are no signs of corrosion. 
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Figure 7.2: Close up of Parylene PCB soak test. (A) Parylene PCB. Since the view is from the 
underside, the titanium layer of the traces is visible. (B) Capacitor after 2 days soaking at 90ᵒC. 
Not the non-uniform coloration on the traces suggesting corrosion of the titanium layer. (C) Similar 
corrosion visible on another capacitor on the same circuit board. 
 
Subsequent versions of the oxygenator relied on Parylene coats of 10 microns. The oxygenerator 
(version 8) has the electronics coated in Parylene, and then potted in silicone. This version was 
soaked for 163 days in saline at 77ºC and remained operational until the experiment's end. The device 
was energized weekly for 10 minutes to verify functionality. At the experiment’s end, corrosion was 
observed at the solder points, but this corrosion did not affect functionality (Figure 7.3). 
 
Figure 7.3: Soak testing osmotically refilled device electronics. (A) Bottom view on day 0 
before soaking over a 1mm square grid. Note that there is no diffusor attached. Electrolysis is 
performed directly into the saline solution, leading to a visible trail of bubbles. (B) Top view of the 
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device. (C) Testing the device on day 0. The primary side coil is placed underneath the container. 
(D) Top view of the device after 167 days of soaking. Note the corrosion indicated by the red 
arrow. (E) Better view of the corrosion in the device. The corrosion occurs where the exposed 
positive platinum wire joins the rectifying diode and capacitor. (F) Function test of the device after 
167 days. Note the primary coil underneath the container powering the device. 
 
Using the Arrhenius equation, the equivalent longevity at 37°C for the 77°C test can be calculated: 
 
𝐴𝑓 = exp(−
𝐸𝑎
𝑘
(𝑇1
−1 − 𝑇2
−1)) (7.1) 
where 𝐸𝑎is the activation energy, and 𝑇 is temperature. Note that the acceleration factor, 𝐴𝑓, depends 
strongly on the activation energy, which be taken from literature. Accordingly, the device may last 
8.2 years, assuming an activation energy of -0.69eV for a 40 micron Parylene-C with 5mm silicone 
[7.1], which results in 𝐴𝑓 = 18.37. 
7.2 OXYGEN PRODUCTION IN DEVICE WITH A RESERVOIR 
The oxygen tension over time was measured on devices with a reservoir before integrating the 
electronics, to confirm their functionality before animal experiments (Figure 7.4).  
 
Figure 7.4: Bench testing needle refilled oxygen generating device. (A) Fully assembled version 
5 of the device. The injection plate is centered over the gold coil. (B) Device without electronics 
being tested. The water bath is purged of oxygen and oxygen is blown over top. (C) A Batch of 4 
devices to test before integrating with electronics. 
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Oxygen tensions at different distances from the oxygenerator's diffusor were measured on bench 
with an AL-300 AP-coat Fluorometrics Instruments oxygen probe and a NeoFox reader. The oxygen 
production rate of 0.24nmol/s was found by fitting a COMSOL simulation of the oxygenator to the 
oxygen tension data, as seen in Figure 7.5 (reduced-χ2 of 1.16). This production rate matches the 
flux required by the AXSY model. 
 
Figure 7.5: Oxygen profile during electrolysis for needle refilled device. (A) Output oxygen 
curves from devices with liquid reservoirs. The electrodes were energized directly from a power 
supply. (B) COMSOL model matched to the data of one of the devices in (A). The model was 
fitted by sweeping the rate of electrolysis, which was assumed to be constant during the active 
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period (5 minutes). The fit is in good agreement with a reduced-χ2 of 1.16 for a rate of 0.24nmol/s 
of oxygen. 
 
Note that oxygen flux can be increased by reducing the thickness of the silicone walls in the diffusor 
(currently 360µm). Using the COMSOL simulation of the oxygenerator, oxygen tension away from 
the diffusor is plotted in Figure 7.6. The drop in oxygen tension at 1 mm away from the diffusor 
shows the importance that must be given to its placement. 
 
Figure 7.6: Simulation of partial oxygen distribution over time for needle refilled device; 
using the model in Figure 7.5B. Note the peak oxygen tension occurs later as the probe moves 
farther away from the diffusor. This shows the large impact the time constant of water on the 
oxygen distribution. Peak oxygen tension 1mm away is less than half that at the device. On the 
other hand, the oxygen tension is much more stable, taking 20 minutes to decrease by 25mmHg, 
vs 5 minutes at the device. 
 
This simulated spatial oxygen distribution matches a measurement, made 2000s after electrolysis, 
from an earlier oxygenerator (version 1) (Figure 7.7). The delay in measurement reduced the rate of 
change of oxygen tension at all measurement points. 
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Figure 7.7: Oxygen tension vs. distance from diffusor. Oxygen measurements taken moving 
away from the device 30 minutes after electrolysis. Note the rapid decline in oxygen tension over 
2mm. 
 
7.2.1 IMPLANTATION OF THE OXYGENERATOR IN RABBITS 
Oxygenerators (version 5) were implanted on 6 healthy pigmented rabbit eyes by Dr. Juan Carlos-
Ramirez at the USC Medical Center. 
The devices were sterilized by gas-phase ethylene oxide (ETO). The surgical procedure is illustrated 
in Figure 7.8. Before surgery, the rabbits were anesthetized, and the reservoir was filled with 
electrolyte. A peritomy was performed to open the conjunctiva in the supra-temporal quadrant. The 
reservoir was sutured to the sclera at the two front ears of the device. The diffusor was placed in the 
mid-vitreous humor with the cannula entering through the sclera at the pars plana. There were no 
surgical complications. 
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Figure 7.8: Rabbit implant procedure. (A) Marking the entry point through the sclera at the pars 
plana. (B) The reservoir is positioned on the sclera. (C) Sutures affix the reservoir to the eye. (D) 
The conjunctiva is pulled over the device, and (E) sutures close the conjunctiva over the device. 
(F) The diffusor viewed through the lens when activated. (G) The rabbit recovering from surgery 
after the device was implanted. 
161 
 
Table 7.1: One week rabbit trials with devices with liquid reservoir. 
Rabbit # Device #        Comments 
Rb003 AO-V5-2-03 
 No inflammation 
 Leak on injection port after 1week. 
 Implanted in fellow eye (L) after 1 week 
for acute experiment. 
Rb004 AO-V5-2-05 
 Cornea opaque with inflammation around 
device. 
 Implanted in fellow eye (L) after 1 week 
for acute experiment. 
Rb005 AO-V5-2-01 
 Implanted farther back (no inflammation) 
 Well covered by conjunctiva 
 No leaks. 
Rb006 AO-V5-2-02 
 Leak out of injection block 
 Device still functional after 1 week 
(confirmed in same eye). 
 
Oxygen measurements surrounding the diffusor were taken before and after activation for a 
minimum of 3 minutes (Figure 7.9). There were no issues with power coupling through tissue. 
According to the measurements, the oxygenerator had a statistically significant effect on the oxygen 
levels in the vitreous. After 7 days, the rabbits were re-anesthetized to measure the oxygen tension 
surrounding the diffusor. One device out of 4 caused inflammation after the week-long trial, the 3 
other devices showed no intraocular damage. The devices survived the implant and maintained 
performance one week after (Figure 7.10). 
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Figure 7.9: In vivo spatial oxygen distribution from the device. Four pigmented rabbits 
weighing 2-3kg where used for this study. An oxygen probe measures the oxygen concentration 
away from the device and towards the retina before and after activating the device for 3 to 5 
minutes. The pre-activation values are elevated over the vitreous baseline, since the device acts 
like a passive transporter while its residual atmospheric oxygen diffuses out. 
 
 
Figure 7.10: In vivo oxygen tension during electrolysis. The graph compares performance 
between day 0 (when the device is implanted), and day 7 (the end of the study). After 7 days the 
device performs as expected having the exact same oxygen curve. The initial oxygen tension at the 
diffusor is near 0 when the device is energized on day 7, since this eye was treated with laser 
photocoagulation to create a retinal vein occlusion to mimic ischemia. 
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Figure 7.11: in vivo vs. in vitro oxygen tension during electrolysis. Oxygen tension at the 
diffusor with 5 minutes of electrolysis for the same device, AO-V5-02-05, in the bench test, and 
after animal implant. The probe used in animal is different from the bench probe, and saturates at 
200mmHg resulting in a flat line for any oxygen values above that point. 
 
It is important to confirm whether the bench model characterizes the behavior of the device. Figure 
7.11 shows that the device behaved identically in vivo and in vitro. Sterilization and implantation did 
not affect performance. Anesthesia is time constrained, thus one cannot wait, as in benchtop, for the 
device internal oxygen tension to reach zero. This fact is reflected in the difference between the two 
curves of Figure 7.11.  
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Figure 7.12: The decay time of 5 minute in vivo activation of the device with a liquid on day 7 
after implantation in a pigmented rabbit. The blue represents the actual oxygen tension at the 
diffusor which is 4mm away from the retina. The oxygen probe saturates at values over 200mmHg, 
so the plot is flat above that value. The grey area represents the region of time during which the 
device was activated. This was fit with an exponential, the red dashed line, with an R2 value of 
99.5. 
 
In the rabbit, the oxygen tension decays to near zero in 2.5 hours (Figure 7.12). Estimates from the 
AXSY model (Figure 2.19, Figure 2.20, and Figure 2.21) inform that 5 minutes of electrolysis will 
supply sufficient oxygen tension to treat a moderate retinopathy (22.7% ischemia) for 1 hour.  
The decay rate of oxygen tension in vivo depends on the permeability of the vitreous, on the 
diffusor’s distance from the retina, and on the retinal consumption. Based on the oxygen tension 
decay, one can calculate the flux out of the diffusor: 
 ?̇? = 𝐴𝐽 (7.2) 
where 𝐴 is the area of the diffusor, 𝐽 is the flux, and ?̇? is the molar change with respect to time. Given 
Fick’s law of diffusion, the flux, 𝐽, can be estimated as: 
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𝐽 = −𝑃𝑣𝑖𝑡
𝜕𝑝𝑂2
𝜕𝑟
≈ −𝑃𝑣𝑖𝑡
𝑝𝑂2
𝐿
 (7.3) 
where 𝑝𝑂2 is the partial pressure of oxygen, 𝑃𝑣𝑖𝑡 is the vitreous’s permeability to oxygen, and 𝐿 is 
the diffusor’s distance from the retina. Assuming the diffusor’s membranes are much higher than of 
the vitreous, the moles of oxygen in the device can be estimated as follows: 
 
𝑛 =
𝑉𝑟𝑒𝑠
𝐻𝐻2𝑂
𝑝𝑂2 +
𝑉𝑎𝑖𝑟
𝑅𝑇
𝑝𝑂2 (7.4) 
Therefore, the oxygen flux can be modeled as: 
 𝑑𝑝𝑂2
𝑝𝑂2
= −𝑃𝑣𝑖𝑡
𝐴
𝐿
(
𝑉𝑟𝑒𝑠
𝐻𝐻2𝑂
+
𝑉𝑎𝑖𝑟
𝑅𝑇
)
−1
𝑑𝑡 (7.5) 
which has a solution of the form: 
 𝑝𝑂2 = 𝑝𝑂2,𝑖𝑒
−𝐵𝑡 (7.6) 
such that the time constant, 𝐵, is: 
 
𝐵 = 𝑃𝑣𝑖𝑡
𝐴
𝐿
(
𝑉𝑟𝑒𝑠
𝐻𝐻2𝑂
+
𝑉𝑎𝑖𝑟
𝑅𝑇
)
−1
 (7.7) 
The regression (segmented red curve) of rabbit data from Figure 7.12 with R2=99.5 and  𝐵 = 
(3.2±0.013)×10-4s-1 fits equation (7.6). Note that the molar flux is given by: 
 
?̇? = 𝐴𝐽 = −𝐵 (
𝑉𝑟𝑒𝑠
𝐻𝐻2𝑂
+
𝑉𝑎𝑖𝑟
𝑅𝑇
)𝑝𝑂2,𝑖𝑒
−𝐵𝑡 (7.8) 
Because the values for solubility of oxygen in water, area of the diffusor (𝐴=5.8mm2), and volumes 
of the different chambers of the device are known (𝑉𝑟𝑒𝑠=6mm
3, and 𝑉𝑎𝑖𝑟=7.3mm
3), the flux is 
estimated as: 
 ?̇? = −(2.7 ∙ 10−11[mol/s]) · 𝑒−(3.2·10
−4[𝑠−1])·𝑡 (7.9) 
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One should be extremely mindful of the size of the diffusor in relation to the eye size and the distance 
from the retina at which the diffusor is implanted.   
Naturally, the smaller the volume of the eye the smaller the radius of the diffusor should be: for the 
rabbit eye the diffusor's radius should be 1.5mm, and for the human eye, 5mm (Figure 7.13). The 
oxygen flux scales with the square of the radius; at peak, with the diffusor 4mm from the retina, the 
flux is 0.042nmol/s for the rabbit and 0.19nmol/s for humans. If the diffusor is brought closer to the 
retina, the flux increases proportionally to the inverse of the distance; since 𝐵 ∝ 𝐿−1; implanting the 
diffusor at 2mm from the retina would increase the oxygen tension to 0.084nmol/s for the rabbit and 
to 0.38nmol/s for humans. A vitreous permeability of 1900Ba was regressed from this data. 
 It is worth noting that measurements were taken with eyeballs anesthetized, so convection resulting 
from eye movement does not increase oxygen flux. 
 
Figure 7.13: Human diffusor versus rabbit diffusor. (A) Diffusor sized for the human macula, 
diameter of 10mm, as integrated in version 1 of the device. (B) Diffusor sized for the rabbit eye 
with a 3mm active area, and a total diameter of 5mm.   
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7.3 MODULATING OXYGEN PRODUCTION IN AN OSMOSIS 
REFILLABLE DEVICE 
Steady state oxygen tension is achieved by pulse width modulation of the primary side.  
7.3.1 OXYGEN PRODUCTION IN AN OSMOSIS REFILLABLE DEVICE 
As noted in section 4.4.2, this oxygenator design eliminates the complications associated with 
refilling an implanted device. With no reservoir, the small volume of the diffusor requires frequent 
activation.  
 
 
Figure 7.14: Bench oxygen tension during electrolysis vs. activation time. (A) An oxygen probe 
was placed next to a 120µm thick diffusor, and the device is energized for different lengths of time. 
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This test was done in an anoxic liquid with nitrogen gas blowing over top. The diffusor was placed 
6mm from the surface of the liquid. Figure 7.19a is an image of the test setup. (B) The maximum 
oxygen tension with respect to amount of time electrolysis occurs for. The regression has an R2 
value of 0.97, with the fit 𝑦 = (6.33 ± 0.41)[mmHg/s] 𝑡 + (29.2 ± 6.9)[mmHg]. The y-
intercept relates to the nonlinear gas generation of oxygen that occurs when the electrodes are 
devoice of occluding bubbles. This seems to stabilize over the first 2 seconds. 
 
The oxygen flux out of the diffusor is estimated from the 5 oxygen decay curves in Figure 7.14A. 
The time constant, 𝐵, of those curves, as defined in equation (7.6), is (2.0±0.2)×10-2s-1; for short 
durations in which the device is energized, the time constant is invariant (only 0.004s-1 difference 
from a mean of 0.02 s-1). By knowing the diffusor’s volume, 𝑉𝑑𝑖𝑓𝑓, the oxygen flux out of the diffusor 
can be found by modifying equation (7.8): 
 
?̇? = 𝐴𝐽 = −𝐵 (
𝑉𝑑𝑖𝑓𝑓
𝑅𝑇
)𝑝𝑂2 (7.10) 
 which results in a flux per oxygen partial pressure of 𝐵 (
𝑉𝑑𝑖𝑓𝑓
𝑅𝑇
) = (1.66 ± 0.16) × 10−12mol ·
s−1 · mmHg. For a flux of 0.25nmol/s, as required by the AXSY model in a human-sized diffusor, 
the oxygen tension must be at least 150mmHg.  
The maximum oxygen tension is approximated as a linear relationship with activation time (Figure 
7.14B). This implies that total area occluded by gas reaches its equilibrium rapidly, which is in 
agreement with video recordings of electrolysis in the diffusor (Figure 4.15).  Note that the response 
time of 45 seconds in this benchtop experiment agrees with an acute animal test of the device, where 
a 50µm osmosis diffusor with electrodes reached 200mmHg in 100 seconds (Figure 7.15). 
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Figure 7.15: In vivo comparison of different device versions implanted in pigmented rabbits. 
Both devices are within 4mm of the rabbit’s retina. The probe saturates around 200mmHg. 
 
Also, note that the diffusor is sized for rabbit experiments with an outer diameter of 3.5mm and that 
the flux scales with the square of the diameter of the diffusor, because oxygen flux is dominated by 
the thinner top and bottom walls of the device.  
 
Figure 7.16: Effect of diffusor membrane thickness on oxygen response. Two diffusors of the 
same size are tested with an oxygen probe against the diffusor in an anoxic water bath. Diffusors 
were powered by activating the primary side for 20 seconds. 
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The effect of membrane thickness is plotted in Figure 7.16. As expected, the peak oxygen value is 
lower in the 120µm thick diffusor membrane with a longer time constant, (1/𝐵), of 79 seconds 
versus 51 seconds for the 50 µm thick diffusor membrane. Oxygen oversupply can be controlled by 
increasing the membrane thickness. 
7.3.2 PULSE-WIDTH MODULATION CONTROL OF OXYGEN TENSION 
Using the dynamics of the device from the section 7.3.1, the device may be controlled with pulse-
width modulation. The time averaged value for oxygen can be taken as the treatment value, because 
the time constants for cell death and activity are measured in tens of minutes [7.2]. The period of 
pulse width modulation is on the order of a minute, since electrolysis increases the oxygen tension 
in the vicinity of the diffusor within tens to hundreds of seconds. The percentage of on time is 
dependent on the desired average oxygen tension. 
This primary side modulation is achieved by controlling power sent to the amplifier. A high side 
PMOS switch circuit (Figure 7.17) connected to a microcontroller can achieve the effect. For this 
experiment, the microcontroller communicates with a computer to allow the period, on time and 
initial on time to be changed with ease. In an implant for humans, the primary circuit can be 
integrated into glasses or a sleep mask.  
 
Figure 7.17: Power amplifier P.W.M. control circuitry. Arduino UNO (Atmel ATmega 328P) 
controls the power supply voltage into the amplifier for the primary side coil through this high side 
switch. 
 
The only additional circuitry required in the secondary is to limit the maximum voltage sent to the 
electrodes. Limiting the voltage removes the variability of delivered power based on the separation 
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between the primary and secondary sides (Figure 5.20). All orientations, where the two coils are 
sufficiently close and aligned to deliver sufficient power, will deliver the same voltage. An LED acts 
as a visual indicator of sufficient voltage. 
 
Figure 7.18: Secondary side diode feedback circuit. (A) Secondary side circuit using an infrared 
LED. (B) Similar results can be achieved using a 3.5V blue LED. This is acceptable for benchtop 
tests, but for an actual implant the blue LED may be uncomfortable. On the other hand, an infrared 
from an IR LED will penetrate tissue (Figure 5.1). 
 
LEDs flatten the voltage-distance curve by shunting current to ground, such that the resistance of the 
system reduces the voltage at the electrodes (Figure 7.18).  
 
Figure 7.19: Implant bench test setup. (A) Close up on the diffusor mounting. Red arrows point 
to the electronics package (lower), and to the diffusor with platinum electrodes (upper). (B) Device 
is energized with oxygen probe in contact with diffusor. 
172 
 
Oxygen tension is measured using an AL-300 AP-coat Fluorometrics Instruments oxygen probe and 
a NeoFox reader. To simulate the eye, the device is submerged with the diffusor placed 4mm below 
the surface of the water. Nitrogen gas circulates in the chamber above the water; acting as a 
consumption source for the generated oxygen (Figure 7.19).  
 
Figure 7.20: Pulse width modulated oxygen output from primary side control with a 50µm 
thick diffusor. A longer pulse of 25 seconds is used to bring the oxygen tension closed to the steady 
state value. Afterwards the power supply is pulsed at a repeatable 10 seconds on with a period of 
65 seconds. The grey shaded area overlays activation onto the oxygen plot. The Amplifier voltage 
output, and the power supply output were acquired from an oscilloscope. The maximum 
acquisition time on the oscilloscope is limited by what can be displayed on the window, which is 
significantly less than the duration of this run. 
 
A pulse-width modulated (PWM) signal controls the primary with an on time of 10 seconds and an 
off time of 55 seconds. Doing so maintains the oxygen tension in the device to 214±29mmHg for 
the 25 cycles (27.5 minutes) of the experiment; this process can be maintained indefinitely. Using 
the final decay portion of the oxygen data, the time constant, 𝐵, is determined to be (2.29±0.4)×10-
3s-1 (R2=99.85) . The instantaneous oxygen flux out of the device is given by equation (7.10), which 
can be integrated over time to provide the number of moles of oxygen provided by the diffusor: 
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𝑛 = ∫ ?̇?𝑑𝑡 = −∫𝐵 (
𝑉𝑑𝑖𝑓𝑓
𝑅𝑇
)𝑝𝑂2𝑑𝑡 (7.11) 
Applying this integration to the data set results in 44nmol of oxygen, and an average flux of 
0.037nmol/s. A larger 10mm diffusor is estimated to provide 0.17nmol/s, since it has 4.5 times the 
area and the volume of the diffusor scales with its area as 𝑉𝑑𝑖𝑓𝑓 = 𝐴𝑑𝑖𝑓𝑓𝐻. These parameters match 
the requirements estimated by the AXSY model with 22.7% ischemia to treat moderate DR.  
Pulse width modulation allows the ophthalmologist to adjust treatment in a human implant by 
adjusting the primary side without modifying the implant. 
7.4 METABOLIC CHANGES IN THE RABBIT 
To test the changes in the retinal metabolism caused by the devices on the presence of retinal vein 
occlusions (RVO), a study was requested to medical researchers at the University of Southern 
California. Tests on the oxytransporter and the oxygenator were planned, but constraints limited the 
study to the oxytransporter. The study was performed by Professor Juan Carlos Martinez-Camarillo, 
Dr. Alejandra Gonzalez-Calle, Dr. Ronald W. Irwin and Professor Enrique Cadenas.  
The rabbits weighed between 2 and 3 kilograms. The rabbits were split in groups of 6: 6 as control 
or healthy (without occlusion and without implant), 6 as non-treated (with occlusion and with non-
functional implant), 6 as treated (with occlusion and with functional implant) for 3 hours, and 6 as 
treated (with occlusion and with functional implant) for 96 hours. 
The retinal veins were occluded by laser photocoagulation. Fluorescein angiography confirmed the 
occlusion 3 days after, and the protein, Hypoxia Inducible Factor-1α (HIF-1α), the hypoxia. Figure 
7.21 shows a rabbit's RVO. During the day of the implant and for 6 hours afterwards, oxygen was 
blown intermittently over the oxytransporters.  
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Figure 7.21: Laser-induced RVO on a rabbit. This image is taken 3 days later when an 
oxygenator was implanted. The top image shows the image using visible light. While the middle 
image looks fluorescence from for fluorescein angiography. The lack of fluorescence in the laser 
treated regions implies no reperfusion has occurred. The lower image was taken after an 
oxygenator device was implanted 
 
 
Figure 7.22: Changes in protein expression after laser-induced retinal vein occlusion. P-PDH, 
and HIF-1α upregulation imply hypoxia. NF-κB upregulation combined with IKKα (Figure 7.23) 
implies inflammation secondary to hypoxia. 
175 
 
 
The study, using Actin as the non-hypoxic and non-inflammatory protein reference, looked for up 
regulation or down regulation of the following proteins in the hypoxic and inflammatory pathways: 
Hypoxia Inducible Factor-1α (HIF-1α), Pyruvate Dehydrogenase (PDH), Nuclear Factor Kappa-
Light-Chain-Enhancer of Activated B Cells (NF-κB), IκB Kinase α (IKKα), and c-Jun N-Terminal 
Kinases 1 and 2 (JNK1 and KNJ2).  
HIF-1α is upregulated in hypoxia exclusively; PDH is upregulated in hypoxia and also in other 
conditions, but retains value as a weak marker of hypoxia because PDH relates to cellular oxygen. 
The ratio NF-κB / IKKα is elevated in inflammation.  
HIF-1α, the strongest hypoxia marker, was calculated only for the control or healthy group and for 
the non-treated group, unfortunately reducing the usefulness of this marker to confirmation of 
hypoxia (Figure 7.22). JNK1 and KNJ2 are multi-causal. One is, thus, left from the study, with PDH 
as weak marker of hypoxia and the ratio NF-κB / IKKα as strong marker of inflammation. 
 
Figure 7.23: Effect of oxytransporter on NF-κB and IKKα expression in rabbit. (A) NF-κB 
is downregulated in the presence of the oxygenator compared to the RVO model, and elevated in 
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the RVO model (non-treated) compared to the healthy case. Actin is used as a baseline for this 
analysis. (B) IKKα shows the opposite trend. (C) The relative expression of NF-κB compared to 
IKKα is not statistically different from the healthy case in the presence of the oxygenator, but 
significantly elevated in sham treatment (non-treated). The (*) over the graphs represents a 
statistically significant difference between those groups. 
 
Unfortunately as well, the oxytransporter was implanted at a minimum of 4mm from the retina 
instead of at 1mm to 1.5mm from the retina, as plotted in Figure 2.19, Figure 2.20, and Figure 2.21. 
As consequence, the oxygen tension provided to the retina was insufficient.   
The ratio NF-κB / IKKα of the treated groups (3 hours and 96 hours) were similar to the control or 
healthy group, and lower than in the non-treated group. Since both comparisons are statistically 
significant, one can say the oxytransporter reduced inflammation (Figure 7.23). The association 
between the ratio of NF-κB and IKKα with hypoxia suggests that oxygen delivery may ameliorate 
the inflammatory response, which is consistent with the expected behavior of the device. 
 
Figure 7.24: Effect of oxytransporter on PDH and JNK expression in rabbit. PDH is 
downregulated in treated tissue compared to untreated. The (*) over the graphs represents a 
statistically significant difference between those groups. 
 
PDH expression was higher in the non-treated group than in the control or healthy group. The 96hr 
treatment group had a lower PHD expression than to the non-treated group. Since the comparison is 
statistically significant, but PDH upregulation is multi-causal, one can say the oxytransporter may 
reduce hypoxia (Figure 7.24). 
Notwithstanding limitations, these conclusions are encouraging and warrant a repetition of the 
experiment in accordance with the parameters calculated in this thesis. 
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7.5 CONCLUSION 
The motivation of this thesis lies in the relationship revealed between oxygen supply and 
consumption by the treatment of diabetic retinopathies through laser photocoagulation. This 
treatment ablates retinal cells to reduce oxygen consumption, so it is natural to wonder why not 
supply the hypoxic retina with more oxygen instead? The analysis of the eye and modeling of the 
retina and its oxygen distribution, the design and optimization of MEMS devices to implant in the 
eye and efficiently supply oxygen to the retina, the selection of the proper materials and methods to 
fabricate those devices, the resolution of condensation in the devices, the optimum power source, 
and the implants in animals, followed and are explained on the pages of this thesis.  
Here only the main conclusions are posited: 
 The computational model of oxygen distribution developed for a retina with 9 calculates the 
oxygen tension required to treat humans for mild (100mmHg) to severe (250mmHg) diabetic 
retinopathy, the location of the diffusor in the vitreous (0.2mm to 1mm from the retina), and 
the oxygen flux (0.25nmol/s) the diffusor must supply. 
 Two MEMS devices that were designed—the oxytransporter (transports oxygen from the 
atmosphere) and the oxygenator (generates oxygen by electrolysis of water taken from the 
vitreous through osmosis)—performed similar in rabbits and in benchtop: oxygen tension of 
100mmHg at the oxytransporter’s diffusor, and oxygen tension greater than 200mmHg at the 
oxygenerator’s diffusor. The oxygenerator provided 0.042nmol/s of oxygen in the rabbit, 
equivalent to 0.19nmol/s for a human-sized diffusor. 
 The metabolic study of ischemia is rabbit eyes implanted with the oxytransporter showed 
improvement on inflammatory markers that are associated with hypoxia, suggesting the 
device may affect hypoxia. More robust trials are needed.   
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